Methionine adenosyltransferase 2A (MAT2A) inhibitors and uses thereof

MAT2A inhibitors, such as Formula (I) and Formula (II), provide a targeted therapeutic solution for MTAP-deficient cancers by inhibiting the MAT2A enzyme, effectively treating various cancer types including liver, colon, pancreatic, prostate, lung, and breast cancers.

JP2024540935APending Publication Date: 2024-11-06INSILICO MEDICINE IP LTD
View PDF 10 Cites 0 Cited by

Patent Information

Application Number
JP2024523611
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-09-01
Filing Date
2022-10-19
Publication Date
2024-11-06

AI Technical Summary

Technical Problem

Current treatments for cancers with deletions of the methylthioadenosine phosphorylase (MTAP) gene, such as MTAP-deficient cancers, lack effective therapeutic agents due to the frequent deficiency of this enzyme, necessitating the development of targeted inhibitors for methionine adenosyltransferase 2A (MAT2A) to address this unmet need.

Method used

Development of compounds, including Formula (I) and Formula (II), which are MAT2A inhibitors, designed to target and inhibit the MAT2A enzyme, potentially providing therapeutic benefits for MTAP-deficient cancers.

Benefits of technology

The compounds effectively inhibit MAT2A, offering a targeted approach to treat cancers like liver cancer, colon cancer, pancreatic cancer, prostate cancer, lung cancer, breast cancer, and T-cell leukemia by selectively targeting MAT2A, thereby addressing the lack of effective treatments for MTAP-deficient cancers.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024540935000001
    Figure 2024540935000001
  • Figure 2024540935000002
    Figure 2024540935000002
  • Figure 2024540935000003
    Figure 2024540935000003
Patent Text Reader

Abstract

Described herein are MAT2A inhibitors and pharmaceutical compositions comprising the MAT2A inhibitors. The subject compounds and compositions are useful for treating diseases or disorders associated with MAT2A.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] cross reference This patent application claims the benefit of international application PCT / CN2021 / 125035, filed October 20, 2021, and international application PCT / CN2022 / 116510, filed September 1, 2022, which are incorporated herein by reference in their entireties. [Background technology]

[0002] Methionine adenosyltransferase 2a (MAT2A) plays an important role in metabolism and epigenetics. Despite its broad role in cells, inhibition of MAT2A has been shown to have selective antiproliferative effects in cancers with deletions of a separate metabolic gene, methylthioadenosine phosphorylase (MTAP). MTAP deficiency frequently occurs in both solid and hematological tumors. Therefore, compounds that inhibit MAT2A are potential agents for treating MTAP-deficient cancers. Summary of the Invention

[0003] Formula (I) or Formula (II)

[0004] [ka] or a pharmaceutically acceptable salt or solvate thereof, During the ceremony,

[0005] [ka] is C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-10 heteroaryl; Z 1 is CR 7 or N, Z2 is CR 9 or N, Z 3 is CR 6 or N, Z 4 is CR 6a or N, X is -N(R 4 )-, -O-, and -C(R 5 )(R 5a )-selected from Y is -N(R 4a )-, -O-, and -C(R 5 )(R 5a )-selected from R 1 is hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), -Si(C 1-6 alkyl)3, and -P(O)(R 10 )2, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is R 15a and optionally substituted with one, two, or three groups selected from R 1a and R 1b are independently hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is R 15aand optionally substituted with one, two, or three groups selected from Each R 2 and each R 3 are each independently hydrogen, halogen, oxo, or C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), -Si(C 1-6 alkyl)3, and -P(O)(R 10 )2, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is R 15b or R 2 and R 3 together with the carbon to which they are attached, C 3-6 Cycloalkyl or C 2-9 forming a heterocycloalkyl, R 4 is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is substituted with halogen, -CN, hydroxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9heteroaryl, or R 4 and R 3 can be combined to form halogens, -CN, hydroxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 C optionally substituted with one, two, or three groups selected from heteroaryl 2-9 forming a heterocycloalkyl, R 4a is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is substituted with halogen, -CN, hydroxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, or R 4a and R 3 can be combined to form halogens, -CN, hydroxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 C optionally substituted with one, two, or three groups selected from heteroaryl 2-9 forming a heterocycloalkyl, R 5 and R 5a are independently hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), -Si(C 1-6 alkyl)3, and -P(O)(R 10 )2, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is substituted with halogen, -CN, hydroxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, or R 5 and R 3 are combined to form C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, or C 2-9 Form a heteroaryl, where C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is substituted with halogen, -CN, hydroxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9optionally substituted with one, two, or three groups selected from heteroaryl; R 6 , R 7 , R 8 , and R 9 are independently hydrogen, halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), -Si(C 1-6 alkyl)3, -P(O)(R 10 )2, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is R 15c and optionally substituted with one, two, or three groups selected from R 6a is hydrogen, halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), -Si(C 1-6 alkyl)3, and -P(O)(R 10 )2, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, and C 1-9 Heteroaryl is R 15c and optionally substituted with one, two, or three groups selected from Each R 10 are independently hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9Heteroaryl is substituted with halogen, -CN, hydroxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 optionally substituted with one, two, or three groups selected from heteroaryl; Each R 11 are independently hydrogen, C 1-6 Alkyl, and C 1-6 haloalkyl, or R 10 and R 11 together with the nitrogen to which they are attached, C 2-9 forming a heterocycloalkyl, Each R 12 are independently hydrogen, C 1-6 Alkyl, and C 1-6 haloalkyl; Each R 13 independently, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is substituted with halogen, -CN, hydroxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9optionally substituted with one, two, or three groups selected from heteroaryl; Each R 14 are independently halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13, -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), -Si(C 1-6 alkyl)3, and -P(O)(R 10 )2, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is R 15d and optionally substituted with one, two, or three groups selected from Each R 15a , R 15b , R 15c , and R 15d are each independently halogen, oxo, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, -CH2-C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Aryl, -CH2-C 6-10 Aryl, C 1-9 Heteroaryl, -CH2-C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), -Si(C 1-6 alkyl)3, and -P(O)(R 10 )2, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, -CH2-C 3-10 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Aryl, -CH2-C 6-10 Aryl, -CH2-C 1-9 Heteroaryl, and C 1-9 Heteroaryl is a group containing halogen, oxo, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), and -P(O)(R 10 Optionally substituted with 1, 2, or 3 groups independently selected from m is 0, 1, 2, 3, 4, or 5; n is 0, 1, 2, 3, 4, 5, or 6.

[0006] Some embodiments are of formula (I)

[0007] [ka] or a pharmaceutically acceptable salt or solvate thereof.

[0008] Some embodiments include Z 3 is CR 6 or a pharmaceutically acceptable salt or solvate thereof. Some embodiments are compounds of formula (I) wherein R 6 But hydrogen, halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , and -N(R 10 )(R 11 ) or a pharmaceutically acceptable salt or solvate thereof. Some embodiments are compounds of formula (I) selected from R 6 But hydrogen and -OR 10 Selected from R 10 C 1-6

[0023] Some embodiments are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R is alkyl. 6 is hydrogen, or a pharmaceutically acceptable salt or solvate thereof. 3 is N. Some embodiments are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein X is —N(R 4 )-, or a pharmaceutically acceptable salt or solvate thereof. Some embodiments are compounds of formula (I) wherein R 4 is hydrogen or C 1-6

[0023] Some embodiments are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R is alkyl. 4 is hydrogen, or a pharmaceutically acceptable salt or solvate thereof.

[0009] Some embodiments are where X is —N(R 4 )- and R 4 and R 3By combining, halogen, -CN, hydroxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 C optionally substituted with one, two, or three groups selected from heteroaryl 2-9 In some embodiments, the compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof forms a heterocycloalkyl.

[0010] [ka] or a pharmaceutically acceptable salt or solvate thereof. Some embodiments are compounds having the structure: 4 is CR 6a or a pharmaceutically acceptable salt or solvate thereof. Some embodiments are compounds of formula (II) wherein R 6a But hydrogen, halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , and -N(R 10 )(R 11 ) or a pharmaceutically acceptable salt or solvate thereof. Some embodiments are compounds of formula (II) selected from R 6a But hydrogen and -OR 10 Selected from R 10 C 1-6 Some embodiments are compounds of formula (II), or a pharmaceutically acceptable salt or solvate thereof, wherein R is alkyl. 6a is hydrogen, or a pharmaceutically acceptable salt or solvate thereof. 4 is N, or a pharmaceutically acceptable salt or solvate thereof.

[0011] Some embodiments include Z4 is CR 6a or a pharmaceutically acceptable salt or solvate thereof. Some embodiments are compounds of formula (II) wherein R 6a But hydrogen, halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , and -N(R 10 )(R 11 ) or a pharmaceutically acceptable salt or solvate thereof. Some embodiments are compounds of formula (II) selected from R 6a But hydrogen and -OR 10 Selected from R 10 is C 1-6 Some embodiments are compounds of formula (II), or a pharmaceutically acceptable salt or solvate thereof, wherein R is alkyl. 6a is hydrogen, or a pharmaceutically acceptable salt or solvate thereof. 4 is N. Some embodiments are compounds of formula (II), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1a and R 1b independently, R 15a and C optionally substituted with one, two, or three groups selected from 1-6 In some embodiments, R is selected from the group consisting of alkyl, aryl ... 1a and R 1b are independently hydrogen and unsubstituted C 1-6 In some embodiments, R is selected from the group consisting of alkyl, aryl ... 1a and R 1b is hydrogen. Some embodiments are compounds of formula (II), or a pharmaceutically acceptable salt or solvate thereof, wherein Y is —N(R 4a )-, or a pharmaceutically acceptable salt or solvate thereof. Some embodiments are compounds of formula (II) 4a is hydrogen or C 1-6Some embodiments are compounds of formula (II), or a pharmaceutically acceptable salt or solvate thereof, wherein R is alkyl. 4a is hydrogen, or a pharmaceutically acceptable salt or solvate thereof.

[0012] Some embodiments provide that each R 2 are independently hydrogen and C 1-6 In some embodiments, each R is selected from the group consisting of alkyl, aryl ... 2 is hydrogen. Some embodiments are compounds of Formula (I), (Ib), or (II), or a pharmaceutically acceptable salt or solvate thereof, wherein each R 3 are independently hydrogen and C 1-6 In some embodiments, each R is selected from the group consisting of alkyl, aryl ... 3 is hydrogen. Some embodiments are compounds of formula (I), (Ib), or (II), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 and R 3 However, together with the carbon to which they are bonded, C 3-6 Some embodiments are compounds of Formula (I), (Ib), or (II), or pharmaceutically acceptable salts or solvates thereof, where n is 1, 2, or 3. Some embodiments are compounds of Formula (I) or (II), or pharmaceutically acceptable salts or solvates thereof, where n is 1. Some embodiments are compounds of Formula (I) or (II), or pharmaceutically acceptable salts or solvates thereof, where n is 1. Some embodiments are compounds of Formula (I) or (II), or pharmaceutically acceptable salts or solvates thereof, where Z 1 is CR 7 Some embodiments are compounds of formula (I) or (II), or a pharmaceutically acceptable salt or solvate thereof, wherein R 7 But hydrogen, halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10, or -N(R 10 )(R 11 ) or a pharmaceutically acceptable salt or solvate thereof. Some embodiments are compounds of formula (I) or (II) wherein R 7 But hydrogen, halogens, C 1-6 Alkyl, or C 1-6 haloalkyl. 7 is hydrogen. 1 is N. Some embodiments are compounds of formula (I) or (II), or a pharmaceutically acceptable salt or solvate thereof, wherein Z 2 is CR 9 Some embodiments are compounds of formula (I) or (II), or a pharmaceutically acceptable salt or solvate thereof, wherein R 9 But hydrogen, halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , or -N(R 10 )(R 11 ) or a pharmaceutically acceptable salt or solvate thereof. Some embodiments are compounds of formula (I) or (II) wherein R 9 But hydrogen, halogens, C 1-6 Alkyl, or C 1-6 haloalkyl. 9 is hydrogen. 2 is N, or a pharmaceutically acceptable salt or solvate thereof.

[0013] Some embodiments are of formula (Ia)

[0014] [ka] or a pharmaceutically acceptable salt or solvate thereof.

[0015] Some embodiments are of formula (Ib)

[0016] [ka] or a pharmaceutically acceptable salt or solvate thereof.

[0017] Some embodiments are represented by formula (IIa):

[0018] [ka] or a pharmaceutically acceptable salt or solvate thereof.

[0019] Some embodiments include:

[0020] [ka] C 1-10 A compound of Formula (I), (Ia), (II), or (IIa), or a pharmaceutically acceptable salt or solvate thereof, wherein: Some embodiments include:

[0021] [ka] is selected from pyridyl, pyrimidyl, pyrazinyl, and pyridazinyl 1-10 A compound of Formula (I), (Ia), (II), or (IIa), or a pharmaceutically acceptable salt or solvate thereof, wherein: Some embodiments include:

[0022] [ka] is pyridyl, or a pharmaceutically acceptable salt or solvate thereof. Some embodiments include:

[0023] [ka] is phenyl. 14 are independently halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , and -N(R 10 )(R 11 In some embodiments, each R is selected from the group consisting of: 14 are independently halogen and C 1-6 In some embodiments, each R is selected from the group consisting of alkyl, aryl, methyl ... 14 is independently selected from halogen. Some embodiments are compounds of Formula (I), (Ia), (II), or (IIa), or a pharmaceutically acceptable salt or solvate thereof, where m is 1. Some embodiments are compounds of Formula (I), (Ia), (II), or (IIa), or a pharmaceutically acceptable salt or solvate thereof, where m is 0. Some embodiments are compounds of Formula (I), (Ia), (II), or (IIa), or a pharmaceutically acceptable salt or solvate thereof, where R 8 But hydrogen, halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10, or C 3-6 cycloalkyl. Some embodiments are compounds of Formula (I), (Ia), (II), or (IIa), or a pharmaceutically acceptable salt or solvate thereof, wherein R 8 is hydrogen, halogen, or C 1-6 haloalkyl. 8 is a halogen. 1 But hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, and C 1-9 heteroaryl; C 1-6 Alkyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, and C 1-9 Heteroaryl is R 15a Some embodiments are compounds of formula (I), (Ia), (II), or (IIa), or a pharmaceutically acceptable salt or solvate thereof, optionally substituted with one, two, or three groups selected from R 1 is hydrogen and unsubstituted C 3-6 cycloalkyl. Some embodiments are compounds of Formula (I), (Ia), (II), or (IIa), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is unsubstituted C 3-6 cycloalkyl. Some embodiments are compounds of Formula (I), (Ia), (II), or (IIa), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is unsubstituted cyclopropyl. 1is hydrogen, or a pharmaceutically acceptable salt or solvate thereof.

[0024] Some embodiments are pharmaceutical compositions comprising a compound of Formula (I), (Ia), (II), or (IIa), or a pharmaceutically acceptable salt or solvate thereof, and at least one pharmaceutically acceptable excipient.

[0025] Some embodiments are methods of treating cancer in a mammal in need thereof, the method comprising administering to the mammal a compound of Formula (I), (Ia), (II), or (IIa), or a pharmaceutically acceptable salt or solvate thereof. Some embodiments are methods of treating cancer in a mammal in need thereof, the method comprising administering to the mammal a compound of Formula (I), (Ia), (II), or (IIa), or a pharmaceutically acceptable salt or solvate thereof, wherein the cancer is an MTAP-deficient cancer. Some embodiments are methods of treating cancer in a mammal in need thereof, the method comprising administering to the mammal a compound of Formula (I), (Ia), (II), or (IIa), or a pharmaceutically acceptable salt or solvate thereof, wherein the cancer is selected from liver cancer, colon cancer, pancreatic cancer, prostate cancer, lung cancer, breast cancer, and T-cell leukemia.

[0026] Incorporation by Reference All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. DETAILED DESCRIPTION OF THE INVENTION

[0027] definition In the following description, certain details are set forth to provide a thorough understanding of various embodiments. However, it will be understood by those skilled in the art that the present invention may be practiced without these details. In other instances, well-known structures have not been shown or described in detail to avoid unnecessarily obscuring the description of the embodiments. Unless the context otherwise requires, throughout the following specification and claims, the word "comprise" and variations thereof (e.g., "comprises" or "comprising") are intended to be interpreted in an open and inclusive sense, i.e., "including, but not limited to." Additionally, the headings provided herein are for convenience only and do not interpret the scope or meaning of the subject invention.

[0028] Throughout this specification, references to "some embodiments" or "embodiments" referring to a particular feature, structure, or characteristic are described in connection with an embodiment and are included in at least one embodiment. Thus, appearances of the phrases ("in one embodiment") or ("in an embodiment") throughout this specification are not necessarily all referring to the same embodiment. Furthermore, particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments. Similarly, as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the content clearly dictates otherwise. It should also be noted that the term "or" is generally used in its sense to include "and / or" unless the content clearly dictates otherwise.

[0029] As used herein, the following terms have the following meanings unless otherwise indicated.

[0030] "Oxo" means =O.

[0031] "Carboxyl" means --COOH.

[0032] "Cyano" means --CN.

[0033] "Alkyl" means a straight or branched chain saturated hydrocarbon monoradical having 1 to about 10 carbon atoms, more preferably 1 to 6 carbon atoms. Examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3-methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, neopentyl, tert-amyl, and hexyl, as well as longer alkyl groups such as heptyl, octyl, and the like. As used herein, the terms "C1-C6 alkyl" or "C 1-6 Whenever a numerical range appears, such as "alkyl," it means that the alkyl group can consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, or 6 carbon atoms, although this definition also encompasses occurrences of the term "alkyl" without a numerical range specified. In some embodiments, alkyl is a C1- 10In some embodiments, the alkyl is an alkyl. In some embodiments, the alkyl is a C alkyl. In some embodiments, the alkyl is a C alkyl. In some embodiments, the alkyl is a C alkyl. In some embodiments, the alkyl is a C alkyl. Unless stated otherwise specifically in the specification, an alkyl group can be optionally substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylic acid, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, the alkyl is optionally substituted with oxo, halogen, —CN, —COOH, —COOMe, —OH, —OMe, —NH, or —NO. In some embodiments, the alkyl is optionally substituted with halogen, —CN, —OH, or —OMe. In some embodiments, the alkyl is optionally substituted with halogen.

[0034] "Alkenyl" means a straight or branched chain hydrocarbon monoradical having one or more carbon-carbon double bonds and having from 2 to about 10 carbon atoms, more preferably from 2 to about 6 carbon atoms. The group may be in either the cis or trans configuration about the double bond and should be understood to include both isomers. Examples include, but are not limited to, ethynyl (-CH=CH), 1-propenyl (-CHCH=CH, isopropenyl [-C(CH)=CH], butenyl, 1,3-butadienyl, and the like. As used herein, the terms "C-C alkenyl" or "C 2-6Whenever a numerical range appears, such as "alkenyl," it means that the alkenyl group can consist of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, or 6 carbon atoms, although this definition also encompasses occurrences of the term "alkenyl" without a numerical range specified. Unless stated otherwise specifically in the specification, an alkenyl group may be optionally substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, an alkenyl is optionally substituted with oxo, halogen, -CN, -COOH, -COOMe, -OH, -OMe, -NH, or -NO. In some embodiments, an alkenyl is optionally substituted with -CN, -OH, or -OMe. In some embodiments, an alkenyl is optionally substituted with halogen.

[0035] "Alkynyl" refers to a straight or branched chain hydrocarbon monoradical having one or more carbon-carbon triple bonds and having from 2 to about 10 carbon atoms, more preferably from 2 to about 6 carbon atoms. Examples include, but are not limited to, ethynyl, 2-propynyl, 2-butenyl, 1,3-butadiynyl, and the like. As used herein, the terms "C2-C6 alkynyl" or "C 2-6Whenever a numerical range appears, such as "alkynyl," it means that the alkynyl group can consist of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, or 6 carbon atoms, although this definition also encompasses occurrences of the term "alkynyl" without a numerical range specified. Unless stated otherwise specifically in the specification, an alkynyl group can be optionally substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, an alkynyl can be substituted with oxo, halogen, -CN, -COOH, COOMe, -OH, -OMe, -NH, or -NO. In some embodiments, an alkynyl can be substituted with halogen, -CN, -OH, or -OMe. In some embodiments, an alkynyl is optionally substituted with halogen.

[0036] "Alkylene" means a straight or branched divalent hydrocarbon chain. Unless stated otherwise specifically in the specification, an alkylene group may be optionally substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, an alkylene may be substituted with oxo, halogen, -CN, -COOH, COOMe, -OH, -OMe, -NH2, or -NO2. In some embodiments, an alkylene may be substituted with halogen, -CN, -OH, or -OMe. In some embodiments, an alkylene is optionally substituted with halogen.

[0037] "Alkoxy" means a group of the formula -OR a (In the formula, R ais an alkyl group as defined above. Unless stated otherwise specifically in the specification, an alkoxy group can be optionally substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, an alkoxy can be substituted with halogen, —CN, —COOH, COOMe, —OH, —OMe, —NH, or —NO. In some embodiments, an alkoxy can be substituted with halogen, —CN, —OH, or —OMe. In some embodiments, an alkoxy is optionally substituted with halogen.

[0038] "Aryl" refers to a radical derived from a hydrocarbon ring system containing 6 to 30 carbon atoms and at least one aromatic ring. Aryl radicals may be monocyclic, bicyclic, tricyclic, or tetracyclic ring systems and may include fused (when fused to a cycloalkyl or heterocycloalkyl ring, the aryl is attached through an aromatic ring atom) or bridged ring systems. In some embodiments, an aryl is a 6-membered to 10-membered aryl. In some embodiments, an aryl is a 6-membered aryl (phenyl). Aryl radicals include, but are not limited to, aryl radicals derived from anthrylene, naphthylene, phenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, as-indacene, s-indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene hydrocarbon ring systems. Unless stated otherwise specifically in the specification, an aryl may be optionally substituted with, for example, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, an aryl may be substituted with halogen, methyl, ethyl, -CN, -COOH, COOMe, -CF, -OH, -OMe, -NH, or -NO. In some embodiments, an aryl may be substituted with halogen, methyl, ethyl, -CN, -CF, -OH, or -OMe. In some embodiments, an aryl may be substituted with halogen.

[0039] "Cycloalkyl" refers to a partially or fully saturated monocyclic or polycyclic carbocyclic ring which can include fused (when fused to an aryl or heteroaryl ring, the cycloalkyl is attached through a non-aromatic ring atom), spirocyclic, or bridged ring systems. In some embodiments, a cycloalkyl is fully saturated. Representative cycloalkyls include, but are not limited to, cycloalkyls having 3 to 15 carbon atoms (C3-C4). 15 Fully saturated cycloalkyl or C3-C 15cycloalkenyl), 3 to 10 carbon atoms (C3-C 10 Fully saturated cycloalkyl or C3-C 10Examples of cycloalkyl include cycloalkyls having 3 to 8 carbon atoms (C-C fully saturated cycloalkyl or C-C cycloalkenyl), cycloalkyls having 3 to 6 carbon atoms (C-C fully saturated cycloalkyl or C-C cycloalkenyl), cycloalkyls having 3 to 5 carbon atoms (C-C fully saturated cycloalkyl or C-C cycloalkenyl), or cycloalkyls having 3 to 4 carbon atoms (C-C fully saturated cycloalkyl or C-C cycloalkenyl). In some embodiments, cycloalkyls are 3- to 10-membered fully saturated cycloalkyls or 3- to 10-membered cycloalkenyls. In some embodiments, cycloalkyls are 3- to 6-membered fully saturated cycloalkyls or 3- to 6-membered cycloalkenyls. In some embodiments, cycloalkyls are 5- to 6-membered fully saturated cycloalkyls or 5- to 6-membered cycloalkenyls. Monocyclic cycloalkyls include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic cycloalkyls include, for example, adamantyl, norbornyl, decalinyl, bicyclo[3.3.0]octane, bicyclo[4.3.0]nonane, cis-decalin, trans-decalin, bicyclo[2.1.1]hexane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, and bicyclo[3.3.2]decane and 7,7-dimethyl-bicyclo[2.2.1]heptanyl. Partially saturated cycloalkyls include, for example, cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl. Unless stated otherwise specifically in the specification, cycloalkyls are optionally substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, cycloalkyls can be substituted with oxo, halogen, methyl, ethyl, —CN, —COOH, COOMe, —CF, —OH, —OMe, —NH, or —NO.In some embodiments, cycloalkyl may be substituted with oxo, halogen, methyl, ethyl, -CN, -CF, -OH, or -OMe. In some embodiments, cycloalkyl is optionally substituted with halogen.

[0040] "Halo" or "halogen" means bromo, chloro, fluoro, or iodo. In some embodiments, halogen is fluoro or chloro. In some embodiments, halogen is fluoro.

[0041] "Haloalkyl" means an alkyl group as defined above that is substituted with one or more halo radicals as defined above, for example, trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, and the like.

[0042] "Hydroxyalkyl" refers to an alkyl group, as defined above, substituted with one or more hydroxyl groups. In some embodiments, the alkyl is substituted with one hydroxyl group. In some embodiments, the alkyl is substituted with one, two, or three hydroxyl groups. Hydroxyalkyl includes, for example, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, or hydroxypentyl. In some embodiments, the hydroxyalkyl is hydroxymethyl.

[0043] "Aminoalkyl" refers to an alkyl group, as defined above, substituted with one or more amines. In some embodiments, the alkyl is substituted with one amine. In some embodiments, the alkyl is substituted with one, two, or three amines. Aminoalkyl includes, for example, aminomethyl, aminoethyl, aminopropyl, aminobutyl, or aminopentyl. In some embodiments, the aminoalkyl is aminomethyl.

[0044] "Heteroalkyl" refers to an alkyl group in which one or more skeletal atoms of the alkyl are selected from an atom other than carbon, e.g., oxygen, nitrogen (e.g., -NH-, -N(alkyl)-), sulfur, phosphorus, or a combination thereof. The heteroalkyl is attached to the remainder of the molecule at a carbon atom of the heteroalkyl. In one aspect, the heteroalkyl is a C1-C6 heteroalkyl, where the heteroalkyl consists of 1 to 6 carbon atoms and one or more atoms other than carbon, e.g., oxygen, nitrogen (e.g., -NH-, -N(alkyl)-), sulfur, phosphorus, or a combination thereof, and the heteroalkyl is attached to the remainder of the molecule at a carbon atom of the heteroalkyl. Examples of such heteroalkyls are, for example, -CH2CCH3, -CH2CCH2CH3, -CH(CH3)OCH3, -CH2NHCH3, -CH2N(CH3)2, -CH2CH2NHCH3, or -CH2CH2N(CH3)2. Unless stated otherwise specifically in the specification, heteroalkyl is optionally substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, heteroalkyl may be substituted with oxo, halogen, methyl, ethyl, -CN, -CF, -OH, -OMe, -NH, or -NO. In some embodiments, heteroalkyl may be substituted with oxo, halogen, methyl, ethyl, -CN, -CF, -OH, or -OMe. In some embodiments, heteroalkyl is optionally substituted with halogen.

[0045] "Heterocycloalkyl" refers to a 3- to 24-membered partially or fully saturated ring group containing 2 to 23 carbon atoms and 1 to 8 heteroatoms selected from the group consisting of nitrogen, oxygen, phosphorus, silicon, and sulfur. In some embodiments, a heterocycloalkyl is fully saturated. In some embodiments, a heterocycloalkyl contains 1 to 3 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. In some embodiments, a heterocycloalkyl contains 1 to 3 heteroatoms selected from the group consisting of nitrogen and oxygen. In some embodiments, a heterocycloalkyl contains 1 to 3 nitrogens. In some embodiments, a heterocycloalkyl contains 1 or 2 nitrogens. In some embodiments, a heterocycloalkyl contains 1 nitrogen. In some embodiments, a heterocycloalkyl contains 1 nitrogen and 1 oxygen. Unless otherwise specified in the specification, a heterocycloalkyl radical can be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which can include fused (when fused to an aryl or heteroaryl ring, the heterocycloalkyl is attached through a non-aromatic ring atom), spirocyclic, or bridged ring systems; in addition, the nitrogen, carbon, or sulfur atoms in the heterocycloalkyl radical can be optionally oxidized; and the nitrogen atom can be optionally quaternized. Representative heterocycloalkyls include, but are not limited to, heterocycloalkyls having 2 to 15 carbon atoms (C2-C3). 15 Fully saturated heterocycloalkyl or C2-C 15 heterocycloalkenyl), 2 to 10 carbon atoms (C2-C 10 Fully saturated heterocycloalkyl or C2-C 10heterocycloalkyl having 2 to 8 carbon atoms (C2-C8 fully saturated heterocycloalkyl or C2-C8 heterocycloalkenyl), heterocycloalkyl having 2 to 7 carbon atoms (C2-C7 fully saturated heterocycloalkyl or C2-C7 heterocycloalkenyl), heterocycloalkyl having 2 to 6 carbon atoms (C2-C6 fully saturated heterocycloalkyl or C2-C6 heterocycloalkenyl), 2 to 5 carbon atoms (C2-C5 fully saturated heterocycloalkyl or C2-C5 heterocycloalkenyl), or 2 to 4 carbon atoms (C2-C4 fully saturated heterocycloalkyl or C2-C4 heterocycloalkenyl). Examples of such heterocycloalkyl groups include, but are not limited to, aziridinyl, azetidinyl, oxetanyl, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidinyl, and 4-piperazinyl. Examples of heterocycloalkyl include thiazolidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, 1,3-dihydroisobenzofuran-1-yl, 3-oxo-1,3-dihydroisobenzofuran-1-yl, methyl-2-oxo-1,3-dioxol-4-yl, and 2-oxo-1,3-dioxol-4-yl. The term heterocycloalkyl includes all ring forms of carbohydrates, including, but not limited to, monosaccharides, disaccharides, and oligosaccharides. In some embodiments, heterocycloalkyls have 2 to 10 carbons in the ring. When referring to the number of carbon atoms in a heterocycloalkyl, it is understood that the number of carbon atoms in the heterocycloalkyl is not the same as the total number of atoms (including heteroatoms) that make up the heterocycloalkyl (i.e., the skeletal atoms of the heterocycloalkyl ring).In some embodiments, a heterocycloalkyl is a 3- to 8-membered fully saturated heterocycloalkyl. In some embodiments, a heterocycloalkyl is a 3- to 7-membered fully saturated heterocycloalkyl. In some embodiments, a heterocycloalkyl is a 3- to 6-membered fully saturated heterocycloalkyl. In some embodiments, a heterocycloalkyl is a 4- to 6-membered fully saturated heterocycloalkyl. In some embodiments, a heterocycloalkyl is a 5- to 6-membered fully saturated heterocycloalkyl. In some embodiments, a heterocycloalkyl is a 3- to 8-membered heterocycloalkenyl. In some embodiments, a heterocycloalkyl is a 3- to 7-membered heterocycloalkenyl. In some embodiments, a heterocycloalkyl is a 3- to 6-membered heterocycloalkenyl. In some embodiments, a heterocycloalkyl is a 4- to 6-membered heterocycloalkenyl. In some embodiments, a heterocycloalkyl is a 5- to 6-membered heterocycloalkenyl. Unless stated otherwise specifically in the specification, a heterocycloalkyl may be optionally substituted as described below, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, a heterocycloalkyl may be substituted with oxo, halogen, methyl, ethyl, -CN, -COOH, COOMe, -CF, -OH, -OMe, -NH, or -NO. In some embodiments, a heterocycloalkyl may be substituted with halogen, methyl, ethyl, -CN, -CF, -OH, or -OMe. In some embodiments, a heterocycloalkyl is optionally substituted with halogen.

[0046] "Heteroaryl" refers to a 5- to 14-membered ring system radical containing 1 to 13 carbon atoms, 1 to 6 heteroatoms selected from the group consisting of nitrogen, oxygen, phosphorus, and sulfur, and at least one aromatic ring. In some embodiments, a heteroaryl contains 1 to 3 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. In some embodiments, a heteroaryl contains 1 to 3 heteroatoms selected from the group consisting of nitrogen and oxygen. In some embodiments, a heteroaryl contains 1 to 3 nitrogen atoms. In some embodiments, a heteroaryl contains 1 or 2 nitrogen atoms. In some embodiments, a heteroaryl contains 1 nitrogen atom. A heteroaryl radical can be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which can include fused (when fused to a cycloalkyl or heterocycloalkyl ring, the heteroaryl is attached through an aromatic ring atom) or bridged ring systems; in addition, the nitrogen, carbon, or sulfur atoms in a heteroaryl radical can be optionally oxidized; and the nitrogen atom can be optionally quaternized. In some embodiments, heteroaryl is a 5- to 10-membered heteroaryl. In some embodiments, heteroaryl is a 5- to 6-membered heteroaryl. In some embodiments, heteroaryl is a 6-membered heteroaryl. In some embodiments, heteroaryl is a 5-membered heteroaryl.Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzoindolyl, benzodioxolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furanonyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl, isoxazolyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 1-oxidopyridinyl, 1-oxidopyridinyl Examples of heteroaryl include phenyl, 1-oxidopyrazinyl, 1-oxidopyridazinyl, 1-phenyl-1H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl, isoquinolinyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetraazolyl, triazinyl, and thiophenyl (i.e., thienyl). Unless otherwise specified in the specification, heteroaryl can be optionally substituted with, for example, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, heteroaryl may be substituted with halogen, methyl, ethyl, -CN, -COOH, COOMe, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, heteroaryl may be substituted with halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe.In some embodiments, the heteroaryl is optionally substituted with halogen.

[0047] The terms "optional" or "optionally" mean that the described event or circumstance may or may not occur, and that the description includes both cases where the event or circumstance occurs and cases where it does not occur. For example, "optionally substituted alkyl" means either "alkyl" or "substituted alkyl" as defined above. Furthermore, optionally substituted groups can be unsubstituted (e.g., -CHCH), fully substituted (e.g., -CFCF), monosubstituted (e.g., -CHCHF), or substituted at any level between fully and monosubstituted (e.g., -CHCHF, -CHCF, -CFCH, -CFHCHF, etc.). Those skilled in the art will understand that with respect to any group containing one or more substituents, such groups are not intended to introduce any substitution or substitution pattern that is sterically impractical and / or synthetically infeasible. Accordingly, any substituents described should generally be understood as having a maximum molecular weight of about 1,000 daltons, more typically up to about 500 daltons.

[0048] An "effective amount" or "therapeutically effective amount" refers to the amount of a compound administered to a mammalian subject, either in a single dose or as part of a series, effective to produce the desired therapeutic effect.

[0049] "Treatment" of an individual (e.g., a mammal such as a human) or cell is any type of intervention used in an attempt to alter the natural course of the individual or cell. In some embodiments, treatment includes administration of a pharmaceutical composition after initiation of a pathological event or contact with a pathogenic agent, and stabilization of disease (e.g., no worsening of the disease) or remission of the disease.

[0050] compound The present invention provides compounds of formula (I), (Ia), (II), and (IIa), or pharmaceutically acceptable salts or solvates thereof, which are useful in treating diseases or disorders associated with MAT2A inhibition. In some embodiments, the compounds of formula (I), (Ia), (II), and (IIa), or pharmaceutically acceptable salts or solvates thereof, are useful in treating cancer. In some embodiments, the cancer is selected from liver cancer, colon cancer, pancreatic cancer, prostate cancer, lung cancer, breast cancer, and T-cell leukemia.

[0051] In some embodiments, Formula (I)

[0052] [ka] or a pharmaceutically acceptable salt or solvate thereof, During the ceremony,

[0053] [ka] is C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-10 heteroaryl; Z 1 is CR 7 or N, Z 2 is CR 9 or N, Z 3 is CR 6 or N, X is -N(R 4 )-, -O-, and -C(R 5 )(R 5a )-selected from R 1 is hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), -Si(C 1-6 alkyl)3, and -P(O)(R 10 )2, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is R 15a and optionally substituted with one, two, or three groups selected from Each R 2 and each R 3 are each independently hydrogen, halogen, oxo, or C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), -Si(C 1-6 alkyl)3, and -P(O)(R 10 )2, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is R 15b or R 2 and R 3 together with the carbon to which they are attached, C 3-6 Cycloalkyl or C 2-9 forming a heterocycloalkyl, R 4 is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is substituted with halogen, -CN, hydroxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, or R 4 and R 3 can be combined to form halogens, -CN, hydroxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 C optionally substituted with one, two, or three groups selected from heteroaryl 2-9 forming a heterocycloalkyl, R 5 and R 5a are independently hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), -Si(C 1-6 alkyl)3, and -P(O)(R 10 )2, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is substituted with halogen, -CN, hydroxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, or R 5 and R 3 are combined to form C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, or C 2-9 Form a heteroaryl, where C 3-6Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is substituted with halogen, -CN, hydroxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 optionally substituted with one, two, or three groups selected from heteroaryl; R 6 , R 7 , R 8 , and R 9 are independently hydrogen, halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13, -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), -Si(C 1-6 alkyl)3, -P(O)(R 10 )2, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is R 15c and optionally substituted with one, two, or three groups selected from Each R 10 are independently hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is substituted with halogen, -CN, hydroxy, C 1-6Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 optionally substituted with one, two, or three groups selected from heteroaryl; Each R 11 are independently hydrogen, C 1-6 Alkyl, and C 1-6 haloalkyl, or R 10 and R 11 together with the nitrogen to which they are attached, C 2-9 forming a heterocycloalkyl, Each R 12 are independently hydrogen, C 1-6 Alkyl, and C 1-6 haloalkyl; Each R 13 independently, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is substituted with halogen, -CN, hydroxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 optionally substituted with one, two, or three groups selected from heteroaryl; Each R 14are independently halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), -Si(C1-6 alkyl)3, and -P(O)(R 10 )2, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is R 15d and optionally substituted with one, two, or three groups selected from Each R 15a , R 15b , R 15c , and R 15d are each independently halogen, oxo, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, -CH2-C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Aryl, -CH2-C 6-10 Aryl, C 1-9 Heteroaryl, -CH2-C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), -Si(C 1-6 alkyl)3, and -P(O)(R 10 )2, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, -CH2-C 3-10 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Aryl, -CH2-C 6-10 Aryl, -CH2-C 1-9 Heteroaryl, and C 1-9 Heteroaryl is a group containing halogen, oxo, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), and -P(O)(R 10 Optionally substituted with 1, 2, or 3 groups independently selected from m is 0, 1, 2, 3, 4, or 5; n is 0, 1, 2, 3, 4, 5, or 6.

[0054] In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, X is —N(R 4 In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, X is —N(R 4 )- and R 4 is hydrogen, C 1-6 Alkyl, C1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is substituted with halogen, -CN, hydroxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, X is optionally substituted with one, two, or three groups selected from -N(R 4 )- and R 4 is hydrogen or C 1-6 In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, X is —N(R 4 )- and R 4 is hydrogen. In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, X is —N(R 4 )- and R 4 is C 1-6 In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, X is —N(R 4 )- and R 4 In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, X is —N(R 4 )- and R 4 and R3 can be combined to form halogens, -CN, hydroxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 C optionally substituted with one, two, or three groups selected from heteroaryl 2-9 In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, X is —N(R 4 )- and R 4 and R 3 By combining, halogen, hydroxy, C 1-6 Alkyl, C 1-6 Haloalkyl, and C 1-6 C optionally substituted with one, two, or three groups selected from alkoxy 2-9 In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, X is —N(R 4 )- and R 4 and R 3 By combining, halogen, hydroxy, C 1-6 Alkyl, C 1-6 Haloalkyl, and C 1-6 In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, X is -N(R 4 )- and R 4 and R 3 combine to form an unsubstituted piperidinyl, piperazinyl, pyrrolidinyl, or azetidinyl ring.

[0055] In some embodiments of the compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, X is —O—.

[0056] In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, X is —C(R 5 )(R 5a In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, X is —C(R 5 )(R 5a )- and R 5 and R 5a are independently hydrogen and C 1-6 In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, X is selected from -C(R 5 )(R 5a )- and R 5 and R 5a is hydrogen. In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, X is —C(R 5 )(R 5a )- and R 5 and R 5a is C 1-6 In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, X is —C(R 5 )(R 5a )- and R 5 is hydrogen and R 5a is C 1-6 It is alkyl.

[0057] In some embodiments of the compound of Formula (I) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, each R 2 are independently hydrogen and C 1-6 In some embodiments of a compound of Formula (I) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, each R 2is hydrogen. In some embodiments of a compound of Formula (I) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, each R 3 are independently hydrogen and C 1-6 In some embodiments of a compound of Formula (I) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, each R 3 is hydrogen. In some embodiments of a compound of Formula (I) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, each R 2 and R 3 together with the carbon to which they are attached, C 3-6 In some embodiments of a compound of Formula (I) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, each R 2 and R 3 together with the carbons to which they are attached form a cyclopropyl ring. In some embodiments of a compound of Formula (I) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, each R 2 and R 3 together with the carbons to which they are attached form a cyclobutyl ring. In some embodiments of a compound of Formula (I) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, each R 2 and R 3 together with the carbons to which they are attached form a cyclopentyl ring. In some embodiments of a compound of Formula (I) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, each R 2 and R 3 together with the carbons to which they are attached form a cyclohexyl ring.

[0058] In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, n is 1, 2, or 3. In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, n is 1. In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, n is 2. In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, n is 3. In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, n is 4. In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, n is 5. In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, n is 6.

[0059] In some embodiments of the compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, Z 1 is CR 7 In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, Z 1 is CR 7 and R 7 is hydrogen, halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , or -N(R 10 )(R 11 In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, Z 1 is CR 7 and R 7 is hydrogen, halogen, C 1-6 Alkyl, or C 1-6 In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, Z is haloalkyl. 1 is CR 7 and R 7 is hydrogen.

[0060] In some embodiments of the compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, Z 1 is N.

[0061] In some embodiments of the compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, Z 2 is CR 9 In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, Z 2 is CR 9 and R 9 is hydrogen, halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , or -N(R 10 )(R 11 In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, Z 2 is CR 9 and R 9 is hydrogen, halogen, C 1-6 Alkyl, or C 1-6 In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, Z is haloalkyl. 2 is CR 9 and R 9 is hydrogen.

[0062] In some embodiments of the compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, Z 2 is N.

[0063] In some embodiments of the compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, Z 3 is CR 6 In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, Z 3 is CR 6 and R 6 is halogen, -CN, C 1-6 Alkyl, C 1-6Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), -Si(C 1-6 alkyl)3, and -P(O)(R 10)2, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is R 15c and optionally substituted with one, two, or three groups selected from:

[0064] In some embodiments of the compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, Z 3 is CR 6 and R 6 is hydrogen, halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , and -N(R 10 )(R 11 In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, Z 3 is CR 6 and R 6 is hydrogen and -OR 10 Selected from R 10 is C 1-6 In some embodiments of the compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, Z is alkyl. 3 is CR 6 and R 6 is hydrogen.

[0065] In some embodiments of the compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, Z 3 is N.

[0066] In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof,

[0067] [ka] is C 1-10 In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof,

[0068] [ka] is selected from pyridyl, pyrimidyl, pyrazinyl, and pyridazinyl 1-10 In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof,

[0069] [ka] is a 5- or 6-membered heteroaryl. In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof,

[0070] [ka] is a 5-membered heteroaryl. In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof,

[0071] [ka] is a 6-membered heteroaryl. In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof,

[0072] [ka] is pyridyl. In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof,

[0073] [ka] is pyrimidyl. In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof,

[0074] [ka] is pyrazinyl. In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof,

[0075] [ka] is pyridazinyl.

[0076] In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof,

[0077] [ka] is C 6-10 In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof,

[0078] [ka] is phenyl.

[0079] In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof,

[0080] [ka] is C 2-9 It is heterocycloalkyl.

[0081] In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof,

[0082] [ka] is C 3-6 It is cycloalkyl.

[0083] In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, each R 14 are independently halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , and -N(R 10 )(R 11 In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, each R 14 are independently halogens and C 1-6 In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, each R 14 is independently selected from halogen. In some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, each R 14 independently, C 1-6 alkyl.

[0084] In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, m is 0, 1, or 2. In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, m is 0 or 1. In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, m is 0. In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, m is 1. In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, m is 2. In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, m is 3.

[0085] In some embodiments of the compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, R8 is halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11), -Si(C 1-6 alkyl)3, and -P(O)(R 10 )2, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is R 15c and optionally substituted with one, two, or three groups selected from:

[0086] In some embodiments of the compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, R 8 is hydrogen, halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , or C 3-6 In some embodiments of the compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, R 8 is hydrogen, halogen, or C 1-6 In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, R 8 is hydrogen. In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, R 8 is halogen. In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, R 8 is C 1-6 In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, R 8 In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, R 8 is C 1-6 In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, R 8is —CH. In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, R 8 is C 3-6 In some embodiments of the compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, R 8 In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, R 8 is -CN.

[0087] In some embodiments of the compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, R 1 is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, and C 1-9 heteroaryl, wherein C 1-6 Alkyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, and C 1-9 Heteroaryl is R 15a and optionally substituted with one, two, or three groups selected from:

[0088] In some embodiments of the compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, R 1 is hydrogen.

[0089] In some embodiments of the compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, R 1 is R 15a C optionally substituted with one, two, or three groups selected from 1-6 In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, R 1 is C 2-9 Heterocycloalkyl, C 1-9 Heteroaryl, -OR 10 , and -N(R10 )(R 11 C optionally substituted with one, two, or three groups selected from 1-6 In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, R 1 is C 2-9 Heterocycloalkyl, C 1-9 Heteroaryl, -OR 10 , and -N(R 10 )(R 11 ) C substituted with one group selected from 1-6 In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, R 1 is C 2-9 Heterocycloalkyl, C 1-9 Heteroaryl, -OR 10 , and -N(R 10 )(R 11 ) C substituted with one group selected from 1-6 alkyl, and R 10 and R 11 are independently hydrogen and C 1-6 In some embodiments of the compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, R 1 is the unsubstituted C 1-6 It is alkyl.

[0090] In some embodiments of the compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, R 1 is R 15a C optionally substituted with one, two, or three groups selected from 3-6 In some embodiments of the compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, R 1 is C 1-6 Alkyl, -OR 10 , and -N(R 10 )(R 11 ) C substituted with one, two, or three groups selected from 3-6In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, R 1 -OR 10 and -N(R 10 )(R 11 ) C substituted with one group selected from 3-6 is cycloalkyl, and R 10 and R 11 are independently hydrogen and C 1-6 In some embodiments of the compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, R 1 is the unsubstituted C 3-6 In some embodiments of the compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, R 1 is unsubstituted cyclopropyl. In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, R 1 is unsubstituted cyclobutyl.

[0091] In some embodiments of the compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, R 1 is C 1-6 It is haloalkyl.

[0092] In some embodiments of the compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, R 1 is R 15a C optionally substituted with one, two, or three groups selected from 2-9 In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, R 1 is C 1-6 Alkyl, -OR 10 , and -N(R 10 )(R 11 C optionally substituted with one, two, or three groups selected from 2-9In some embodiments of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, R 1 is the unsubstituted C 2-9 It is heterocycloalkyl.

[0093] In some embodiments of the compounds of Formula (I), or pharmaceutically acceptable salts or solvates thereof, R 1 is R 15a C optionally substituted with one, two, or three groups selected from 1-9 In some embodiments of the compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, R 1 is C 1-6 Alkyl, -OR 10 , and -N(R 10 )(R 11 C optionally substituted with one, two, or three groups selected from 1-9 In some embodiments of the compounds of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, R 1 is the unsubstituted C 1-9 It is heteroaryl.

[0094] In some embodiments, Formula (Ia)

[0095] [ka] or a pharmaceutically acceptable salt or solvate thereof, During the ceremony,

[0096] [ka] is C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-10 heteroaryl; R 1 is hydrogen, halogen, C1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), -Si(C 1-6alkyl)3, and -P(O)(R 10 )2, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is R 15a and optionally substituted with one, two, or three groups selected from R 6 and R 8 are independently hydrogen, halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13)2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), -Si(C 1-6 alkyl)3, -P(O)(R 10 )2, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is R 15c and optionally substituted with one, two, or three groups selected from Each R 10 are independently hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is substituted with halogen, -CN, hydroxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 optionally substituted with one, two, or three groups selected from heteroaryl; Each R 11 are independently hydrogen, C 1-6 Alkyl, and C 1-6 haloalkyl, or R 10 and R 11 together with the nitrogen to which they are attached, C 2-9 forming a heterocycloalkyl, Each R 12 are independently hydrogen, C 1-6 Alkyl, and C 1-6 haloalkyl; Each R 13 independently, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is substituted with halogen, -CN, hydroxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 optionally substituted with one, two, or three groups selected from heteroaryl; Each R 14 are independently halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), -Si(C 1-6 alkyl)3, and -P(O)(R 10 )2, where C 1-6Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is R 15d and optionally substituted with one, two, or three groups selected from Each R 15a , R 15c , and R 15d are each independently halogen, oxo, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, -CH2-C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Aryl, -CH2-C 6-10 Aryl, C 1-9 Heteroaryl, -CH2-C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), -Si(C 1-6 alkyl)3, and -P(O)(R 10 )2, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, -CH2-C 3-10 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Aryl, -CH2-C 6-10 Aryl, -CH2-C 1-9 Heteroaryl, and C 1-9 Heteroaryl is a group containing halogen, oxo, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12)S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), and -P(O)(R 10 Optionally substituted with 1, 2, or 3 groups independently selected from m is 0, 1, 2, 3, 4, or 5.

[0097] In some embodiments, Formula (Ia)

[0098] [ka] or a pharmaceutically acceptable salt or solvate thereof, During the ceremony,

[0099] [ka] is C 3-6 Cycloalkyl, C 2-9Heterocycloalkyl, C 6-10 Aryl, and C 1-10 heteroaryl; R 1 is hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), -Si(C 1-6 alkyl)3, and -P(O)(R 10 )2, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is R 15a and optionally substituted with one, two, or three groups selected from R 6 and R 8 are independently hydrogen, halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), -Si(C 1-6 alkyl)3, -P(O)(R 10 )2, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is R 15c and optionally substituted with one, two, or three groups selected from Each R 10 are independently hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9Heteroaryl is substituted with halogen, -CN, hydroxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 optionally substituted with one, two, or three groups selected from heteroaryl; Each R 11 are independently hydrogen, C 1-6 Alkyl, and C 1-6 haloalkyl, or R 10 and R 11 together with the nitrogen to which they are attached, C 2-9 forming a heterocycloalkyl, Each R 12 are independently hydrogen, C 1-6 Alkyl, and C 1-6 haloalkyl; Each R 13 independently, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is substituted with halogen, -CN, hydroxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9optionally substituted with one, two, or three groups selected from heteroaryl; Each R 14 are independently halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13, -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), -Si(C 1-6 alkyl)3, and -P(O)(R 10 )2, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is R 15d and optionally substituted with one, two, or three groups selected from Each R 15a , R 15c , and R 15d are each independently halogen, oxo, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, -CH2-C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Aryl, -CH2-C 6-10 Aryl, C 1-9 Heteroaryl, -CH2-C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), -Si(C 1-6 alkyl)3, and -P(O)(R 10 )2, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, -CH2-C 3-10 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Aryl, -CH2-C 6-10 Aryl, -CH2-C 1-9 Heteroaryl, and C 1-9 Heteroaryl is a group containing halogen, oxo, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), and -P(O)(R 10 Optionally substituted with 1, 2, or 3 groups independently selected from m is 0, 1, 2, 3, 4, or 5.

[0100] In some embodiments, Formula (Ib)

[0101] [ka] or a pharmaceutically acceptable salt or solvate thereof, During the ceremony,

[0102] [ka] is C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-10 heteroaryl; R 1 is hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), -Si(C 1-6 alkyl)3, and -P(O)(R 10 )2, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is R 15a and optionally substituted with one, two, or three groups selected from Each R 2 and each R 3 are each independently hydrogen, halogen, oxo, or C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13, -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), -Si(C 1-6 alkyl)3, and -P(O)(R 10 )2, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is R 15b or R 2 and R 3 together with the carbon to which they are attached, C 3-6 Cycloalkyl or C 2-9 forming a heterocycloalkyl, R 6 and R 8 are independently halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), -Si(C 1-6 alkyl)3, -P(O)(R 10 )2, where C1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is R 15c and optionally substituted with one, two, or three groups selected from Each R 10 are independently hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is substituted with halogen, -CN, hydroxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 optionally substituted with one, two, or three groups selected from heteroaryl; Each R 11 are independently hydrogen, C 1-6 Alkyl, and C 1-6 haloalkyl, or R 10 and R 11 together with the nitrogen to which they are attached, C 2-9 forming a heterocycloalkyl, Each R 12 are independently hydrogen, C 1-6 Alkyl, and C1-6 haloalkyl; Each R 13 independently, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is substituted with halogen, -CN, hydroxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 optionally substituted with one, two, or three groups selected from heteroaryl; Each R 14 are independently halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13, -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), -Si(C 1-6 alkyl)3, and -P(O)(R 10 )2, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is R 15d and optionally substituted with one, two, or three groups selected from Each R 15a , R 15c , and R 15d are each independently halogen, oxo, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10Cycloalkyl, -CH2-C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Aryl, -CH2-C 6-10 Aryl, C 1-9 Heteroaryl, -CH2-C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), -Si(C1-6 alkyl)3, and -P(O)(R 10 )2, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, -CH2-C 3-10 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Aryl, -CH2-C 6-10 Aryl, -CH2-C 1-9 Heteroaryl, and C 1-9 Heteroaryl is a group containing halogen, oxo, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), and -P(O)(R 10 Optionally substituted with 1, 2, or 3 groups independently selected from m is 0, 1, 2, 3, 4, or 5.

[0103] In some embodiments, Formula (Ib)

[0104] [ka] or a pharmaceutically acceptable salt or solvate thereof, During the ceremony,

[0105] [ka] is C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-10 heteroaryl; R 1 is hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), -Si(C 1-6 alkyl)3, and -P(O)(R 10 )2, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is R 15aand optionally substituted with one, two, or three groups selected from Each R 2 and each R 3 are each independently hydrogen, halogen, oxo, or C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), -Si(C 1-6 alkyl)3, and -P(O)(R 10 )2, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is R 15b or R 2 and R 3 together with the carbon to which they are attached, C 3-6 Cycloalkyl or C 2-9 forming a heterocycloalkyl, R 6 and R 8 are independently halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13, -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), -Si(C 1-6 alkyl)3, -P(O)(R 10 )2, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is R 15c and optionally substituted with one, two, or three groups selected from Each R 10 are independently hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is substituted with halogen, -CN, hydroxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 optionally substituted with one, two, or three groups selected from heteroaryl; Each R 11 are independently hydrogen, C 1-6 Alkyl, and C 1-6 haloalkyl, or R 10 and R 11 together with the nitrogen to which they are attached, C 2-9 forming a heterocycloalkyl, Each R 12 are independently hydrogen, C 1-6 Alkyl, and C 1-6 haloalkyl; Each R 13 independently, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is substituted with halogen, -CN, hydroxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 optionally substituted with one, two, or three groups selected from heteroaryl; Each R 14 are independently halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10)(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), -Si(C 1-6 alkyl)3, and -P(O)(R 10 )2, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is R 15d and optionally substituted with one, two, or three groups selected from Each R 15a , R 15c , and R 15d are each independently halogen, oxo, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, -CH2-C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Aryl, -CH2-C 6-10 Aryl, C 1-9 Heteroaryl, -CH2-C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), -Si(C 1-6 alkyl)3, and -P(O)(R 10 )2, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, -CH2-C 3-10 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Aryl, -CH2-C 6-10 Aryl, -CH2-C 1-9 Heteroaryl, and C 1-9 Heteroaryl is a group containing halogen, oxo, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 10 , -SR 10 , -SF5, -N(R10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), and -P(O)(R 10 Optionally substituted with 1, 2, or 3 groups independently selected from m is 0, 1, 2, 3, 4, or 5.

[0106] In some embodiments of the compounds of Formula (Ia) or (Ib), or pharmaceutically acceptable salts or solvates thereof, R 6 and R 8are independently halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -OR 10 , and -N(R 10 )(R 11 ), where C 1-6 Alkyl, C 3-6 Cycloalkyl, and C 2-9 Heterocycloalkyl is R 15c and optionally substituted with one, two, or three groups selected from:

[0107] In some embodiments of the compounds of Formula (Ia) or (Ib), or pharmaceutically acceptable salts or solvates thereof, R 6 is hydrogen, halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , and -N(R 10 )(R 11 In some embodiments of the compound of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, R 6 is hydrogen and -OR 10 Selected from R 10 is C 1-6 In some embodiments of the compounds of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, R 6 is hydrogen.

[0108] In some embodiments of the compound of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof,

[0109] [ka] is C 1-10 In some embodiments of the compound of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof,

[0110] [ka] is selected from pyridyl, pyrimidyl, pyrazinyl, and pyridazinyl 1-10 In some embodiments of the compound of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof,

[0111] [ka] is a 5- or 6-membered heteroaryl. In some embodiments of the compound of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof,

[0112] [ka] is a 5-membered heteroaryl. In some embodiments of the compound of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof,

[0113] [ka] is a 6-membered heteroaryl. In some embodiments of the compound of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof,

[0114] [ka] is pyridyl. In some embodiments of the compound of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof,

[0115] [ka] is pyrimidyl. In some embodiments of the compound of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof,

[0116] [ka] In some embodiments of the compound of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof,

[0117] [ka] is pyridazinyl.

[0118] In some embodiments of the compound of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof,

[0119] [ka] is C 6-10 In some embodiments of the compound of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof,

[0120] [ka] is phenyl.

[0121] In some embodiments of the compound of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof,

[0122] [ka] is C 2-9 It is heterocycloalkyl.

[0123] In some embodiments of the compound of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof,

[0124] [ka] is C 3-6 It is cycloalkyl.

[0125] In some embodiments of the compound of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, each R 14 are independently halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , and -N(R 10 )(R 11 In some embodiments of the compound of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, each R 14 are independently halogens and C 1-6 In some embodiments of the compound of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, each R 14 is independently selected from halogen. In some embodiments of a compound of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, each R 14 independently, C 1-6 alkyl.

[0126] In some embodiments of the compound of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, m is 0, 1, or 2. In some embodiments of the compound of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, m is 0 or 1. In some embodiments of the compound of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, m is 0. In some embodiments of the compound of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, m is 1. In some embodiments of the compound of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, m is 2. In some embodiments of the compound of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, m is 3.

[0127] In some embodiments of the compounds of Formula (Ia) or (Ib), or pharmaceutically acceptable salts or solvates thereof, R 8 is hydrogen, halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , or C 3-6 In some embodiments of the compounds of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, R 8 is hydrogen, halogen, or C 1-6 In some embodiments of the compounds of Formula (Ia) or (Ib), or pharmaceutically acceptable salts or solvates thereof, R 8 is hydrogen. In some embodiments of the compounds of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, R 8 In some embodiments of the compounds of Formula (Ia) or (Ib), or pharmaceutically acceptable salts or solvates thereof, R 8 is C 1-6 In some embodiments of the compounds of Formula (Ia) or (Ib), or pharmaceutically acceptable salts or solvates thereof, R 8 In some embodiments of the compound of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, R 8 is C 1-6 In some embodiments of the compounds of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, R 8 In some embodiments of the compound of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, R 8 is C 3-6 In some embodiments of the compounds of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, R 8In some embodiments of the compounds of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, R 8 is -CN.

[0128] In some embodiments of the compounds of Formula (Ia) or (Ib), or pharmaceutically acceptable salts or solvates thereof, R 1 is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, and C 1-9 heteroaryl, wherein C 1-6 Alkyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, and C 1-9 Heteroaryl is R 15a and optionally substituted with one, two, or three groups selected from:

[0129] In some embodiments of the compounds of Formula (Ia) or (Ib), or pharmaceutically acceptable salts or solvates thereof, R 1 is hydrogen.

[0130] In some embodiments of the compounds of Formula (Ia) or (Ib), or pharmaceutically acceptable salts or solvates thereof, R 1 is R 15a C optionally substituted with one, two, or three groups selected from 1-6 In some embodiments of the compounds of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, R 1 is C 2-9 Heterocycloalkyl, C 1-9 Heteroaryl, -OR 10 , and -N(R 10 )(R 11 C optionally substituted with one, two, or three groups selected from 1-6In some embodiments of the compounds of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, R 1 is C 2-9 Heterocycloalkyl, C 1-9 Heteroaryl, -OR 10 , and -N(R 10 )(R 11 ) C substituted with one group selected from 1-6 In some embodiments of the compounds of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, R 1 is C 2-9 Heterocycloalkyl, C 1-9 Heteroaryl, -OR 10 , and -N(R 10 )(R 11 ) C substituted with one group selected from 1-6 alkyl, and R 10 and R 11 are independently hydrogen and C 1-6 In some embodiments of the compounds of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, R 1 is the unsubstituted C 1-6 It is alkyl.

[0131] In some embodiments of the compounds of Formula (Ia) or (Ib), or pharmaceutically acceptable salts or solvates thereof, R 1 is R 15a C optionally substituted with one, two, or three groups selected from 3-6 In some embodiments of the compounds of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, R 1 is C 1-6 Alkyl, -OR 10 , and -N(R 10 )(R 11 ) C substituted with one, two, or three groups selected from 3-6In some embodiments of the compound of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, R 1 -OR 10 and -N(R 10 )(R 11 ) C substituted with one group selected from 3-6 is cycloalkyl, and R 10 and R 11 are independently hydrogen and C 1-6 In some embodiments of the compounds of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, R 1 is the unsubstituted C 3-6 In some embodiments of the compounds of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, R 1 is unsubstituted cyclopropyl. In some embodiments of the compounds of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, R 1 is unsubstituted cyclobutyl.

[0132] In some embodiments of the compounds of Formula (Ia) or (Ib), or pharmaceutically acceptable salts or solvates thereof, R 1 is C 1-6 It is haloalkyl.

[0133] In some embodiments of the compounds of Formula (Ia) or (Ib), or pharmaceutically acceptable salts or solvates thereof, R 1 is R 15a C optionally substituted with one, two, or three groups selected from 2-9 In some embodiments of the compound of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, R 1 is C 1-6 Alkyl, -OR 10 , and -N(R 10 )(R 11 C optionally substituted with one, two, or three groups selected from2-9 In some embodiments of the compound of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, R 1 is the unsubstituted C 2-9 It is heterocycloalkyl.

[0134] In some embodiments of the compounds of Formula (Ia) or (Ib), or pharmaceutically acceptable salts or solvates thereof, R 1 is R 15a C optionally substituted with one, two, or three groups selected from 1-9 In some embodiments of the compounds of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, R 1 is C 1-6 Alkyl, -OR 10 , and -N(R 10 )(R 11 C optionally substituted with one, two, or three groups selected from 1-9 In some embodiments of the compounds of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, R 1 is the unsubstituted C 1-9 It is heteroaryl.

[0135] In some embodiments, formula (II)

[0136] [ka] or a pharmaceutically acceptable salt or solvate thereof, During the ceremony,

[0137] [ka] is C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-10heteroaryl; Z 1 is CR 7 or N, Z 2 is CR 9 or N, Z 4 is CR 6a or N, Y is -N(R 4a )-, -O-, and -C(R 5 )(R 5a )-selected from R 1 is hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13)2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), -Si(C 1-6 alkyl)3, and -P(O)(R 10 )2, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is R 15a and optionally substituted with one, two, or three groups selected from R 1a and R 1b are independently hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is R 15a and optionally substituted with one, two, or three groups selected from Each R 2and each R 3 are each independently hydrogen, halogen, oxo, or C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10)(R 11 ), -Si(C 1-6 alkyl)3, and -P(O)(R 10 )2, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is R 15b or R 2 and R 3 together with the carbon to which they are attached, C 3-6 Cycloalkyl or C 2-9 forming a heterocycloalkyl, R 4a is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is substituted with halogen, -CN, hydroxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, or R 4a and R 3can be combined to form halogens, -CN, hydroxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 C optionally substituted with one, two, or three groups selected from heteroaryl 2-9 forming a heterocycloalkyl, R 5 and R 5a are independently hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13)2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), -Si(C 1-6 alkyl)3, and -P(O)(R 10 )2, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is substituted with halogen, -CN, hydroxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, or R 5 and R 3 are combined to form C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, or C 2-9 Form a heteroaryl, where C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is substituted with halogen, -CN, hydroxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 optionally substituted with one, two, or three groups selected from heteroaryl; R 6a is hydrogen, halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), -Si(C 1-6 alkyl)3, and -P(O)(R 10 )2, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, and C 1-9 Heteroaryl is R 15c and optionally substituted with one, two, or three groups selected from R 7 , R 8 , and R 9 are independently hydrogen, halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), -Si(C 1-6 alkyl)3, -P(O)(R 10 )2, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is R 15c and optionally substituted with one, two, or three groups selected from Each R 10 are independently hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is substituted with halogen, -CN, hydroxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 optionally substituted with one, two, or three groups selected from heteroaryl; Each R 11 are independently hydrogen, C 1-6 Alkyl, and C 1-6 haloalkyl, or R 10 and R 11 together with the nitrogen to which they are attached, C 2-9 forming a heterocycloalkyl, Each R 12 are independently hydrogen, C 1-6 Alkyl, and C 1-6 haloalkyl; Each R 13 independently, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is substituted with halogen, -CN, hydroxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C1-9 optionally substituted with one, two, or three groups selected from heteroaryl; Each R 14 are independently halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13, -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), -Si(C 1-6 alkyl)3, and -P(O)(R 10 )2, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is R 15d and optionally substituted with one, two, or three groups selected from Each R 15a , R 15b , R 15c , and R 15d are each independently halogen, oxo, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, -CH2-C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Aryl, -CH2-C 6-10 Aryl, C 1-9 Heteroaryl, -CH2-C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), -Si(C 1-6 alkyl)3, and -P(O)(R 10 )2, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, -CH2-C 3-10 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Aryl, -CH2-C 6-10 Aryl, -CH2-C 1-9 Heteroaryl, and C 1-9 Heteroaryl is a group containing halogen, oxo, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), and -P(O)(R 10 Optionally substituted with 1, 2, or 3 groups independently selected from m is 0, 1, 2, 3, 4, or 5; n is 0, 1, 2, 3, 4, 5, or 6.

[0138] In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, Y is —N(R 4aIn some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, Y is —N(R 4a )- and R 4a is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is substituted with halogen, -CN, hydroxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, Y is optionally substituted with one, two, or three groups selected from -N(R 4a )- and R 4a is hydrogen or C 1-6 In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, Y is —N(R 4a )- and R 4a is hydrogen. In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, Y is —N(R 4a )- and R 4a is C 1-6 In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, Y is —N(R4a )- and R 4a is -CH3.

[0139] In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, Y is —O—.

[0140] In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, Y is —C(R 5 )(R 5a In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, Y is —C(R 5 )(R 5a )- and R 5 and R 5a are independently hydrogen and C 1-6 In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, Y is selected from -C(R 5 )(R 5a )- and R 5 and R 5a is hydrogen. In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, Y is —C(R 5 )(R 5a )- and R 5 and R 5a is C 1-6 In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, Y is —C(R 5 )(R 5a )- and R 5 is hydrogen and R 5a is C 1-6 It is alkyl.

[0141] In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, each R 2 are independently hydrogen and C 1-6In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, each R 2 is hydrogen. In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, each R 3 are independently hydrogen and C 1-6 In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, each R 3 is hydrogen. In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, each R 2 and R 3 together with the carbon to which they are attached, C 3-6 In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, each R 2 and R 3 , together with the carbons to which they are attached, form a cyclopropyl ring. In some embodiments of a compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, each R 2 and R 3 together with the carbons to which they are attached form a cyclobutyl ring. In some embodiments of a compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, each R 2 and R 3 together with the carbons to which they are attached form a cyclopentyl ring. In some embodiments of a compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, each R 2 and R 3 together with the carbons to which they are attached form a cyclohexyl ring.

[0142] In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, n is 1, 2, or 3. In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, n is 1. In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, n is 2. In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, n is 3. In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, n is 4. In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, n is 5. In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, n is 6.

[0143] In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, Z 1 is CR 7 In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, Z 1 is CR 7 and R 7 is hydrogen, halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , or -N(R 10 )(R 11 In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, Z 1 is CR 7 and R 7 is hydrogen, halogen, C 1-6 Alkyl, or C 1-6 In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, Z is haloalkyl. 1 is CR 7 and R 7 is hydrogen.

[0144] In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, Z 1 is N.

[0145] In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, Z 2 is CR 9 In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, Z 2 is CR 9 and R 9 is hydrogen, halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , or -N(R 10 )(R 11 In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, Z 2 is CR 9 and R 9 is hydrogen, halogen, C 1-6 Alkyl, or C 1-6 In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, Z is haloalkyl. 2 is CR 9 and R 9 is hydrogen.

[0146] In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, Z 2 is N.

[0147] In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, Z 4 is CR 6a In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, Z 4 is CR 6a and R 6a is hydrogen, halogen, -CN, C 1-6 Alkyl, C1-6 Haloalkyl, -OR 10 , and -N(R 10 )(R 11 In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, Z 4 is CR 6a and R 6a is hydrogen and -OR 10 Selected from R 10 is C 1-6 In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, Z is alkyl. 4 is CR 6a and R 6a is hydrogen.

[0148] In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, Z 4 is N.

[0149] In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof,

[0150] [ka] is C 1-10 In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof,

[0151] [ka] is selected from pyridyl, pyrimidyl, pyrazinyl, and pyridazinyl 1-10 In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof,

[0152] [ka] is a 5- or 6-membered heteroaryl. In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof,

[0153] [ka] is a 5-membered heteroaryl. In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof,

[0154] [ka] is a 6-membered heteroaryl. In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof,

[0155] [ka] is pyridyl. In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof,

[0156] [ka] is pyrimidyl. In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof,

[0157] [ka] In some embodiments of the compound of formula (II), or a pharmaceutically acceptable salt or solvate thereof,

[0158] [ka] is pyridazinyl.

[0159] In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof,

[0160] [ka] is C 6-10 In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof,

[0161] [ka] is phenyl.

[0162] In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof,

[0163] [ka] is C 2-9 It is heterocycloalkyl.

[0164] In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof,

[0165] [ka] is C 3-6 It is cycloalkyl.

[0166] In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, each R 14 are independently halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , and -N(R 10 )(R 11 In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, each R 14are independently halogens and C 1-6 In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, each R 14 is independently selected from halogen.

[0167] In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, m is 0, 1, or 2. In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, m is 0 or 1. In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, m is 0. In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, m is 1. In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, m is 2. In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, m is 3.

[0168] In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, R 8 is hydrogen, halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , or C 3-6 In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, R 8 is hydrogen, halogen, or C 1-6 In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, R 8 is hydrogen. In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, R 8 is halogen. In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, R 8 is C 1-6In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, R 8 In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, R 8 is C 1-6 In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, R 8 is —CH. In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, R 8 is C 3-6 In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, R 8 In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, R 8 is -CN.

[0169] In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, R 1a is hydrogen.

[0170] In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, R 1b is hydrogen.

[0171] In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, R 1 is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, and C 1-9 heteroaryl, wherein C 1-6 Alkyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, and C 1-9 Heteroaryl is R 15aand optionally substituted with one, two, or three groups selected from:

[0172] In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, R 1 is hydrogen.

[0173] In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, R 1 is R 15a C optionally substituted with one, two, or three groups selected from 1-6 In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, R 1 is C 2-9 Heterocycloalkyl, C 1-9 Heteroaryl, -OR 10 , and -N(R 10 )(R 11 C optionally substituted with one, two, or three groups selected from 1-6 In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, R 1 is C 2-9 Heterocycloalkyl, C 1-9 Heteroaryl, -OR 10 , and -N(R 10 )(R 11 ) C substituted with one group selected from 1-6 In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, R 1 is C 2-9 Heterocycloalkyl, C 1-9 Heteroaryl, -OR 10 , and -N(R 10 )(R 11 ) C substituted with one group selected from 1-6 alkyl, and R 10 and R 11 are independently hydrogen and C 1-6In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, R 1 is the unsubstituted C 1-6 It is alkyl.

[0174] In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, R 1 is R 15a C optionally substituted with one, two, or three groups selected from 3-6 In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, R 1 is C 1-6 Alkyl, -OR 10 , and -N(R 10 )(R 11 ) C substituted with one, two, or three groups selected from 3-6 In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, R 1 -OR 10 and -N(R 10 )(R 11 ) C substituted with one group selected from 3-6 is cycloalkyl, and R 10 and R 11 are independently hydrogen and C 1-6 In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, R 1 is the unsubstituted C 3-6 In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, R 1 is unsubstituted cyclopropyl. In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, R 1 is unsubstituted cyclobutyl.

[0175] In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, R 1 is C 1-6 It is haloalkyl.

[0176] In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, R 1 is R 15a C optionally substituted with one, two, or three groups selected from 2-9 In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, R 1 is C 1-6 Alkyl, -OR 10 , and -N(R 10 )(R 11 C optionally substituted with one, two, or three groups selected from 2-9 In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, R 1 is the unsubstituted C 2-9 It is heterocycloalkyl.

[0177] In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, R 1 is R 15a C optionally substituted with one, two, or three groups selected from 1-9 In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, R 1 is C 1-6 Alkyl, -OR 10 , and -N(R 10 )(R 11 C optionally substituted with one, two, or three groups selected from 1-9 In some embodiments of the compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, R 1 is the unsubstituted C 1-9It is heteroaryl.

[0178] In some embodiments, Formula (IIa)

[0179] [ka] or a pharmaceutically acceptable salt or solvate thereof, During the ceremony,

[0180] [ka] is C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-10 heteroaryl; R 1 is hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10)(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), -Si(C 1-6 alkyl)3, and -P(O)(R 10 )2, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is R 15a and optionally substituted with one, two, or three groups selected from R 6a is hydrogen, halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), -Si(C 1-6 alkyl)3, and -P(O)(R 10 )2, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, and C 1-9 Heteroaryl is R 15c and optionally substituted with one, two, or three groups selected from R 8is hydrogen, halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), -Si(C1-6 alkyl)3, and -P(O)(R 10 )2, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is R 15c and optionally substituted with one, two, or three groups selected from Each R 10 are independently hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is substituted with halogen, -CN, hydroxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 optionally substituted with one, two, or three groups selected from heteroaryl; Each R 11 are independently hydrogen, C 1-6 Alkyl, and C 1-6 haloalkyl, or R 10 and R 11 together with the nitrogen to which they are attached, C 2-9 forming a heterocycloalkyl, Each R 12 are independently hydrogen, C 1-6 Alkyl, and C 1-6 haloalkyl; Each R 13 independently, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is substituted with halogen, -CN, hydroxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 optionally substituted with one, two, or three groups selected from heteroaryl; Each R 14 are independently halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), -Si(C 1-6 alkyl)3, and -P(O)(R 10 )2, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is R 15d and optionally substituted with one, two, or three groups selected from Each R 15a , R 15c , and R 15d are each independently halogen, oxo, -CN, C 1-6 Alkyl, C2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, -CH2-C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Aryl, -CH2-C 6-10 Aryl, C 1-9 Heteroaryl, -CH2-C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13 )2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13, -CH2S(O)2N(R 10 )(R 11 ), -Si(C 1-6 alkyl)3, and -P(O)(R 10 )2, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, -CH2-C 3-10 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Aryl, -CH2-C 6-10 Aryl, -CH2-C 1-9 Heteroaryl, and C 1-9 Heteroaryl is a group containing halogen, oxo, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 10 , -SR 10 , -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 , -S(O)2R 13 , -S(O)2N(R 10 )(R 11 )-, -N=S(=O)(R 13)2, -S(=O)(=NH)N(R 10 )(R 11 ), -S(=O)(=NH)C(R 10 )(R 11 ), -S(=O)(=NR 13 )R 13 , -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 , -CH2S(O)2R 13 , -CH2S(O)2N(R 10 )(R 11 ), and -P(O)(R 10 Optionally substituted with 1, 2, or 3 groups independently selected from m is 0, 1, 2, 3, 4, or 5.

[0181] In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof, R 6a is hydrogen, halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , and -N(R 10 )(R 11 In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof, R 6a is hydrogen and -OR 10 Selected from R 10 is C 1-6 In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof, R 6a is hydrogen.

[0182] In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof,

[0183] [ka] is C 1-10In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof,

[0184] [ka] is selected from pyridyl, pyrimidyl, pyrazinyl, and pyridazinyl 1-10 In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof,

[0185] [ka] is pyridyl. In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof,

[0186] [ka] is pyrimidyl. In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof,

[0187] [ka] In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof,

[0188] [ka] is pyridazinyl.

[0189] In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof,

[0190] [ka] is C6-10 In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof,

[0191] [ka] is phenyl.

[0192] In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof,

[0193] [ka] is C 2-9 It is heterocycloalkyl.

[0194] In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof,

[0195] [ka] is C 3-6 It is cycloalkyl.

[0196] In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof, each R 14 are independently halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , and -N(R 10 )(R 11 In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof, each R 14 are independently halogens and C 1-6 In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof, each R 14is independently selected from halogen.

[0197] In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof, m is 0, 1, or 2. In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof, m is 0 or 1. In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof, m is 0. In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof, m is 1. In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof, m is 2. In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof, m is 3.

[0198] In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof, R 8 is hydrogen, halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , or C 3-6 In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof, R 8 is hydrogen, halogen, or C 1-6 In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof, R 8 is hydrogen. In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof, R 8 is halogen. In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof, R 8 is C 1-6 In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof, R 8In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof, R 8 is C 1-6 In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof, R 8 In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof, R 8 is C 3-6 In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof, R 8 In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof, R 8 is -CN.

[0199] In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof, R 1 is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, and C 1-9 heteroaryl, wherein C 1-6 Alkyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, and C 1-9 Heteroaryl is R 15a and optionally substituted with one, two, or three groups selected from:

[0200] In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof, R 1 is hydrogen.

[0201] In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof, R 1 is R 15aC optionally substituted with one, two, or three groups selected from 1-6 In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof, R 1 is C 2-9 Heterocycloalkyl, C 1-9 Heteroaryl, -OR 10 , and -N(R 10 )(R 11 C optionally substituted with one, two, or three groups selected from 1-6 In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof, R 1 is C 2-9 Heterocycloalkyl, C 1-9 Heteroaryl, -OR 10 , and -N(R 10 )(R 11 ) C substituted with one group selected from 1-6 In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof, R 1 is C 2-9 Heterocycloalkyl, C 1-9 Heteroaryl, -OR 10 , and -N(R 10 )(R 11 ) C substituted with one group selected from 1-6 alkyl, and R 10 and R 11 are independently hydrogen and C 1-6 In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof, R 1 is the unsubstituted C 1-6 It is alkyl.

[0202] In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof, R 1 is R 15a C optionally substituted with one, two, or three groups selected from 3-6In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof, R 1 is C 1-6 Alkyl, -OR 10 , and -N(R 10 )(R 11 ) C substituted with one, two, or three groups selected from 3-6 In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof, R 1 -OR 10 and -N(R 10 )(R 11 ) C substituted with one group selected from 3-6 is cycloalkyl, and R 10 and R 11 are independently hydrogen and C 1-6 In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof, R 1 is the unsubstituted C 3-6 In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof, R 1 is unsubstituted cyclopropyl. In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof, R 1 is unsubstituted cyclobutyl.

[0203] In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof, R 1 is C 1-6 It is haloalkyl.

[0204] In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof, R 1 is R 15a C optionally substituted with one, two, or three groups selected from 2-9In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof, R 1 is C 1-6 Alkyl, -OR 10 , and -N(R 10 )(R 11 C optionally substituted with one, two, or three groups selected from 2-9 In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof, R 1 is the unsubstituted C 2-9 It is heterocycloalkyl.

[0205] In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof, R 1 is R 15a C optionally substituted with one, two, or three groups selected from 1-9 In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof, R 1 is C 1-6 Alkyl, -OR 10 , and -N(R 10 )(R 11 C optionally substituted with one, two, or three groups selected from 1-9 In some embodiments of the compound of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof, R 1 is the unsubstituted C 1-9 It is heteroaryl.

[0206] Any combination of the above groups for the various variables is contemplated herein. Throughout the specification, groups and substituents thereof will be chosen by one of ordinary skill in the art to provide stable moieties and compounds.

[0207] In some embodiments, the compound, or a pharmaceutically acceptable salt or solvate thereof, is selected from the compounds found in Table 1.

[0208]

Table 1-1

[0209]

Table 1-2

[0210]

Table 1-3

[0211]

Table 1-4

[0212]

Table 1-5

[0213]

Table 1-6

[0214]

Table 1-7

[0215] [Table 1-8]

[0216] [Table 1-9]

[0217] [Table 1-10]

[0218] [Table 1-11]

[0219] Further forms of the compounds disclosed herein Isomers / stereoisomers In some embodiments, the compounds described herein exist as geometric isomers. In some embodiments, the compounds described herein contain one or more double bonds. The compounds provided herein include all cis, trans, syn, anti, entgegen (E), and zusammen (Z) isomers, as well as their corresponding mixtures. In some circumstances, the compounds described herein possess one or more chiral centers, with each center being in the R or S configuration. The compounds described herein include all diastereomeric, enantiomeric, and epimeric forms, as well as their corresponding mixtures. In additional embodiments of the compounds and methods provided herein, mixtures of enantiomers and / or diastereoisomers resulting from a single preparation step, combination, or interconversion are useful for the applications described herein. In some embodiments, the compounds described herein are prepared as individual stereoisomers of the compound by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers, and recovering the optically pure enantiomers. In some embodiments, separable complexes are preferred. In some embodiments, diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) and are separated by taking advantage of these dissimilarities. In some embodiments, diastereomers are separated by chiral chromatography, or preferably, by separation / resolution techniques based upon differences in solubility. In some embodiments, the optically pure enantiomers are then recovered, along with the resolving agent, by any practical means that does not result in racemization.

[0220] Labeled Compound In some embodiments, the compounds described herein exist in their isotopically labeled form. In some embodiments, the methods disclosed herein include methods for treating diseases by administering such isotopically labeled compounds. In some embodiments, the methods disclosed herein include methods for treating diseases by administering isotopically labeled compounds as pharmaceutical compositions. Thus, in some embodiments, the compounds disclosed herein include isotopically labeled compounds, which are identical to those listed herein except for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number normally found in nature. Examples of isotopes that can be incorporated into the compounds disclosed herein include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chloride, such as 2H(D), 3H, 13C, 14C, 15N, 18O, 17O, 31P, 32P, 35S, 18F, and 36Cl, respectively. The compounds described herein, and their pharmaceutically acceptable salts, solvates, or stereoisomers, containing the aforementioned isomers and / or other isomers of other atoms, are within the scope of the present invention. Certain isotopically labeled compounds, for example, those incorporating radioactive isotopes such as H and C, are useful in drug and / or substrate tissue distribution assays. Tritiated (i.e., H) and carbon-14 (i.e., C) isotopes are particularly preferred for their ease of preparation and detectability.

[0221] In some embodiments, the abundance of deuterium in each of the substituents disclosed herein is independently at least 1%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or 100% of the total number of hydrogen and deuterium. In some embodiments, one or more of the substituents disclosed herein contain deuterium at a percentage higher than the natural abundance of deuterium. In some embodiments, one or more hydrogens are replaced with one or more deuteriums in one or more of the substituents disclosed herein.

[0222] In some embodiments, the compounds described herein are labeled by other means, including but not limited to, the use of chromophores or fluorescent moieties, bioluminescent labels, or chemiluminescent labels.

[0223] Pharmaceutically acceptable salts In some embodiments, the compounds described herein are present as their pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating diseases by administering pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating diseases by administering pharmaceutically acceptable salts as pharmaceutical compositions.

[0224] In some embodiments, the compounds described herein possess acidic or basic groups and thus react with a number of inorganic or organic bases, as well as inorganic and organic acids, to form pharmaceutically acceptable salts. In some embodiments, these salts are prepared in situ during the final isolation and purification of the compounds disclosed herein, or solvates or stereoisomers thereof, or by separately reacting the purified compounds in their free form with the appropriate acid or base and isolating the salt thus formed.

[0225] Examples of pharmaceutically acceptable salts include salts prepared by reaction of a compound described herein with a mineral acid, organic acid, or inorganic base, such as acetate, acrylate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, bisulfite, bromide, butyrate, butyne-1,4-dioate, camphorate, camphorsulfonate, caproate, caprylate, chlorobenzoate, chloride, citrate, cyclopentanepropionate, decanoate, digluconate, dihydrogenphosphate, dinitrobenzoate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hexyne-1,6-dioate, hydroxybenzoate, γ-hydroxybutylene, hydroxybenzoate ... ester, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isobutyrate, lactate, maleate, malonate, methanesulfonate, mandelate metaphosphate, methanesulfonate, methoxybenzoate, methylbenzoate, monohydrogenphosphate, 1-naphthalenesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, palmitate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, pyrosulfate, pyrophosphate, propiolate, phthalate, phenylacetate, phenylbutyrate, propanesulfonate, salicylate, succinate, sulfate, sulfite, succinate, suberate, sebacate, sulfonate, tartrate, thiocyanate, tosylate undeconate, and xylenesulfonate.

[0226] Additionally, the compounds described herein can be used to dissolve the free base form of the compound in inorganic acids such as, but not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, metaphosphoric acid, and organic acids such as, for example, acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, p-toluenesulfonic acid, tartaric acid, trifluoroacetic acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, arylsulfonic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, and the like. The compounds can be prepared as pharmaceutically acceptable salts formed by reacting them with pharmaceutically acceptable inorganic or organic acids, including 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 2-naphthalenesulfonic acid, 4-methylbicyclo[2.2.2]oct-2-ene-1-carboxylic acid, glucoheptonic acid, 4,4'-methylenebis-(3-hydroxy-2-ene-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tert-butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, and muconic acid. In some embodiments, other acids, such as oxalic acid, are not themselves pharmaceutically acceptable but are used in the preparation of salts useful as intermediates in obtaining the compounds disclosed herein, their solvates, or stereoisomers, and their pharmaceutically acceptable acid addition salts.

[0227] In some embodiments, compounds described herein containing free acid groups are reacted with a suitable base, such as hydroxides, carbonates, bicarbonates, sulfates, ammonia, or pharmaceutically acceptable organic primary, secondary, tertiary, or quaternary amines of pharmaceutically acceptable metal cations. Representative salts include alkali or alkaline earth salts, such as lithium, sodium, potassium, calcium, and magnesium, and aluminum salts. Illustrative examples of bases include sodium hydroxide, potassium hydroxide, choline hydroxide, sodium carbonate, N + (C 1-4 alkyl)4.

[0228] Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, and the like. It is understood that the compounds described herein also include the quaternization of any basic nitrogen-containing groups they contain. In some embodiments, water- or oil-soluble or dispersible products are obtained by such quaternization.

[0229] solvate In some embodiments, the compounds described herein exist as solvates. The present invention provides methods of treating diseases by administering such solvates. The present invention further provides methods of treating diseases by administering such solvates as pharmaceutical compositions.

[0230] Solvates contain either stoichiometric or non-stoichiometric amounts of solvent, and in some embodiments, are formed during the crystallization process using pharmaceutically acceptable solvents such as water, ethanol, etc. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. Solvates of the compounds described herein can be conveniently prepared or formed during the processes described herein. By way of example only, hydrates of the compounds described herein can be conveniently prepared by recrystallization from an aqueous / organic solvent mixture using organic solvents, including, but not limited to, dioxane, tetrahydrofuran, or methanol. In addition, the compounds provided herein can exist in unsolvated and solvated forms. Generally, solvated forms are considered equivalent to unsolvated forms for the purposes of the compounds and methods provided herein.

[0231] tautomers In some situations, compounds exist as tautomers.The compounds described herein include all possible tautomers within the formulas described herein.Tautomers are compounds that can be interconverted by the movement of hydrogen atoms, with the switch of a single bond and an adjacent double bond.In bonding configurations where tautomerization is possible, there is a chemical equilibrium of tautomers.All tautomeric forms of the compounds disclosed herein are contemplated.The exact ratio of tautomers depends on several factors, including temperature, solvent, and pH.

[0232] Treatment method Disclosed herein are methods for treating diseases in which inhibition of MAT2A is beneficial, the methods comprising administering a compound of Formula (I), (Ia), (Ib), (II), and (IIa) disclosed herein, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the methods comprise administering a pharmaceutical composition comprising a compound of Formula (I), (Ia), (Ib), (II), and (IIa) disclosed herein, or a pharmaceutically acceptable salt or solvate thereof.

[0233] Disclosed herein are methods for treating a disease or disorder associated with MAT2A, the methods comprising administering to a subject a compound of Formula (I), (Ia), (Ib), (II), and (IIa) disclosed herein, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the methods comprise administering a pharmaceutical composition comprising a compound of Formula (I), (Ia), (Ib), (II), and (IIa) disclosed herein, or a pharmaceutically acceptable salt or solvate thereof.

[0234] Disclosed herein are methods for treating cancer in a subject, comprising administering to the subject a compound of Formula (I), (Ia), (Ib), (II), and (IIa) disclosed herein, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, provided are methods for treating cancer in a subject, comprising administering to the subject a compound of Formula (I), (Ia), (Ib), (II), and (IIa) disclosed herein, or a pharmaceutically acceptable salt or solvate thereof, wherein the cancer is selected from liver cancer, colon cancer, pancreatic cancer, prostate cancer, lung cancer, breast cancer, and T-cell leukemia. In some embodiments, provided are methods for treating liver cancer in a subject, comprising administering to the subject a compound of Formula (I), (Ia), (Ib), (II), and (IIa) disclosed herein, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, provided are methods for treating colon cancer in a subject, comprising administering to the subject a compound of Formula (I), (Ia), (Ib), (II), and (IIa) disclosed herein, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, provided are methods for treating pancreatic cancer in a subject, comprising administering to the subject a compound of Formula (I), (Ia), (Ib), (II), and (IIa) disclosed herein, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, provided are methods for treating prostate cancer in a subject, comprising administering to the subject a compound of Formula (I), (Ia), (Ib), (II), and (IIa) disclosed herein, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, provided are methods of treating lung cancer in a subject, the method comprising administering to the subject a compound of Formula (I), (Ia), (Ib), (II), and (IIa), or a pharmaceutically acceptable salt or solvate thereof, as disclosed herein.In some embodiments, methods are provided for treating breast cancer in a subject, comprising administering to the subject a compound of Formula (I), (Ia), (Ib), (II), and (IIa) disclosed herein, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, methods are provided for treating T-cell leukemia in a subject, comprising administering to the subject a compound of Formula (I), (Ia), (Ib), (II), and (IIa) disclosed herein, or a pharmaceutically acceptable salt or solvate thereof.

[0235] Administration In certain embodiments, compositions containing a compound(s) described herein are administered for prophylactic and / or therapeutic treatment. In certain therapeutic applications, the compositions are administered to a patient already suffering from a disease or condition in an amount sufficient to cure or at least partially halt at least one symptom of the disease or condition. Amounts effective for this use will depend on the severity and course of the disease or condition, previous treatments, the patient's health status, weight, and response to the drugs, and the judgment of the treating physician. Therapeutically effective amounts are optionally determined by methods including, but not limited to, dose escalation and / or dose ranging clinical trials.

[0236] In prophylactic applications, compositions containing the compounds described herein are administered to a patient susceptible to or otherwise at risk of a particular disease, disorder, or condition. Such an amount is defined to be a "prophylactically effective amount or dose." For this use, the precise amount will also depend on the patient's health, weight, and the like. When used in a patient, the effective amount for this use will depend on the severity and course of the disease, disorder, or condition, previous treatments, the patient's health status and response to the drugs, and the judgment of the treating physician. In one aspect, prophylactic treatment involves administering a pharmaceutical composition containing a compound described herein, or a pharmaceutically acceptable salt thereof, to a mammal that has previously experienced and is currently in remission of at least one symptom or risk factor of the disease being treated, in order to prevent the return of the disease or condition.

[0237] In certain embodiments where the patient's disease does not improve, at the physician's discretion, administration of the compound is administered chronically, i.e., for an extended period of time, including for the life of the patient, to improve or otherwise control or limit the symptoms of the patient's disease or disorder.

[0238] In certain embodiments where the patient's disease improves, the dose of the administered drug is temporarily reduced or temporarily suspended for a specified period of time (i.e., a "drug holiday period"). In specific embodiments, the length of the drug holiday period is between 2 days and 1 year, including, by way of example only, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 12 days, 15 days, 20 days, 28 days, or more than 28 days. The dose reduction during the drug holiday period is, by way of example only, between 10% and 100%, including, by way of example only, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, and 100%.

[0239] Once improvement of the patient's disease has occurred, maintenance doses are administered as needed. Thereafter, in certain embodiments, the dosage or frequency of administration, or both, is reduced as a function of symptoms to a level at which the improved disease, disorder, or condition is maintained. However, in certain embodiments, the patient requires intermittent or daily treatment on a long-term basis upon any recurrence of symptoms.

[0240] The amount of a given agent that corresponds to such an amount will vary depending on factors such as the particular compound, the disease state and its severity, the identity (e.g., weight, sex) of the subject or host requiring treatment, but will nevertheless be determined by the particular circumstances surrounding the case, including, for example, the particular agent being administered, the route of administration, the condition being treated, and the subject or host being treated.

[0241] In general, however, dosages used for adult human treatment typically range from 0.01 mg to 5000 mg per day. In one aspect, dosages used for adult human treatment are from about 1 mg to about 1000 mg per day. In one embodiment, the desired dosage is conveniently presented as a single dose or as divided doses administered simultaneously or at appropriate intervals, e.g., two, three, four, or more subdoses per day.

[0242] In certain aspects, a suitable daily dosage for a compound described herein or a pharmaceutically acceptable salt thereof is about 0.01 to about 50 mg / kg body weight. In some embodiments, the daily dose or amount of active agent in a dosage form is less than or greater than the ranges set forth herein, depending on many variables related to the individual treatment regimen. In various embodiments, the daily dose and unit dose will vary depending on numerous variables, including, but not limited to, the activity of the compound used, the disease or condition being treated, the mode of administration, the requirements of the individual subject, the severity of the disease or condition being treated, and the judgment of the physician.

[0243] The toxicity and therapeutic efficacy of such treatment regimens include, but are not limited to, LD 10 and ED 90 The dose ratio between toxic and therapeutic effects is the therapeutic index, or LD. 50 and ED 50 In certain embodiments, data obtained from cell culture assays and animal studies are used in formulating a therapeutically effective daily dose range and / or a therapeutically effective unit dose for use in mammals, including humans. In some embodiments, the daily dosage of the compounds described herein is sufficient to achieve an ED with minimal toxicity. 50 In certain embodiments, the daily dose range and / or unit dose varies within this range depending upon the dosage form employed and the route of administration utilized.

[0244] Any of the foregoing aspects are further embodiments wherein an effective amount of a compound described herein or a pharmaceutically acceptable salt thereof is (a) administered systemically to a mammal, (b) administered orally to a mammal, (c) administered intravenously to a mammal, (d) administered by injection to a mammal, and / or (e) administered locally to a mammal, and / or (f) administered non-systemically or locally to a mammal.

[0245] Any of the foregoing aspects are further embodiments that include a single administration of an effective amount of the compound, including further embodiments where (i) the compound is administered once daily, or (ii) the compound is administered to the mammal multiple times over the course of a day.

[0246] Any of the above aspects are further embodiments that include multiple administrations of an effective amount of the compound, including further embodiments in which (i) the compound is administered continuously or intermittently: as in a single administration, (ii) the time between multiple administrations is every 6 hours; (iii) the compound is administered to the mammal every 8 hours; (iv) the compound is administered to the subject every 12 hours; or (v) the compound is administered to the subject every 24 hours. In further or alternative embodiments, the method includes a drug holiday during which administration of the compound is temporarily suspended or the dose of the administered compound is temporarily reduced, and at the end of the drug holiday, administration of the compound is resumed. In one embodiment, the length of the drug holiday varies from 2 days to 1 year.

[0247] Administration route Suitable routes of administration include, but are not limited to, oral, intravenous, rectal, aerosol, parenteral, ocular, pulmonary, transmucosal, transdermal, vaginal, otic, nasal, and topical administration. Further, by way of example only, parenteral delivery includes intramuscular, subcutaneous, intravenous, intramedullary injection, as well as intrathecal, direct intraventricular, intraperitoneal, intralymphatic, and intranasal injection.

[0248] In certain embodiments, the compounds described herein are administered in a local rather than systemic manner, for example, by injecting the compound directly into an organ, often in a depot preparation or sustained-release formulation. In certain embodiments, long-acting formulations are administered by implantation (e.g., subcutaneous or intramuscular) or intramuscular injection. Furthermore, in other embodiments, the drug is delivered in a targeted drug delivery system, for example, in a liposome coated with an organ-specific antibody. In such embodiments, the liposome targets the organ and is selectively taken up by the organ. In still other embodiments, the compounds described herein are provided in the form of a rapid-release formulation, a sustained-release formulation, or an intermediate-release formulation. In still other embodiments, the compounds described herein are administered locally.

[0249] Pharmaceutical Compositions / Formulations The compounds described herein can be administered to a subject in need thereof in a pharmaceutical composition, either alone or in combination with a pharmaceutically acceptable carrier, excipient, or diluent, according to standard pharmaceutical practice. In some embodiments, the compounds of the present invention can be administered to animals. The compounds can be administered orally or parenterally, including intravenously, intramuscularly, intraperitoneally, subcutaneously, rectally, and topically.

[0250] In another aspect, provided herein are pharmaceutical compositions comprising a compound of Formula (I), (Ia), (Ib), (II), and (IIa) described herein, or a pharmaceutically acceptable salt or solvate thereof, and at least one pharmaceutically acceptable excipient. Some embodiments are pharmaceutical compositions comprising a compound of Formula (I) described herein, or a pharmaceutically acceptable salt or solvate thereof, and at least one pharmaceutically acceptable excipient. Some embodiments are pharmaceutical compositions comprising a compound of Formula (Ia) described herein, or a pharmaceutically acceptable salt or solvate thereof, and at least one pharmaceutically acceptable excipient. Some embodiments are pharmaceutical compositions comprising a compound of Formula (Ib) described herein, or a pharmaceutically acceptable salt or solvate thereof, and at least one pharmaceutically acceptable excipient. Some embodiments are pharmaceutical compositions comprising a compound of Formula (II) described herein, or a pharmaceutically acceptable salt or solvate thereof, and at least one pharmaceutically acceptable excipient. Some embodiments are pharmaceutical compositions comprising a compound of Formula (IIa) described herein, or a pharmaceutically acceptable salt or solvate thereof, and at least one pharmaceutically acceptable excipient.

[0251] Pharmaceutical compositions are formulated in a conventional manner, using one or more pharmaceutically acceptable excipients to facilitate the processing of active compound into pharmaceutically usable preparations.Suitable formulation depends on the route of administration selected.The summary of pharmaceutical compositions described herein can be found in, for example, Remington: The Science and Practice of Pharmacy, Nineteenth Edition (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, HA and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, NY, 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Edition (Lippincott Williams & Wilkins 1999), which are incorporated herein by reference for their disclosure.

[0252] In some embodiments, the pharmaceutically acceptable excipient is selected from a carrier, a binder, a filler, a suspending agent, a flavoring agent, a sweetening agent, a disintegrant, a dispersing agent, a surfactant, a lubricant, a coloring agent, a diluent, a solubilizer, a humectant, a plasticizer, a stabilizer, a penetration enhancer, a wetting agent, an antifoaming agent, an antioxidant, a preservative, and any combination thereof.

[0253] The pharmaceutical compositions described herein are administered to a subject by a suitable route, including, but not limited to, oral, parenteral (e.g., intravenous, subcutaneous, intramuscular), intranasal, buccal, topical, rectal, or transdermal routes. Pharmaceutical formulations described herein include, but are not limited to, aqueous liquid dispersions, liquids, gels, syrups, elixirs, slurries, suspensions, self-emulsifying dispersions, solid solutions, liposomal dispersions, aerosols, solid oral dosage forms, powders, immediate-release formulations, controlled-release formulations, fast-dissolving formulations, tablets, capsules, pills, powders, dragees, effervescent formulations, lyophilized formulations, delayed-release formulations, sustained-release formulations, pulsed-release formulations, multiparticulate formulations, and immediate- and controlled-release combination formulations.

[0254] Pharmaceutical compositions comprising a compound described herein, or a pharmaceutically acceptable salt or solvate thereof, are manufactured in a conventional manner, including, by way of example only, by conventional mixing, dissolving, granulating, dragee-making, pulverizing, emulsifying, encapsulating, entrapping, or compressing processes.

[0255] Pharmaceutical compositions for oral use can be prepared by mixing one or more solid excipients with one or more compounds described herein, optionally grinding the resulting mixture, and optionally adding suitable excipients, and then processing the granular mixture to obtain tablets or dragee cores.Suitable excipients include, for example, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations, such as corn starch, wheat starch, rice starch, potato starch, gelatin, tragacanth gum, methylcellulose, microcrystalline cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose; or others, such as polyvinylpyrrolidone (PVP or povidone) or calcium phosphate.If desired, disintegrants can be added, such as cross-linked croscarmellose sodium, polyvinylpyrrolidone, agar, or alginic acid or its salts, such as sodium alginate.In some embodiments, dyes or pigments are added to tablets or dragee coatings for identification or to distinguish different combinations of active compound doses.

[0256] Orally administered pharmaceutical compositions include push-fit capsules made of gelatin and soft sealed capsules made of gelatin and plasticizers such as glycerol or sorbitol.Push-fit capsules contain active ingredients in a mixture with fillers such as lactose, binders such as starch, and / or lubricants such as talc or magnesium stearate, and optionally stabilizers.In soft capsules, active compounds are dissolved or suspended in suitable liquids such as fatty oils, liquid paraffin, or liquid polyethylene glycol.In some embodiments, stabilizers are added.

[0257] Pharmaceutical compositions for parenteral use are formulated as injections or infusions. In some embodiments, pharmaceutical compositions suitable for injection or infusion include sterile aqueous solutions or dispersions or sterile powders containing the compounds described herein, or their pharmaceutically acceptable salts or solvates. In some embodiments, pharmaceutical compositions include liquid carriers. In some embodiments, liquid carriers are solvents or liquid dispersion media, including, for example, water, saline, ethanol, polyols (e.g., glycerol, propylene glycol, liquid polyethylene glycol, etc.), vegetable oils, non-toxic glyceryl esters, and any combination thereof. In some embodiments, pharmaceutical compositions further include preservatives to prevent the growth of microorganisms. [Example]

[0258] The following examples are provided for illustrative purposes only and are not intended to limit the scope of the claims provided herein.

[0259] As used above, and throughout the description of the present invention, the following abbreviations, unless otherwise indicated, shall be understood to have the following meanings: ACN or MeCN acetonitrile AcOH acetic acid Ac Acetyl Bn Benzyl BOC or Boc tert-butyl carbamate i-Bu iso-butyl t-Bu tert-butyl CDI 1,1-carbonyldiimidazole DBU Diazabicycloundecene (1,8- diazabicyclo[5.4.0] undec-7-ene) DCE Dichloroethane (ClCH2CH2Cl) DCM dichloromethane (CH2Cl2) DIBAL-H Diisobutylaluminum hydride DIPEA or DIEA Diisopropylethylamine DMAP 4-(N,N-dimethylamino)pyridine DME 1,2-dimethoxyethane DMF N,N-dimethylformamide DMA N,N-dimethylacetamide DMPU N,N-dimethylpropylene urea DMSO dimethyl sulfoxide DPPA Diphenylphosphoryl azide Dppf or dppf 1,1'-bis(diphenylphosphino) Ferrocene EDC or EDCI N-(3-dimethylaminopropyl)-N'- Ethylcarbodiimide Hydrochloride eq equivalent Et Ethyl Et2O diethyl ether EtOH ethanol EtOAc ethyl acetate HATU 1-[bis(dimethylamino) methylene]- 1H-1,2,3-triazolo[4,5-b] Pyridinium 3- Oxide Hexafluorophosphate HOBt 1-hydroxybenzotriazole HPLC High Performance Liquid Chromatography KOAc Potassium Acetate KotBu potassium tert-butoxide KHMDS Potassium bis(trimethylsilyl)amide NaHMDS Sodium bis(trimethylsilyl)amide LiHMDS Lithium bis(trimethylsilyl)amide LAH / LiAlH4 Lithium Aluminum Anhydrous LCMS Liquid Chromatography Mass Spectrometry Me methyl MeOH Methanol MS mass spectrometry MTBE Methyl tert-butyl ether NBS N-Bromosuccinimide NMP N-methyl-pyrrolidin-2-one NMR nuclear magnetic resonance PE Petroleum Ether Ph phenyl iPr / i-Pr iso-propyl PyAOP (7-azabenzotriazol-1-yloxy) Tripyrrolidinophosphonium hexafluorophosphate RP-HPLC Reversed-phase high-performance liquid chromatography Rt room temperature SEM 2-(trimethylsilyl)ethoxymethyl TBS tert-butyldimethylsilyl TEA Triethylamine TFA trifluoroacetic acid THF tetrahydrofuran TLC thin layer chromatography TMS trimethylsilyl

[0260] Intermediate A: Synthesis of 7-chloro-4-hydroxy-5-methoxy-1-(pyridin-3-yl)quinazolin-2(1H)-one

[0261] [ka] Step 1: A solution of 4-chloro-2,6-difluorobenzoic acid (23.0 g, 119.45 mmol) in SOCl (100 mL) was stirred at 80° C. for 3 hours. The mixture was concentrated under reduced pressure, and the residue was dissolved in dioxane (60 mL), followed by dropwise addition of NH OH (60 mL) at 0° C. The mixture was then stirred at 25° C. for 0.5 hours, concentrated, and diluted with water with stirring until a white solid precipitated. The solid was filtered, washed with water, and dried to give compound INTA-1 (15.0 g, 65.6% yield). 1 H NMR (400MHz, DMSO-d6) δ 8.17 (brs, 1H), 7.92 (brs, 1H), 7.49-7.42 (m, 2H).

[0262] Step 2: To a stirred suspension of compound INTA-1 (5.0 g, 26.10 mmol) in MeOH (50 mL) was added sodium methanolate (1.6 g, 28.71 mmol) at room temperature, and the mixture was stirred at 60° C. for 5 hours. The reaction was concentrated and diluted with water with stirring until a white solid precipitated. The solid was then collected, washed with water, and dried to give compound INTA-2 (5.0 g, 94.1% yield). LCMS: 204.0 [M+H] + .

[0263] Step 3: To a stirred suspension of compound INTA-2 (11.0 g, 54.0 mmol) in DCE (100 mL) was added oxalyl dichloride (7.54 g, 59.4 mmol). The suspension was heated to 80° C. for 1 h. The mixture was cooled to 25° C., and then pyridin-3-amine (10.2 g, 108 mmol) was added. The mixture was stirred at 25° C. for 0.5 h and then concentrated. The crude was triturated with MeOH (100 mL) at 25° C. for 30 min to give compound INTA-3 (16.0 g, 89.6% yield). LC-MS: 324.1 [M+H] + .

[0264] Step 4: To a solution of compound INTA-3 (10.0 g, 30.9 mmol) in THF (100 mL) was added KHMDS (1.0 M, 67.9 mL) dropwise at −20° C. The mixture was quenched with NH4Cl (200.0 mL), then filtered, and the residue was concentrated to give compound intermediate A (5.50 g, 55.7% yield). LC-MS: 304.1 [M+H] + . 1 H NMR:(400MHz,DMSO-d6)δ 11.54(brs,1H),8.74(dd,J=4.8,1.6Hz,1H),8.64(d,J=2.0Hz,1H),8.02 -7.86(m,1H),7.68-7.64(m,1H),6.96(s,1H),5.86(s,1H),3.90(s,3H).

[0265] Intermediate B: Synthesis of 7-chloro-4-hydroxy-5-methoxy-1-(2-methylpyridin-3-yl)quinazolin-2(1H)-one

[0266] [ka] Step 1: To a solution of compound INTA-2 (6.0 g, 29.47 mmol) in DCE (100 mL) was added oxalyl dichloride (4.1 g, 32.42 mmol) at room temperature. The mixture was stirred at 80° C. for 1 hour and then cooled to room temperature. 2-Methylpyridin-3-amine (6.4 g, 58.94 mmol) was added, and the mixture was stirred at room temperature for an additional 1 hour and then cooled to 0° C. The formed precipitate was collected by filtration, washed with water, and dried to give compound INTB-1 (6.2 g, 62.3% yield). LCMS: 338.1 [M+H] + .

[0267] Step 2: To a solution of compound INTB-1 (500.0 mg, 1.48 mmol) in THF (10 mL) was added KHMDS (3.3 mL, 3.26 mmol, 1.0 M in THF) at -20 °C, and the mixture was then stirred at room temperature for 7 h. The mixture was concentrated, diluted with water, and the pH was adjusted to 6-7 with 4.0 M aqueous HCl. The precipitate was collected by filtration, washed with water, and dried to give compound intermediate B (400.0 mg, 85.8% yield). LCMS: 318.1 [M+H] + .

[0268] Intermediate C: Synthesis of 4-hydroxy-5-methoxy-1-(2-methylpyridin-3-yl)-7-(trifluoromethyl)quinazolin-2(1H)-one

[0269] [ka] Step 1: To a solution of sodium methanolate (358.0 mg, 6.63 mmol) in MeOH (5 mL), 2,6-difluoro-4-(trifluoromethyl)benzoic acid (500.0 mg, 2.21 mmol) was added, and the reaction was stirred at 80 °C for 2 h. The mixture was then cooled to room temperature and concentrated. The residue was diluted with water (10 mL), and the pH was adjusted to 2-3 with 6.0 M aqueous HCl. The mixture was extracted with DCM (15.0 mL × 3), and the organic layer was washed with brine, dried, and concentrated to give compound INTC-1 (215.0 mg, 40.8% yield). 1 H NMR (400MHz, DMSO-d6) δ 7.37 (d, J = 8.8 Hz, 1H), 7.28 (s, 1H), 3.92 (s, 3H).

[0270] Step 2: Compound INTC-1 (380.0 mg, 1.59 mmol) was mixed in SOCl2 (6.0 mL), and the resulting solution was then heated at 80 °C for 2 h. The solution was then cooled to room temperature and concentrated to remove excess SOCl2. The residue was dissolved in dioxane (6.0 mL) and treated with NH4OH (40% w / w, 6.0 mL). The resulting solution was stirred from 0 °C to room temperature for 1 h. The mixture was concentrated under reduced pressure and diluted with water. The solid product that formed was then collected, washed with water, and dried to give compound INTC-2 (230 mg, 60.8% yield). 1 H NMR (400MHz, DMSO-d6) δ 7.96 (s, 1H), 7.71 (s, 1H), 7.31 (dd, J = 8.8Hz, 0.4Hz, 1H), 7.23 (s, 1H), 3.89 (s, 3H).

[0271] Step 3: To a stirred suspension of compound INTC-2 (230 mg, 0.97 mmol) in dichloroethane (5 mL) at room temperature, oxalyl dichloride (135 mg, 1.07 mmol) was added. The resulting suspension was heated to 80° C. for 1 hour. The mixture was cooled to room temperature, and 2-methylpyridin-3-amine (209.8 mg, 1.94 mmol) was added. The mixture was stirred at room temperature for 16 hours. The precipitate was collected, washed with water, and dried to give compound INTC-3 (120 mg, 33.3% yield). LCMS: 372.0 [M+H] + .

[0272] Step 4: To a mixture of compound INTC-3 (80.0 mg, 0.21 mmol) in THF (3.0 mL) was added KHMDS (0.47 mL, 0.47 mmol, 1.0 M in THF) at -20 °C, and the resulting mixture was warmed to room temperature over 1 h. The mixture was concentrated, diluted with water, and the pH was adjusted to 6-7 with 4.0 M aqueous HCl. The precipitate was collected, washed with water, and dried to give compound intermediate C (60.0 mg, 79.2% yield). 1H NMR(400MHz,DMSO-d6)δ 11.71(s,1H),8.66(dd,J=4.8Hz,1.6Hz,1H),7.88(dd,J=8.0Hz,1.6Hz,1H),7.5 2(dd,J=7.6Hz,4.8Hz,1H),7.15(s,1H),5.98(s,1H),3.98(s,3H),2.25(s,3H).

[0273] Example 1: Synthesis of 7-chloro-4-(prop-2-yn-1-ylamino)-1-(pyridin-3-yl)quinazolin-2(1H)-one

[0274] [ka] Steps 1 and 2: 4-Chloro-2-fluorobenzoic acid (10.0 g, 57.29 mmol) was dissolved in SOCl (20.0 mL), and the resulting solution was heated at 70 °C for 2 h. The solution was then cooled to room temperature. Excess SOCl was removed under vacuum, and the residue was dissolved in dioxane (30.0 mL) and treated with NH OH (40%, 30.0 mL). The resulting solution was stirred at 0 °C for 1 h until room temperature. The mixture was concentrated under reduced pressure and diluted with water with stirring until a white solid precipitated. The solid was removed by filtration, washed with water (50.0 mL), and dried under reduced pressure to give compound 1-3 (7.80 g, 78% yield) as a white solid. LCMS: Rt: 1.250 min; MS m / z (ESI): 174.0 [M+H] + .

[0275] Step 3: To a stirred suspension of compound 1-3 (7.80 g, 44.94 mmol) in dichloroethane (60.0 mL) at room temperature, oxalyl dichloride (6.37 g, 49.43 mmol) was added. The resulting suspension was heated to 80° C. for 1 h and then cooled to room temperature. Pyridin-3-amine (8.2 mL, 89.88 mmol) was added to the reaction mixture. The resulting mixture was stirred at room temperature for 30 min and then cooled to 0° C. for 10 min. The precipitate was collected by filtration, washed with water (60.0 mL), and dried under vacuum to give compound 1-4 (12.6 g, 95% yield).

[0276] Step 4: To a stirred solution of compound 1-4 (12.6 g, 42.90 mmol) in THF (100.0 mL) was added KHMDS (21.5 mL, 94.39 mmol, 2.2 equiv.) at −20° C., and the resulting mixture was allowed to warm to room temperature over 3 h. The reaction mixture was then diluted with EtOAc (40.0 mL) and washed with saturated aqueous ammonium chloride. The organic layer was dried over NaSO, filtered, and concentrated in vacuo. The residue was further sonicated in DCM (15.0 mL). The resulting solid was collected by filtration and dried in vacuo to give compound 1-5 (10.0 g, 85% yield). LCMS: Rt: 1.077 min; MS m / z (ESI): 274.0 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ 11.92(s,1H),8.76(dd,J=4.8,1.2Hz,1H),8.68(d,J=2.0Hz,1H),8.06(d,J=8.4Hz,1H),7.99- 7.97(m,1H),7.70-7.67(dd,J=4.2,1.6Hz,1H),7.35(dd,J=4.8Hz,1H),6.39(d,J=1.6Hz,1H).

[0277] Step 5: A mixture of compound 1-5 (100.0 mg, 0.37 mmol), prop-2-yn-1-amine (121.0 mg, 2.19 mmol), PyAOP (286.0 mg, 0.55 mmol), and DBU (280.0 mg, 1.83 mmol) in DMF (2.0 mL) was stirred at room temperature for 8 hours. Water (20.0 mL) was added to the resulting mixture. The organic layer was separated, and the aqueous layer was extracted with EtOAc (50.0 mL × 3). The combined organic layers were washed with water and brine. The organic solution was dried over Na2SO4, filtered, concentrated, and purified by preparative TLC (dichloromethane:methanol = 20:1) to give the crude adduct, which was further purified by preparative HPLC to give Example 1 (8.6 mg, 8% yield). LCMS:Rt:1.255min;MS m / z(ESI):311.1[M+H] + . 1H NMR(400MHz,DMSO-d6)δ 9.08(dd,J=4.8,4.8Hz1H),8.72(dd,J=4.8,1.2Hz,1H),8.57(d,J=2.0Hz,1H),8.20(d,J=8.8Hz,1H),7.87(d,J=8.8Hz,1H) ,7.64(dd,J=8.0,3.2Hz,1H),7.33(dd,J=8.8,1.6Hz,1H),6.37(d,J=2.0Hz,1H),4.32(dd,J=4.8,2.0Hz,2H),3.22(s,1H).

[0278] Example 2: Synthesis of 7-chloro-4-((3-cyclopropylprop-2-yn-1-yl)amino)-1-(pyridin-3-yl)quinazoline-2(1H)-1

[0279] [ka] A mixture of compound 1-5 (100.0 mg, 0.37 mmol, 1.0 equiv.), 3-cyclopropylprop-2-yn-1-amine hydrochloride (96.0 mg, 0.73 mmol), PyAOP (286 mg, 0.55 mmol), DBU (340.0 mg, 2.19 mmol), and DMAP (23 mg, 0.18 mmol) in DMF (2.0 mL) was stirred at room temperature for 16 hours. Water (20.0 mL) was added to the resulting solution. The aqueous phase was extracted with EtOAc (50.0 mL × 3). The combined organic layers were washed with water, brine, dried over Na2SO4, filtered, concentrated, and purified by preparative TLC (dichloromethane:methanol = 20:1) to give the crude adduct. The crude product was further purified by preparative HPLC to give Example 2 (16.6 mg, 13% yield). LCMS:Rt:1.450min;MS m / z(ESI):351.1[M+H] + . 1H NMR(400MHz,DMSO-d6)δ 8.99(t,J=5.2Hz,1H),8.71(d,J=3.6Hz,1H),8.56(s,1H),8.20(d,J=8.8Hz,1H),7.88-7.85(m,1H),7.64(dd,J=8.0,4.8Hz,1H),7.3 0(dd,J=8.8,2.0Hz,1H),6.36(d,J=1.6Hz,1H),4.28(dd,J=4.8,1.6Hz,2H),1.35-1.32(m,1H),0.79-0.74(m,2H),0.62-0.58(m,2H).

[0280] Example 3: Synthesis of 7-chloro-4-((4-(dimethylamino)but-2-yn-1-yl)amino)-1-(pyridin-3-yl)quinazolin-2(1H)-one

[0281] [ka] Step 1: To a stirred solution of di-tert-butyliminodicarbonate (3.54 g, 16.3 mmol) in DMF (50.0 mL) at 0 °C, NaH (60%, 585 mg, 24.4 mmol) was added. The cooling bath was removed, and additional DMF (70.0 mL) was added over 15 min. 1,4-Dichlorobut-2-yne (4.00 g, 32.5 mmol) was then added, and the resulting mixture was stirred at room temperature for 2 h. The reaction mixture was poured into a cold LiCl (5% aqueous solution, 500.0 mL) solution and extracted with EtOAc (100.0 mL × 3). The combined organic layers were washed with water, brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to give the crude residue. The residue was purified by gel column chromatography (petroleum ether:ethyl acetate = 10:1) to give compound 3-2 (960.0 mg, 10% yield) as a clear oil. 1 H NMR (400MHz, DMSO-d6) δ 4.46 (s, 2H), 4.34 (s, 2H), 1.46 (s, 18H).

[0282] Step 2: To a stirred solution of 3-2 (300.0 mg, 0.99 mmol) in THF (3.0 mL) was added dimethylamine (2.0 M in THF) (2.0 mL, 1.98 mmol) at 0 °C. The resulting mixture was stirred at room temperature for 16 h. The reaction was diluted with ethyl acetate (5.0 mL) and water (5.0 mL). The aqueous layer was extracted with ethyl acetate (50.0 mL × 3). The combined organic layers were washed with water, brine, dried over Na2SO4, filtered, and concentrated in vacuo to give 3-3 (200.0 mg, 0.64 mmol, 65% yield) as a clear oil. 1 H NMR (400MHz, DMSO-d6) δ 4.28 (s, 2H), 3.19 (s, 2H), 2.14 (s, 6H), 1.45 (s, 18H).

[0283] Step 3: To a stirred solution of 3-3 (200.0 mg, 0.64 mmol) in DCM (3.0 mL) and MeOH (3.0 mL) was added HCl solution (3.0 mL, 3.0 M in EtOAc), and the reaction was stirred at room temperature for 1.5 h. The resulting reaction was concentrated in vacuo to give 3-4 (105.0 mg, 89% yield), which was used in the next step without further purification.

[0284] Steps 4 and 5: To a stirred solution of 1-5 (100.0 mg, 0.37 mmol) in toluene (1.0 mL) was added DIPEA (472.0 mg, 3.65 mmol) and POCl (280.0 mg, 1.83 mmol) at 0 °C. The resulting suspension was heated to 100 °C for 2 h and then cooled to room temperature. A solution of 3-4 (105.0 mg, 0.57 mmol) and DIPEA (0.24 mL, 1.46 mmol) in NMP (1.0 mL) was added. The mixture was stirred at room temperature for 16 h. Water (20.0 mL) was added, and the mixture was extracted with EtOAc (20.0 mL × 3). The aqueous layer was concentrated and purified by preparative HPLC to give the residue. This residue was further purified by preparative TLC (petroleum ether:ethyl acetate = 10:1) to give Example 3 (6.4 mg, 5% yield). LCMS:Rt:0.895min;MS m / z(ESI):368.1[M+H] + . 1H NMR(400MHz,DMSO-d6)δ 8.76(dd,J=4.8,1.6Hz,1H),8.58(d,J=2.4Hz,1H),8.29(d,J=8.8Hz,1H),7.91(s,1H),7.71-7.68(m,1H)7. 56~7.53(m,1H),7.19(dd,J=8.0,4.2Hz,1H),6.50(d,J=2.0Hz,1H),4.54(s,2H),3.78(s,2H),2.86(s,6H).

[0285] Example 4: Synthesis of 7-chloro-4-((1-ethynylcyclopropyl)amino)-1-(pyridin-3-yl)quinazoline-2(1H)-1

[0286] [ka] To a solution of 1-5 (100.0 mg, 0.37 mmol) in toluene (1.0 mL) was added DIPEA (472 mg, 3.65 mmol) and POCl (280.0 mg, 1.83 mmol) at 0 °C. The resulting mixture was heated to 100 °C for 2 h and then cooled to room temperature. A solution of 1-ethynylcyclopropan-1-amine hydrochloride (43.0 mg, 0.73 mmol) and DIPEA (0.24 mL, 1.46 mmol) in NMP (0.5 mL) was added. The mixture was stirred at room temperature for 16 h. Water (20.0 mL) was added to the resulting mixture. The aqueous layer was extracted with EtOAc (20.0 mL × 3). The combined organic layers were washed with brine, dried over NaSO, filtered, concentrated, and purified by preparative TLC (petroleum ether: EtOAc = 1:1) to give the residue. The residue was purified by preparative HPLC to give Example 4 (6.4 mg, 5% yield). LCMS: Rt: 5.747 min; MS m / z (ESI): 337.0 [M+H] + . 1H NMR(400MHz,DMSO-d6)δ 9.13(s,1H),8.72(dd,J=4.8,1.2Hz,1H),8.58(d,J=2.4Hz,1H),8.16(d,J=8.4Hz,1H),7.90-7.87(m,1H),7.65(dd,J=8.0,4.8Hz,1H). 7.31(dd,J=8.4,1.6Hz,1H),6.36(d,J=1.6Hz,1H),3.05(s,1H),1.32~1.20(m,4H).

[0287] Example 5: Synthesis of 4-(allylamino)-7-chloro-1-(pyridin-3-yl)quinazolin-2(1H)-one

[0288] [ka] To a solution of A-5 (100.0 mg, 0.37 mmol) in toluene (1.0 mL) was added DIPEA (472.0 mg, 3.65 mmol) and POCl (280.0 mg, 1.83 mmol) at 0 °C. The resulting mixture was heated to 100 °C for 2 h and then cooled to room temperature. A solution of DIPEA (236.0 mg, 1.83 mmol) and prop-2-en-1-amine (68.0 mg, 0.73 mmol) in NMP (0.5 mL) was added to the resulting solution. The mixture was further stirred at 50 °C for 2 h. Water (15.0 mL) was added, and the pH was adjusted to 8–9 by adding aqueous NaCO solution. The resulting aqueous solution was extracted with EtOAc (50.0 mL × 3). The combined organic layers were washed with brine, dried over NaSO, filtered, concentrated, and purified by preparative TLC to give a residue. The residue was purified by preparative HPLC to give Example 5 (6.2 mg, 5% yield over two steps). LCMS: Rt: 1.057 min; MS m / z (ESI): 313.1 [M+H] + . 1H NMR(400MHz,DMSO-d6)δ 8.86(t,J=4.4Hz,1H),8.70(d,J=3.6Hz,1H),8.55(d,J=1.2Hz,1H),8.24(d,J=8.4Hz,1H),7.85(d,J=8 .0Hz,1H),7.65-7.62(m,1H),7.32(d,J=8.4Hz,1H),6.36(s,1H),6.04-5.95(m,1H),5.27-5.15(m,2H). 4.17(s,2H).

[0289] Example 6: Synthesis of 7-chloro-4-(pent-4-yn-1-ylamino)-1-(pyridin-3-yl)quinazoline-2(1H)-1

[0290] [ka] A mixture of A-5 (100.0 mg, 0.37 mmol), pent-4-yn-1-amine hydrochloride (87.4 mg, 0.73 mmol), PyAOP (286.0 mg, 0.55 mmol), and DBU (334.0 mg, 2.19 mmol) in DMF (2.0 mL) was stirred at room temperature for 3 hours. Water (20.0 mL) was added, and the aqueous solution was extracted with EtOAc (50.0 mL × 3). The combined organic layers were washed with water, brine, dried over NaSO, filtered, concentrated, and purified by preparative TLC to give Example 6 (7.8 mg, 6% yield). LCMS: Rt: 1.360 min; MS m / z (ESI): 339.1 [M+H] + . 1 H NMR(400MHz,MeOD)δ 8.73(d,J=3.6Hz,1H),8.56(d,J=1.6Hz,1H),8.06(d,J=8.4Hz,1H),7.88(d,J=8.4Hz,1H),7.70(dd,J=8.0,5.2Hz,1H). 7.28(dd,J=8.8,2.0Hz,1H),6.52(d,J=1.6Hz,1H),3.73(t,J=7.2Hz,2H),2.35~2.25(m,2.0Hz,2H),1.99~1.94(m,1H)1.35~1.28(m,2H).

[0291] Example 7: Synthesis of 4-(prop-2-yn-1-ylamino)-1-(pyridin-3-yl)-7-(trifluoromethyl)quinazoline-2(1H)-1

[0292] [ka] Step: To a stirred solution of 2-fluoro-4-(trifluoromethyl)benzamide (2.00 g, 9.66 mmol) in dichloroethane (15.0 mL) at room temperature was added oxalyl dichloride (1.37 g, 10.62 mmol). The resulting solution was heated at 80° C. for 1 h. The reaction mixture was cooled to room temperature. Pyridin-3-amine (1.82 g, 19.31 mmol) was added, and the mixture was stirred at room temperature for 30 min and then cooled to 0° C. The resulting solution was stirred for an additional 10 min. The precipitate was collected by filtration, washed with water, and dried under vacuum to give 7-1 (2.70 g, 86% yield). LCMS: Rt: 1.390 min; MS m / z (ESI): 328.1 [M+H] + .

[0293] Step 2: LiHMDS (1.5 mL, 6.72 mmol) was added to a mixture of 7-1 (1.00 g, 3.06 mmol) in THF (10.0 mL) at −20° C., and the resulting mixture was allowed to warm to room temperature over 2 h. The reaction mixture was then diluted with EtOAc (30.0 mL) and washed with saturated aqueous ammonium chloride. The organic layer was dried over NaSO, filtered, and concentrated in vacuo. The residue was further sonicated in water, collected by filtration, and dried in vacuo to give 7-2 (600.0 mg, 64% yield). LCMS: Rt: 1.405 min; MS m / z (ESI): 308.1 [M+H] + .

[0294] Steps 3 and 4: To a stirred solution of 7-2 (100.0 mg, 0.33 mmol) in toluene (1.0 mL) was added DIPEA (0.55 mL, 3.30 mmol) and POCl (0.15 mL, 1.65 mmol) at 0 °C. The resulting mixture was heated at 100 °C for 2 h. After cooling to room temperature, a solution of prop-2-yn-1-amine (37 mg, 0.66 mmol) and DIPEA (0.27 mL, 1.65 mmol) in NMP (0.5 mL) was added. The mixture was stirred at room temperature for 16 h. Water (20.0 mL) was added, and the aqueous layer was extracted with EtOAc (20.0 mL × 3). The combined organic layer was washed with brine, dried over NaSO, filtered, concentrated, and purified by preparative TLC (EtOAc:methanol = 30:1) to give Example 7 (21.0 mg, 19% yield). LCMS:Rt:1.177min;MS m / z(ESI):345.1[M+H] + . 1 H NMR(400MHz,DMSO-d6)δ 9.27(t,J=5.2Hz,1H),8.74(d,J=4.4Hz,1H),8.61(d,J=2.0Hz,1H),8.42(d,J=8.4Hz,1H),7. 91(d,J=6.8Hz,1H),8.68~8.62(m,2H),6.58(s,1H),4.36~4.34(m,2H),3.24(t,J=4.4Hz,1H). 19 F NMR(376MHz,DMSO-d6)-62.11.

[0295] Example 8: Synthesis of 4-(but-3-yn-1-ylamino)-7-chloro-1-(2-chlorophenyl)quinazolin-2(1H)-one

[0296] [ka] To a solution of 1-3 (10.0 g, 57.80 mmol) in anhydrous THF (100.0 mL) was added (COCl) (11.01 g, 86.70 mmol) at 0 °C. The resulting solution was stirred at 80 °C for 1 h. The crude product was dissolved in THF (150.0 mL). 2-Chloroaniline (11.01 g, 86.70 mmol) was added to the resulting mixture and stirred for 1 h. The resulting precipitated solid was filtered and washed with water (100.0 mL) to give 8-1 (13.0 g, 69% yield). 1 H NMR(400MHz,DMSO-d6)δ 11.35(s,1H),10.96(s,1H),8.24(d,J=5.8Hz,1H),7.73(d,J=7.9Hz,1H),7.61(d,J=1 2.9Hz, 1H), 7.52 (d, J=7.2Hz, 1H), 7.45-7.39 (m, 1H), 7.39-7.31 (m, 1H), 7.13 (s, 1H).

[0297] Step 2: To a solution of 8-1 (14.0 g, 42.8 mmol) in anhydrous THF (150.0 mL) was added KHMDS (128.0 mL, 128 mmol). The resulting solution was stirred at 70 °C for 1 h. The reaction mixture was quenched with water (100.0 mL), and the aqueous layer was acidified to pH = 7 by adding 3.0 M HCl solution. The aqueous was extracted with ethyl acetate (100.0 mL x 3). The combined organic layers were dried over MgSO4 and concentrated to give 8-2 (7.3 g, 56% yield). LCMS: Rt: 982 min; MS m / z (ESI): 307.0 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ 11.96(s,1H),8.08(m,1H),7.75(s,1H),7.66-7.56(m,3H),7.36(d,J=8.8Hz,1H),6.24(s,1H).

[0298] Step 3: A mixture of 8-2 (40.0 mg, 0.13 mmol), but-3-yn-1-amine hydrochloride (21.0 mg, 0.20 mmol), PyAOP (102.0 mg, 0.20 mmol), and TEA (66.0 mg, 0.65 mmol) in DMF (0.5 mL) was stirred at room temperature for 2 hours. Water (10.0 mL) was added, and the aqueous layer was extracted with EtOAc (10.0 mL × 3). The combined organic layers were washed with brine, dried over Na2SO4, filtered, concentrated, and purified by preparative TLC to give Example 8 (2.3 mg, 5% yield). LCMS: Rt: 1.705 min; MS m / z (ESI): 358.0 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ 8.88(t,J=5.2Hz,1H),8.20(d,J=8.4Hz,1H),7.76-7.73(m,1H),7.59-7.56(m,2H),7.53-7.52(m,1H), 7.36-7.33(m,1H),6.22(d,J=3.2Hz,1H),3.65-3.60(m,2H),2.91(t,J=2.6Hz,1H),2.60-2.56(m,2H).

[0299] Example 9: Synthesis of 7-chloro-4-(prop-2-yn-1-yloxy)-1-(pyridin-3-yl)quinazolin-2(1H)-one (Compound 9)

[0300] [ka] To a solution of A-5 (100.0 mg, 0.37 mmol) in toluene (1.0 mL) was added DIPEA (472 mg, 3.65 mmol) and POCl3 (280.0 mg, 1.83 mmol) at 0 °C. The resulting mixture was heated to 100 °C for 2 h and then cooled to room temperature. A solution of prop-2-yn-1-ol (82.0 mg, 1.46 mmol) and t-BuOK (123.0 mg, 1.10 mmol) in THF (0.5 mL) was added. The reaction mixture was stirred at room temperature for 30 min and at 80 °C for 16 h. After cooling to room temperature, water (20.0 mL) was added to the resulting mixture. The aqueous solution was extracted with EtOAc (30.0 mL × 3). The combined organic layers were washed with brine, dried over Na2SO4, filtered, concentrated, and purified by preparative HPLC to give compound 9 (2.1 mg, 2% yield over two steps). LCMS: Rt: 1.287 min; MS m / z (ESI): 312.1 [M+H] + . 1 H NMR(400MHz,MeOD-d4)δ 8.81-8.80(m,1H),8.65(s,1H),8.16-8.14(dd,J=8.8,2.0Hz,1H),7.99-7.97(dd,J=8.0, 1.2Hz, 1H), 7.79-7.75 (m, 1H), 7.42-7.40 (m, 1H), 6.67 (s, 1H), 4.61 (s, 2H), 3.15 (s, 1H).

[0301] Example 10: Synthesis of 7-chloro-1-(2-chlorophenyl)-4-(prop-2-yn-1-ylamino)quinazoline-2(1H)-1

[0302] [ka] To a solution of 8-2 (100.0 mg, 325.59 μmol) in DMF (3.0 mL) was added prop-2-yn-1-amine (179.33 mg, 3.26 mmol), PyAOP (254.6 mg, 488.39 μmol), and DBU (173.6 mg, 1.14 mmol). The mixture was stirred at 120 °C for 0.5 h under microwave conditions and a nitrogen atmosphere. The residue was purified by preparative HPLC (elution solvent system: (0.1% FA) water-MeCN, column: Xbridge C18 250 mm*19 mm, starting gradient (%): 37, final gradient (%): 58, gradient time (min): 15, flow rate (mL / min): 20) to give Example 10 (15.7 mg, 14% yield). LCMS:Rt:2.420min;MS m / z(ESI):344.10[M+H] + . 1 H NMR(400MHz,DMSO-d6)δ 9.06(t,J=5.4Hz,1H),8.18(d,J=8.7Hz,1H),7.76-7.68(m,1H),7.57-7.48(m,3H),7. 31(d,J=10.7Hz,1H),6.20(s,1H),4.29(dd,J=10.3,2.7Hz,2H),3.19(t,J=2.5Hz,1H).

[0303] Example 11: Synthesis of 7-chloro-1-(2-chlorophenyl)-4-(3-ethynylpiperidin-1-yl)quinazoline-2(1H)-1

[0304] [ka] To a solution of 8-2 (100.0 mg, 325.59 μmol) in DMF (3.0 mL) was added 3-ethynylpiperidine hydrochloride salt (89.2 mg, 488.39 μmol), PyAOP (254.6 mg, 488.39 μmol), and DBU (247.84 mg, 1.63 mmol). The mixture was stirred at 120° C. for 0.5 h under microwave conditions and a nitrogen atmosphere. The residue was purified by preparative HPLC to give Example 11 (39.2 mg, 30% yield). LCMS: Rt: 2.756 min; MS m / z (ESI): 398.20 [M+H]. + .1 H NMR(400MHz,DMSO-d6)δ 7.89(dd,J=8.7,5.6Hz,1H),7.75-7.68(m,1H),7.59-7.45(m,3H),7.25(d,J=10.8Hz,1H),6.25(d,J=4.8Hz,1H),4.12-3.94( m,1H),3.78(d,J=15.3Hz,1H),3.69-3.47(m,2H),3.01(d,J=19.3Hz,1H),2.79(s,1H),2.02-1.80(m,2H),1.76-1.56(m,2H).

[0305] Example 12: Synthesis of 7-chloro-1-(2-chlorophenyl)-4-(3-ethynyl-3-hydroxyazetidin-1-yl)quinazoline-2(1H)-1

[0306] [ka] To a solution of 8-2 (100.0 mg, 325.59 μmol) in DMF (3.0 mL) was added 3-ethynylazetidin-3-ol trifluoroacetate (102.64 mg, 488.39 μmol), PyAOP (254.6 mg, 488.39 μmol), and DBU (247.84 mg, 1.63 mmol). The mixture was stirred at 120 °C for 0.5 h under microwave conditions and a nitrogen atmosphere. The residue was purified by preparative HPLC to give Example 12 (15.7 mg, 13% yield). LCMS: Rt: 2.359 min; MS m / z (ESI): 386.10 [M+H]. + . 1 H NMR(400MHz,DMSO-d6)δ 7.82(d,J=8.8Hz,1H),7.71(dd,J=6.1,3.4Hz,1H),7.56-7.52(m,2H),7.49-7.44(m,1H),7.1 9(dd,J=8.7,2.1Hz,1H),6.78(s,1H),6.21(d,J=2.0Hz,1H),5.21-4.04(m,4H),3.75(s,1H).

[0307] Example 13: Synthesis of 7-chloro-1-(2-chlorophenyl)-4-(4-ethynylpiperidin-1-yl)quinazoline-2(1H)-1

[0308] [ka] To a solution of 8-2 (100.0 mg, 325.59 μmol) in DMF (3.0 mL) was added 4-ethynylpiperidine hydrochloride salt (71.12 mg, 488.39 μmol), PyAOP (254.6 mg, 488.39 μmol), and DBU (247.84 mg, 1.63 mmol). The mixture was stirred at 120 °C for 0.5 h under microwave conditions and a nitrogen atmosphere. The residue was purified by preparative HPLC to give Example 13 (28.6 mg, 22% yield). LCMS: Rt: 2.736 min; MS m / z (ESI): 398.10 [M+H]. + . 1 H NMR(400MHz,DMSO-d6)δ 7.84(d,J=8.7Hz,1H),7.76-7.68(m,1H),7.58-7.46(m,3H),7.22(dd,J=8.7,2.1Hz,1H),6.24(d,J=2.0Hz,1H),4.04-3.93( m,2H),3.58-3.42(m,2H),3.01(d,J=2.4Hz,1H),2.80(d,J=9.7Hz,1H),1.95(d,J=10.7Hz,2H),1.69(dd,J=16.6,3.9Hz,2H).

[0309] Example 14: Synthesis of 4-((4-morpholinobut-2-yn-1-yl)amino)-1-(pyridin-3-yl)-7-(trifluoromethyl)quinazoline-2(1H)-1

[0310] [ka] Step 1: To a solution of di-tert-butyliminodicarbonate (4.4 g, 20.33 mmol) in DMF (50 mL) was added NaH (1.2 g, 30.49 mmol, 60% oil dispersion) at 0 °C. The cold bath was removed, and additional DMF (50 mL) was added. After stirring for 15 min, 1,4-dichlorobut-2-yne (5.0 g, 40.66 mmol) was quickly added, and the mixture was stirred at room temperature for 2 h. The mixture was poured into cold LiCl solution (5% aqueous solution, 500 mL) and extracted with EtOAc (100 mL × 3). The combined organic layers were washed with water, brine, dried over Na2SO4, and concentrated. The residue was purified by gel column chromatography to give compound 14-1 (1.7 g, 13.8% yield). 1 H NMR (400MHz, DMSO-d6) δ 4.46 (s, 2H), 4.34 (s, 2H), 1.46 (s, 18H).

[0311] Step 2: To a solution of morpholine (732.0 mg, 8.40 mmol) and compound 14-1 (1.7 g, 5.60 mmol) in MeCN (30 mL) was added KCO (1.6 g, 11.20 mmol) at room temperature, and then the mixture was stirred at 60° C. for 4 h. The reaction mixture was cooled to room temperature, filtered, washed with EA, and the filtrate was concentrated and purified by gel column chromatography to give compound 14-2 (1.1 g, 55.4% yield). 1 H NMR(400MHz,DMSO-d6)δ 4.28(s,2H),3.56(t,J=4.4Hz,4H),3.26(s,2H),2.41(t,J=4.8Hz,4H),1.46(s,18H). Step 3: To a solution of compound 14-2 (1.1 g, 3.10 mmol) in DCM (10 mL) and MeOH (5 mL) was added HCl (3.0 mL, 3 M in EtOAc) at 0 °C, and the reaction was stirred at room temperature for 5 h. The mixture was concentrated to give compound 14-3 (600.0 mg, 85.2% yield). 1 H NMR (400MHz, DMSO-d6) δ 8.64 (s, 3H), 4.16 (s, 2H), 3.96-3.83 (m, 6H), 3.20-3.45 (m, 4H). Step 4: To a stirred solution of compound C-2 (100.0 mg, 0.33 mmol) in toluene (1 mL) was added DIEA (420.7 mg, 3.25 mmol) and POCl3 (249.0 mg, 1.63 mmol) at 0 °C. The resulting suspension was heated to 100 °C for 2 h and then cooled to room temperature. A mixture of DIEA (252.5 mg, 1.95 mmol) and compound 14-3 (300.0 mg, 1.30 mmol) in MeCN (1.5 mL) was added to the reaction at 0 °C. The mixture was then stirred at room temperature for 16 h and concentrated. The residue was purified by column chromatography to give compound 14. LCMS: 444.1 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ 9.28(t,J=5.2Hz,1H),8.73(dd,J=4.8Hz,1.6Hz,1H),8.60(d,J=2.0Hz,1H),8.43(d,J=8.4Hz,1H),7.92-7.89(m,1H),7 .68-7.61(m,2H),6.58(s,1H),4.40(dd,J=3.2Hz,2.0Hz,2H),3.57(t,J=4.8Hz,4H),3.28(s,2H),2.33(t,J=2.0Hz,4H).

[0312] [Table 2]

[0313] Example 15: Synthesis of 7-chloro-1-(2-methylpyridin-3-yl)-4-(prop-2-yn-1-ylamino)quinazoline-2(1H)-1

[0314] [ka] Step 1: To a stirred suspension of 4-chloro-2-fluorobenzamide (500.0 mg, 2.88 mmol) in dichloroethane (15 mL) was added oxalyl dichloride (402.0 mg, 3.17 mmol) at room temperature. The resulting suspension was heated to 80° C. for 1 hour. The mixture was cooled to room temperature, and 2-methylpyridin-3-amine (623.0 mg, 5.76 mmol) was added. The mixture was stirred at room temperature for 1 hour and then cooled to 0° C. The precipitate was collected by filtration, washed with water, and dried to give compound 15-1. LCMS: 308.1 [M+H] + .

[0315] Step 2: KHMDS (3.9 mL, 3.93 mmol, 1.0 M in THF) was added to a mixture of compound 15-1 (550.0 mg, 1.79 mmol) in THF (10 mL) at −20° C., and the resulting mixture was allowed to warm to room temperature over 3 hours. The mixture was concentrated, diluted with water, and the pH was adjusted to 6-7 with 4.0 M aqueous HCl. The precipitate was collected by filtration, washed with water, and dried to give compound 15-2. LCMS: 288.1 [M+H] + .

[0316] Step 3: To a stirred suspension of compound 15-2 (100.0 mg, 0.35 mmol) in toluene (3 mL) was added DIPEA (450.0 mg, 3.48 mmol) and POCl (266.0 mg, 1.74 mmol) at 0 °C. The suspension was heated at 100 °C for 2 h and then cooled to room temperature. A mixture of DIPEA (225.0 mg, 1.74 mmol) and prop-2-yn-1-amine (192.0 mg, 3.48 mmol) in NMP (2 mL) was added. The mixture was stirred at 50 °C for 1 h and concentrated. The residue was diluted with DCM (20 mL) and water (20 mL) and extracted with DCM (20 mL × 3). The combined organic phase was washed with water (50 mL × 3), brine, dried over anhydrous NaSO, and concentrated. The residue was purified by preparative TLC to give compound 15. LCMS: 325.1 [M+H] + . 1H NMR(400MHz,DMSO-d6)δ 9.11(t,J=5.6Hz,1H),8.61(m,1H),8.23(d,J=8.8Hz,1H),7.74(dd,J=8.0Hz,1.6Hz),7.49-7.44(m,1 H),7.35(dd,J=8.8Hz,2.0Hz,1H),6.28(d,J=2.0Hz,1H),4.42-4.24(m,2H),3.23(s,1H),2.17(s,3H).

[0317] Example 16: Synthesis of 7-chloro-4-((1-ethynylcyclopropyl)amino)-1-(2-methylpyridin-3-yl)quinazoline-2(1H)-1

[0318] [ka] To a stirred suspension of compound 15-2 (110.0 mg, 0.38 mmol) in toluene (2.0 mL) was added DIPEA (494.0 mg, 3.82 mmol) and POCl (293.0 mg, 1.91 mmol) at 0 °C. The resulting suspension was heated to 100 °C for 2 h and then cooled to room temperature. A mixture of DIPEA (494.0 mg, 3.82 mmol) and 1-ethynylcyclopropan-1-amine hydrochloride (269.0 mg, 2.29 mmol) in NMP (0.5 mL) was added, and the mixture was stirred at room temperature for 16 h. The mixture was diluted with DCM (5 mL) and water (15 mL), extracted with DCM (10 mL × 3), and the combined organic phase was washed with water (10 mL × 3), brine, dried over Na SO , and concentrated. The residue was purified by gel column chromatography to give compound 16 (80.4 mg, yield 60.0%). LCMS: 351.0 [M+H] + . 1H NMR(400MHz,DMSO-d6)δ 9.13(s,1H),8.61(d,J=4.0Hz,1H),8.20(d,J=8.8Hz,1H),7.77(d,J=7.2Hz,1H),7.49-7.4 5(m,1H),7.33(d,J=7.6Hz,1H),6.27(s,1H),3.05(s,1H),2.17(s,3H),1.32-1.20(m,4H).

[0319] Example 17: Synthesis of 7-chloro-4-(prop-2-yn-1-ylamino)-1-(pyrazin-2-yl)quinazoline-2(1H)-1

[0320] [ka] Step 1: To a solution of compound A-3 (1.0 g, 5.76 mmol) in DCE (15 mL) was added oxalyl dichloride (805.0 mg, 6.34 mmol) at room temperature, and the reaction was stirred at 80 °C for 1 h. After cooling to room temperature, pyrazin-2-amine (1.1 g, 11.52 mmol) was added, and a precipitate formed. The mixture was stirred at room temperature for an additional 1 h, and the precipitate was collected by filtration, washed with water, and dried to give compound 17-1 (1.3 g, 76.4% yield). LCMS: 295.1 [M+H] + .

[0321] Step 2: To a solution of compound 17-1 (800.0 mg, 2.71 mmol) in DMF (8 mL) was added KHMDS (6.0 mL, 5.97 mmol, 1 M in THF) at -20 °C, and the mixture was then stirred at room temperature for 16 h. The reaction was diluted with water (80 mL) and the pH was adjusted to 6-7 with 4 M aqueous HCl. The precipitate was collected by filtration, washed with water, and dried to give compound 17-2 (520 mg, 69.7% yield). LCMS: 275.0 [M+H] + .

[0322] Step 3: To a solution of compound 17-2 (100.0 mg, 0.36 mmol) in toluene (1 mL) was added POCl (279.0 mg, 1.82 mmol) and DIEA (470.5 mg, 3.64 mmol). The suspension was heated to 100 °C for 2 h and then cooled to room temperature. A mixture of prop-2-yn-1-amine (100.3 mg, 1.82 mmol) and DIEA (235.3 mg, 1.82 mmol) in NMP (1 mL) was added, and the resulting mixture was stirred at room temperature for 16 h. The mixture was concentrated, and the residue was diluted with DCM (20 mL) and water (20 mL). Extraction was performed with DCM (20 mL × 3). The combined organic phase was washed with water (50 mL × 3), brine, dried over anhydrous NaSO, and concentrated. The residue was purified by preparative HPLC to give compound 17. LCMS: 312.1 [M+H] + . 1 H NMR(400MHz,CD3OD)δ 8.81-8.76(m,3H),8.08(d,J=8.8Hz,1H),7.32(dd,J=8.8Hz,1.6Hz,1H),6.20(d,J=2.0Hz,1H),4.45(d,J=2.4Hz,2H),2.68(t,J=2.4Hz,1H). Example 18: Synthesis of 7-bromo-4-(prop-2-yn-1-ylamino)-1-(pyridin-3-yl)quinazoline-2(1H)-1

[0323] [ka] Step 1: To a solution of 4-bromo-2-fluorobenzoic acid (30.0 g, 137.7 mmol) in anhydrous THF (300 mL) was added oxalyl chloride (26.25 g, 206.7 mmol) and DMF (0.5 mL). The mixture was stirred at room temperature for 1 hour and concentrated. The crude was dissolved in DCM (50 mL) and added dropwise to a solution of ammonia (93.6 mL, 1.37 mol) in MeOH (200 mL). The mixture was stirred at room temperature for 1 hour, concentrated, and dried to give compound 18-1. LCMS: 217.9 [M+H] + .

[0324] Step 2: To a solution of compound 18-1 (2.0 g, 9.17 mmol) in anhydrous THF (40 mL) was added (COCl) (1.75 g, 13.76 mmol) dropwise at 0 °C. The solution was stirred at 80 °C for 1 h and then concentrated. The crude was diluted with THF (30 mL) and pyridin-3-amine (950.0 mg, 10.1 mmol) was added dropwise. The mixture was filtered and the precipitated solid was washed to give compound 18-2. LCMS: 337.9 [M+H] + .

[0325] Step 3: To a solution of compound 18-2 (1.7 g, 5.03 mmol) in anhydrous THF (20 mL) was added KHMDS (20.0 mL, 20.1 mmol). The resulting solution was stirred at 70 °C for 1 h. The mixture was diluted with water (40 mL), and the aqueous layer was acidified to pH = 8 with 3.0 M HCl solution. The mixture was filtered, and the filtrate was washed with THF (20 mL x 2) to give compound 18-3. LCMS: 317.8 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ 11.89(s,1H),8.68(d,2H),8.02-7.85(m,2H),7.72-7.57(m,1H),7.51-7.37(m,1H),6.48(s,1H).

[0326] Step 4: To a stirred solution of compound 18-3 (100.0 mg, 0.32 mmol) in DMF (1 mL) was added prop-2-yn-1-amine (35.0 mg, 0.63 mmol), PyAOP (246.0 mg, 0.47 mmol), and DBU (144.0 mg, 0.94 mmol). The suspension was stirred at room temperature for 1 h. Water (15.0 mL) was added, and the mixture was extracted with DCM (10 mL × 3). The organic layer was washed with brine, dried over Na2SO4, filtered, concentrated, and purified by preparative HPLC to give compound 18. 1H NMR(400MHz,DMSO-d6)δ 9.09(s,1H),8.71(d,1H),8.57(d,1H),8.11(d,1H),7.88(m,1H),7.66(m,1H),7.46(d,1H),6.51(d,1H),4.32(s,2H),3.23-3.21(m,1H).

[0327] Example 19: Synthesis of 7-bromo-5-methoxy-1-(2-methylpyridin-3-yl)-4-(prop-2-yn-1-ylamino)quinazoline-2(1H)-1

[0328] [ka] Step 1: 4-Bromo-2,6-difluorobenzoic acid (3.0 g, 12.66 mmol) was mixed with SOCl (25.0 mL), and the resulting solution was heated at 80 °C for 2 h. The solution was cooled to room temperature and then concentrated. The residue was dissolved in dioxane (15 mL) and treated with NH OH (40%) (15.0 mL). The resulting mixture was stirred at 0 °C to room temperature for 1 h and concentrated. Water was added with stirring until a white solid precipitated. The solid product was then filtered and washed to give compound 19-1 (2.7 g, 83.7% yield). LCMS: 235.9 [M+H] + . Step 2: To a solution of sodium methanolate (50.5 mg, 0.93 mmol) in MeOH (4 mL), compound 19-1 (200 mg, 0.85 mmol) was added and the reaction was stirred at 80 °C for 6 h. The mixture was then cooled to room temperature and concentrated to give compound 19-2 (200 mg, 94.7% yield). LCMS: 248.0 [M+H] + .

[0329] Step 3: To a stirred suspension of compound 19-2 (200.0 mg, 0.80 mmol) in dichloroethane (4 mL) at room temperature, oxalyl chloride (112.0 mg, 0.88 mmol) was added. The resulting suspension was heated to 80° C. for 1 h. The mixture was cooled to room temperature, and 2-methylpyridin-3-amine (174.0 mg, 1.61 mmol) was added. The resulting reaction was stirred at room temperature for 20 min and then cooled to 0° C. The mixture was stirred at room temperature for 16 h. The precipitate was collected, washed, and dried to give compound 19-3 (200.0 mg, 58.4% yield). LCMS: 381.9 [M+H] + .

[0330] Step 4: NaH (50.0 mg, 1.25 mmol, 60% dispersion) was added to a mixture of compound 19-3 (160.0 mg, 0.42 mmol) in THF (5 mL) at -20 °C, and the resulting mixture was warmed to room temperature and then stirred for 2 h. The mixture was poured into ice water (3 mL), and the pH was adjusted to 6-7 with 4 M aqueous HCl. The precipitate was collected by filtration, washed with water, and dried to give compound 19-4 (120 mg, 71.2% yield). LCMS: 362.0 [M+H] + .

[0331] Step 5: To a stirred suspension of compound 19-4 (110.0 mg, 0.30 mmol) in toluene (3 mL) was added DIEA (392.0 mg, 3.03 mmol) and POCl (233.0 mg, 1.52 mmol) at 0 °C. The resulting suspension was heated to 100 °C for 2 h and then cooled to room temperature. A mixture of DIEA (392.0 mg, 3.03 mmol) and prop-2-yn-1-amine (167.0 mg, 3.03 mmol) in NMP (1 mL) was added and stirred at 50 °C for 1 h. The mixture was diluted with DCM (5 mL) and water (15 mL), extracted with DCM (10 mL × 3), and the combined organic phase was washed with water (10 mL × 3), brine, dried over anhydrous NaSO, and concentrated. The residue was purified by gel column chromatography to give compound 19. LCMS: 399.0 [M+H] + . 1H NMR(400MHz,DMSO-d6)δ 8.82(t,J=5.6Hz,1H),8.60(dd,J=4.8Hz,1.6Hz,1H),7.72(dd,J=8.0Hz,1.2Hz,1H),7.46(dd,J=8.0Hz,4.8Hz,1H) ,7.10(d,J=1.6Hz,1H),5.97(d,J=1.6Hz,1H),7.37-7.24(m,2H),4.05(s,3H),3.15(t,J=2.8Hz,1H),2.16(s,3H).

[0332] Example 20: Synthesis of 7-chloro-5-methoxy-4-(prop-2-yn-1-ylamino)-1-(pyridin-3-yl)quinazoline-2(1H)-1

[0333] [ka] To a solution of compound intermediate A (100 mg, 0.37 mmol) in DMF (2.5 mL) was added prop-2-yn-1-amine (36.3 mg, 0.74 mmol), PyAOP (253.0 mg, 0.49 mmol), and DBU (175.5 mg, 1.15 mmol). The reaction mixture was stirred at room temperature for 2 hours. Water (25 mL) was added, extracted with DCM (20 mL × 3), and the organic layer was washed with brine, dried over Na2SO4, filtered, concentrated, and purified by preparative HPLC to give compound 20 (41.2 mg, 36.7% yield). LCMS: 341.0 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ 8.81(t,J=5.2Hz,1H),8.70(dd,J=4.8Hz,1.6Hz,1H),8.53(d,J=2.0Hz,1H),7.87-7.80(m,1H),7.63(dd,J=8.0Hz ,4.8Hz,1H),6.98(d,J=1.6Hz,1H),5.91(d,J=1.6Hz,1H),4.31-4.29(m,2H),4.05(s,3H),3.13(t,J=2.4Hz,1H).

[0334] [Table 3]

[0335] Example 21: Synthesis of 7-chloro-5-methoxy-4-(prop-2-yn-1-ylamino)-1-(pyrazin-2-yl)quinazoline-2(1H)-1

[0336] [ka] Step 1: To a solution of compound INTA-2 (1.0 g, 4.91 mmol) in DCE (10 mL) was added oxalyl dichloride (686.0 mg, 5.40 mmol) at room temperature, and the mixture was then stirred at 80° C. for 1 hour. The mixture was cooled to room temperature, and pyrazin-2-amine (935.0 mg, 9.82 mmol) was added. A precipitate formed, and the mixture was stirred at room temperature for an additional hour and then cooled to 0° C. The precipitate was collected by filtration, washed with water, and dried to give compound 21-1 (800.0 mg, 50.3% yield). LCMS: 325.0 [M+H] + .

[0337] Step 2: To a solution of compound 21-1 (300.0 mg, 0.92 mmol) in THF (5 mL) was added KHMDS (2.0 mL, 2.03 mmol, 1 M in THF) at -20 °C, and the mixture was then stirred at 40 °C for 4 h. The mixture was concentrated, diluted with water, and the pH was adjusted to 6-7 with 4 M aqueous HCl. The precipitate was collected by filtration, washed with water and EtO, and dried to give compound 21-2 (220.0 mg, 78.2% yield). LCMS: 305.0 [M+H] + .

[0338] Step 3: To a stirred solution of compound 21-2 (150.0 mg, 0.49 mmol) in ACN (3 mL) was added DIEA (190.8 mg, 1.48 mmol) and POCl (226.0 mg, 1.48 mmol) at 0 °C. The suspension was heated to 80 °C for 2 h. After cooling to room temperature, a solution of prop-2-yn-1-amine (272.0 mg, 4.92 mmol) and DIEA (636.0 mg, 4.92 mmol) in ACN (1 mL) was added. The reaction was stirred at room temperature for 16 h and concentrated. The crude product was diluted with water (30 mL) and extracted with DCM (50 mL × 3). The combined organic layers were further washed with water (50 mL × 2), brine, dried over anhydrous NaSO, and concentrated. The residue was purified by column chromatography to give compound 21 (75.0 mg, 42.9% yield). LCMS: 342.0 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ 8.93(brs,1H),8.82-8.79(m,3H),7.01(d,J=1.6Hz,1H),6.06(d,J=1.6Hz,1H),4.31(s,2H),4.05(s,3H),3.15(s,1H).

[0339] Example 22: Synthesis of 7-chloro-5-methoxy-1-(2-methylpyridin-3-yl)-4-(prop-2-yn-1-ylamino)quinazoline-2(1H)-1

[0340] [ka] To a stirred solution of compound intermediate B (200.0 mg, 0.63 mmol) in toluene (3 mL) was added POCl (482.5 mg, 3.15 mmol) and DIPEA (813.5 mg, 6.29 mmol) at 0 °C. The suspension was heated to 100 °C for 2 h. After cooling to room temperature, a mixture of DIPEA (813.5 mg, 6.29 mmol) and prop-2-yn-1-amine (346.7 mg, 6.29 mmol) in NMP (2 mL) was added. The resulting mixture was stirred at room temperature for 16 h. The mixture was concentrated, and the residue was diluted with DCM (20 mL) and water (20 mL). Extraction was performed with DCM (50 mL × 3). The combined organic phase was washed with water (50 mL × 3), brine, dried over anhydrous NaSO, and concentrated. The residue was purified by gel column chromatography to give compound 22 (65.5 mg, yield 29.3%). LCMS: 355.1 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ 8.81(t,J=5.2Hz,1H),8.59(dd,J=4.8Hz,1.6Hz,1H),7.72(dd,J=8.0Hz,1.6Hz,1H),7.46(dd,J=8.0Hz,4.8Hz,1H) ,6.99(d,J=1.6Hz,1H),5.83(d,J=2.0Hz,1H),4.24-4.40(m,2H),4.06(s,3H),3.15(t,J=2.0Hz,1H),2.16(s,3H).

[0341] [Table 4]

[0342] Example 23: Synthesis of 7-chloro-5-methoxy-1-(3-methylpyrazin-2-yl)-4-(prop-2-yn-1-ylamino)quinazoline-2(1H)-1

[0343] [ka] Step 1: To a stirred suspension of INTA-2 (1.0 g, 4.91 mmol) in dichloroethane (15 mL) at room temperature, oxalyl dichloride (686.0 mg, 5.40 mmol) was added. The suspension was heated to 80° C. for 1 h. After cooling to room temperature, 3-methylpyrazin-2-amine (1.1 g, 9.82 mmol) was added. A precipitate formed, and the mixture was stirred at room temperature for an additional 1 h. The precipitate was collected by filtration, washed with water, and dried to give compound 23-1 (940 mg, 56.5%). LCMS: 339.0 [M+H] + .

[0344] Step 2: To a solution of compound 23-1 (900.00 mg, 2.66 mmol) in THF (15 mL) was added NaH (319.0 mg, 7.98 mmol, 60% oil dispersion) at -20 °C, and the resulting mixture was then heated to 40 °C for 16 h. The mixture was concentrated, poured into ice water (20 mL), and the pH was adjusted to 6-7 with 4 M aqueous HCl. The precipitate was collected by filtration, washed with water and EtO, and dried to give compound 23-2 (500.0 mg, 59.0% yield). LCMS: 319.0 [M+H] + .

[0345] Step 3: To a stirred solution of compound 23-2 (150.0 mg, 0.47 mmol) in ACN (3 mL) was added DIEA (182.5 mg, 1.41 mmol) and POCl (217.0 mg, 1.41 mmol) at 0 °C. The resulting suspension was heated to 80 °C for 2 h. After cooling to room temperature, a solution of prop-2-yn-1-amine (255.0 mg, 4.71 mmol) and DIEA (608.0 mg, 4.71 mmol) in ACN (1 mL) was added. The mixture was stirred at room temperature for 16 h and then concentrated. The mixture was added to water (50 mL) and extracted with DCM (50 mL × 3). The combined organic layer was washed with water (50 mL × 2), brine, dried over anhydrous NaSO, and concentrated. The residue was purified by column chromatography to give compound 23. LCMS: 356.0 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ8.89(t,J=5.6Hz,1H),8.71(d,J=2.8Hz,1H),8.60(d,J=2.4Hz,1H),7.02(d,J=1.6Hz,1H) ,5.96(d,J=1.6Hz,1H),4.34-4.31(m,2H),4.06(s,3H),3.15(t,J=2.4Hz,1H),2.30(s,3H).

[0346] Example 24: Synthesis of 7-chloro-4-((1-ethynylcyclopropyl)amino)-5-methoxy-1-(pyrazin-2-yl)quinazoline-2(1H)-1

[0347] [ka] To a stirred solution of compound 21-2 (100.0 mg, 0.32 mmol) in MeCN (2 mL) was added DIEA (127.5 mg, 0.98 mmol) and POCl (151.2 mg, 0.98 mmol) at 0 °C. The suspension was heated to 80 °C for 2 h. After cooling to room temperature, a mixture of 1-ethynylcyclopropanamine hydrochloride (193.3 mg, 1.64 mmol) and DIEA (425.0 mg, 3.28 mmol) in NMP (1 mL) was added. The mixture was stirred at room temperature for 16 h and concentrated. The crude product was added to water (30 mL) and extracted with DCM (50 mL × 3). The combined organic layers were further washed with water (50 mL × 2), brine, dried over anhydrous NaSO, and concentrated. The residue was purified by column chromatography to give compound 24. LCMS: 368.1 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ 8.83-8.79(m,4H),6.98(d,J=1.6Hz,1H),6.05(d,J=1.6Hz,1H),4.05(s,3H),3.03(s,1H),1.29-1.28(m,2H),1.25-1.24(m,2H).

[0348] Example 25: Synthesis of 7-chloro-4-((1-ethynylcyclopropyl)amino)-5-methoxy-1-(3-methylpyrazin-2-yl)quinazoline-2(1H)-1

[0349] [ka] To a stirred mixture of compound 23-2 (100.0 mg, 0.31 mmol) in toluene (1 mL) was added DIEA (406.4 mg, 3.14 mmol) and POCl (241.0 mg, 1.57 mmol) at 0 °C. The suspension was heated to 100 °C for 2 h and then cooled to room temperature. A solution of 1-ethynylcyclopropan-1-amine hydrochloride (184.0 mg, 1.57 mmol) and DIEA (406.4 mg, 3.14 mmol) in NMP (1 mL) was added. The mixture was stirred at room temperature for 16 h and concentrated. The mixture was diluted with DCM (30 mL) and water (30 mL) and further extracted with DCM (30 mL × 2). The combined organic phase was washed with water (30 mL × 3), brine, dried over anhydrous NaSO, and concentrated. The residue was purified by column chromatography to give compound 25 (80.9 mg, yield 67.5%). LCMS: 382.0 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ 8.81(s,1H),8.72(d,J=2.4Hz,1H),8.60(d,J=2.4Hz,1H),6.99(d,J=1.6Hz,1H),5.96(d,J =1.6Hz,1H),4.05(s,3H),3.03(s,1H),2.30(s,3H),1.31-1.28(m,2H),1.26-1.23(m,2H).

[0350] Example 27: Synthesis of 7-chloro-4-((1-ethynylcyclopropyl)amino)-5-methoxy-1-(2-methylpyridin-3-yl)quinazolin-2(1H)-one

[0351] [ka] To a stirred solution of intermediate B (2.0 g, 6.30 mmol) in toluene (20 mL) was added POCl (4.8 g, 31.47 mmol) and DIEA (8.1 g, 62.95 mmol) at 0 °C. The suspension was heated to 100 °C for 2 h. After cooling to room temperature, a mixture of 1-ethynylcyclopropanamine hydrochloride (2.6 g, 31.47 mmol) and DIEA (8.1 g, 62.95 mmol) in NMP (50 mL) was added. The mixture was stirred at room temperature for 16 h. After concentration, the residue was diluted with DCM (200 mL) and water (200 mL) and extracted with DCM (50 mL × 3). The organic phase was washed with water, brine, dried over NaSO, and concentrated. The residue was purified by gel column chromatography to give compound 27 (500.3 mg). LCMS: 381.0 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ 8.74(s,1H),8.61(dd,J=4.8Hz,1.6Hz,1H),7.74(dd,J=8.0Hz,1.6Hz,1H),7.47(dd,J=8.0Hz,4.8Hz,1H),6.97(d, J=2.0Hz,1H), 5.84(d,J=1.6Hz,1H),4.05(s,3H),3.03(s,1H),2.17(s,3H),1.31-1.27(m,2H),1.25-1.22(m,2H).

[0352] Example 29: Synthesis of 7-chloro-5-fluoro-4-(prop-2-yn-1-ylamino)-1-(pyridin-3-yl)quinazoline-2(1H)-1

[0353] [ka] Step 1: A solution of 4-chloro-2,6-difluorobenzoic acid (23.0 g, 119.45 mmol) in SOCl (100.0 mL) was stirred at 80 °C for 3 h. The mixture was concentrated, and the residue was dissolved in dioxane (60 mL), followed by dropwise addition of NH OH solution (60 mL) at 0 °C. The mixture was then stirred at 25 °C for 0.5 h and concentrated. The crude was diluted with water with stirring until a white solid precipitated. The solid product was filtered, washed with water, and dried to give compound 29-1 (15.0 g, 65.6% yield). 1 H NMR (400MHz, DMSO-d6) δ 8.17 (brs, 1H), 7.92 (brs, 1H), 7.49-7.42 (m, 2H).

[0354] Step 2: To a stirred suspension of compound 29-1 (350.0 mg, 1.83 mmol) in DCE (5 mL), oxalyl dichloride (255.0 mg, 2.01 mmol) was added, and the mixture was heated to 80° C. for 1 h. After cooling to room temperature, pyridin-3-amine (344.0 mg, 3.65 mmol) was added. The resulting mixture was stirred at room temperature for 1 h and then cooled to 0° C. The precipitate was collected by filtration, washed with water, and dried to give compound 29-2 (400.0 mg, 70.2% yield). LCMS: 312.0 [M+H] + .

[0355] Step 3: To a solution of compound 29-2 (400.0 mg, 1.28 mmol) in THF (10 mL) was added KHMDS (2.8 mL, 2.82 mmol, 1.0 M in THF) at -20 °C, and the resulting mixture was warmed to room temperature over 3 h. The mixture was concentrated, diluted with water, and the pH was adjusted to 6-7 with 4.0 M aqueous HCl. The precipitate was collected by filtration, washed with water, and dried to give compound 29-3 (250.0 mg, 66.8% yield). LCMS: 292.0 [M+H] + .

[0356] Step 4: To a stirred mixture of compound 29-3 (230.0 mg, 0.79 mmol) in toluene (3 mL), POCl (604.5 mg, 3.94 mmol) and DIPEA (1.0 g, 7.89 mmol) were added at 0 °C. The suspension was heated to 100 °C for 2 h and then cooled to room temperature. A mixture of DIPEA (1.0 g, 7.89 mmol) and prop-2-yn-1-amine (434.3 mg, 7.89 mmol) in NMP (3 mL) was added. The resulting mixture was stirred at room temperature for 16 h and concentrated. The residue was diluted with water (20 mL) and extracted with DCM (50 mL × 3). The combined organic phase was washed with water, brine, dried over NaSO, and concentrated. The residue was purified by gel column chromatography to give compound 29. LCMS: 329.1 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ 8.72(dd,J=4.8Hz,1.2Hz,1H),8.57(d,J=2.4Hz,1H),8.38(s,1H),7.87(dd,J=6.4Hz,2.0Hz,1H),7.64(d d,J=8.0Hz,4.8Hz,1H),7.37(dd,J=12.0Hz,1.6Hz,1H),6.21(s,1H),4.29(s,2H),3.15(t,J=2.0Hz,1H).

[0357] Example 30: Synthesis of 7-chloro-5-fluoro-1-(2-methylpyridin-3-yl)-4-(prop-2-yn-1-ylamino)quinazoline-2(1H)-1

[0358] [ka] Step 1: To a solution of compound 29-1 (500.0 mg, 191.56 mmol) in DCE (10 mL) was added oxalyl dichloride (370.1 mg, 2.87 mmol) at room temperature, and the mixture was stirred at 80° C. for 1 hour. After cooling to room temperature, 2-methylpyridin-3-amine (564.5 mg, 5.22 mmol) was added. The mixture was stirred at room temperature for another 40 minutes. The reaction mixture was filtered, and the filter cake was washed with water (20 mL×3) and dried to give compound 30-1 (560.0 mg, 63.5% yield). LCMS: 326.0 [M+H] + .

[0359] Step 2: To a solution of compound 30-1 (560.0 mg, 1.66 mmol) in THF (10 mL) was added KHMDS (3.8 mL, 3.78 mmol, 1 M in THF) at -20 °C, and the mixture was then stirred at room temperature for 7 h. The mixture was concentrated, diluted with water, and the pH was adjusted to 6-7 with 4.0 M aqueous HCl. The precipitate was collected by filtration, washed with water, and dried to give compound 30-2 (350.0 mg, 66.6% yield). LCMS: 306.0 [M+H] + .

[0360] Step 3: A mixture of compound 30-2 (150.0 mg, 0.49 mmol), POCl (376.2 mg, 2.45 mmol), and DIPEA (634.2 mg, 4.91 mmol) in toluene (2 mL) was stirred at 100 °C for 2 h. After cooling to room temperature, a mixture of DIPEA (634.2 mg, 4.91 mmol) and prop-2-yn-1-amine (270.3 mg, 4.91 mmol) in NMP (2 mL) was added. The resulting mixture was stirred at room temperature for 2 h and concentrated. The residue was diluted with DCM (20 mL) and water (20 mL) and extracted with DCM (20 mL × 3). The combined organic phase was washed with water, brine, dried over NaSO, and concentrated. The residue was purified by gel column chromatography to give compound 30 (30.0 mg, 17.8% yield). LCMS: 343.1 [M+H] + . 1H NMR(400MHz,DMSO-d6)δ 8.61(dd,J=4.8Hz,1.6Hz,1H),8.41-8.36(m,1H),7.78-7.74(m,1H),7.47(dd,J=7.6Hz,4.8Hz,1H), 7.39(dd,J=12.0Hz,2.0Hz,1H),6.13(s,1H),4.33-4.27(m,2H),3.16(t,J=2.4Hz,1H),2.19(s,3H).

[0361] Example 31: Synthesis of 7-chloro-4-((1-ethynylcyclopropyl)amino)-5-fluoro-1-(2-methylpyridin-3-yl)quinazoline-2(1H)-1

[0362] [ka] To a stirred solution of compound 30-2 (150.0 mg, 0.49 mmol) in toluene (3 mL) was added DIEA (634.2 mg, 4.91 mmol) and POCl (376.2 mg, 2.45 mmol) at 0 °C. The suspension was heated to 100 °C for 2 h. After cooling to room temperature, a solution of 1-ethynylcyclopropan-1-amine hydrochloride (346.2 mg, 2.94 mmol) and DIEA (634.2 mg, 4.91 mmol) in NMP (2 mL) (2 mL) was added. The mixture was stirred at room temperature for 16 h and concentrated. Water (50 mL) was added, and the suspension was extracted with DCM (50 mL × 3). The combined organic layers were washed with water, brine, dried over NaSO, and concentrated. The residue was purified by column chromatography to give compound 31 (29.6 mg, 16.3% yield). LCMS: 369.0 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ 8.61(dd,J=4.8Hz,1.6Hz,1H),8.38(d,J=11.6Hz,1H),7.76(dd,J=8.0Hz,1.2Hz,1H),7.47(dd,J=8.0Hz ,4.8Hz,1H),7.37(dd,J=12.0Hz,2.0Hz,1H),6.12(s,1H),3.04(s,1H),2.18(s,3H),1.29-1.26(m,4H).

[0363] Example 32: Synthesis of 5-fluoro-4-(prop-2-yn-1-ylamino)-1-(pyrazin-2-yl)-7-(trifluoromethyl)quinazoline-2(1H)-1

[0364] [ka] Step 1: To a solution of 2,6-difluoro-4-(trifluoromethyl)benzene-1-carboxamide (400.0 mg, 1.78 mmol) in DCE (10 mL) was added oxalyl dichloride (250.0 mg, 1.95 mmol) at room temperature, and the mixture was stirred at 80° C. for 2 hours. After cooling to room temperature, pyrazin-2-amine (337.9 mg, 3.55 mmol) was added, and the solution was stirred at room temperature for 40 minutes. The precipitate was collected by filtration, washed with water, and dried to give compound 32-1 (350.0 mg, 56.9% yield). LCMS: 347.1 [M+H] + .

[0365] Step 2: To a solution of compound 32-1 (350.0 mg, 1.01 mmol) in THF (10 mL) was added KHMDS (2.3 mL, 2.22 mmol, 1 M in THF) at -20 °C, and the mixture was then stirred at room temperature for 2 h. The mixture was quenched with water (20 mL) and concentrated to remove THF. The aqueous layer was washed with EtOAc (10 mL) and acidified to pH = 6-7 with 1.0 M HCl. The formed precipitate was filtered, washed with water (20 mL), and dried to give compound 32-2 (250.0 mg, 75.8% yield). LCMS: 327.0 [M+H] + .

[0366] Step 3: To a solution of compound 32-2 (150.0 mg, 0.46 mmol) in MeCN (2 mL), POCl (211.5 mg, 1.38 mmol) and DIPEA (178.3 mg, 1.38 mmol) were added, and the reaction was stirred at 80 °C for 2 h. After cooling to room temperature, prop-2-yn-1-amine (253.3 mg, 4.59 mmol) and DIPEA (594.3 mg, 4.59 mmol) in MeCN (2 mL) were added, and the reaction was stirred at room temperature for 16 h. The mixture was diluted with DCM (20 mL) and water (20 mL), extracted with DCM (20 mL × 2), and the combined organic phase was washed with water, dried over anhydrous NaSO, and concentrated. The residue was purified by silica gel column to give compound 32 (52.8 mg, 31.7% yield).

[0367] Example 33: Synthesis of 1-(2-methylpyridin-3-yl)-4-(prop-2-yn-1-ylamino)-7-(trifluoromethyl)quinazoline-2(1H)-1

[0368] [ka] Step 1: To a solution of 2-fluoro-4-(trifluoromethyl)benzene-1-carboxamide (2.0 g, 9.66 mmol) in dichloroethane (50 mL) was added oxalyl dichloride (1.4 g, 10.62 mmol) at room temperature, and the mixture was stirred at 80 °C for 1 hour. After cooling to room temperature, 2-methylpyridin-3-amine (2.1 g, 19.30 mmol) was added. The formed precipitate was collected, washed with water, and dried to give compound 33-1 (3.0 g, 91.0% yield). LCMS: 342.0 [M+H] + .

[0369] Step 2: KHMDS (19.3 mL, 19.30 mmol, 1 M in THF) was added to a mixture of compound 33-1 (3.0 g, 8.79 mmol) in THF (50 mL) at -20 °C, and the mixture was stirred at room temperature for 2 h. The reaction mixture was concentrated, diluted with water, and the pH was adjusted to 6-7 with 4 M aqueous HCl. The precipitate was collected, washed with water and EtO, and dried to give compound 33-2 (2.7 g, 95.6% yield). LCMS: 322.1 [M+H] + .

[0370] Step 3: To a stirred suspension of compound 33-2 (200.0 mg, 0.62 mmol) in toluene (3 mL) was added POCl (477.0 mg, 3.11 mmol) and DIPEA (805.0 mg, 6.23 mmol) at 0 °C. The resulting suspension was heated at 100 °C for 2 h. After cooling to room temperature, a mixture of DIPEA (805.0 mg, 6.23 mmol) and prop-2-yn-1-amine (342.0 mg, 6.22 mmol) in NMP (2 mL) was added. The mixture was stirred at room temperature for 16 h. The reaction mixture was diluted with DCM (20 mL) and water (20 mL) and extracted with DCM (30 mL × 3). The combined organic phase was washed with water, brine, dried over anhydrous NaSO, and concentrated. The residue was purified by silica gel column chromatography to give compound 33 (72.6 mg, 32.5% yield). LCMS: 359.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ 9.32(t,J=5.2Hz,1H),8.63(dd,J=4.8Hz,1.6Hz,1H),8.45(d,J=8.4Hz,1H),7.79(dd,J=8.0Hz,1.6Hz,1H),7.65 (d,J=8.0Hz,1H),7.49(dd,J=8.0Hz,4.8Hz,1H),6.47(s,1H),4.43-4.29(m,2H),3.31-3.24(m,1H),2.08(s,3H).

[0371] Example 34: Synthesis of 5-methoxy-4-(prop-2-yn-1-ylamino)-1-(pyridin-3-yl)-7-(trifluoromethyl)quinazoline-2(1H)-1

[0372] [ka] Step 1: To a stirred suspension of compound INTC-2 (450.0 mg, 1.89 mmol) in dichloroethane (5 mL) at room temperature, oxalyl dichloride (264.9 mg, 2.08 mmol) was added. The resulting suspension was heated to 80° C. for 1 hour. After cooling to room temperature, pyridin-3-amine (357.2 mg, 3.79 mmol) was added to the reaction mixture. The resulting reaction mixture was stirred at room temperature for 16 hours. The precipitate was collected, washed with water, and dried to give compound 34-1 (512 mg, 75.3% yield). LCMS: 358.0 [M+H] + .

[0373] Step 2: KHMDS (3.07 mL, 3.07 mmol) was added to a mixture of compound 34-1 (500.0 mg, 1.40 mmol) in THF (5 mL) at -20 °C, and the resulting mixture was warmed to room temperature over 3 h. The reaction mixture was concentrated, diluted with water, and the pH was adjusted to 6-7 with 4.0 M aqueous HCl. The precipitate was collected, washed with water, and dried to give compound 34-2 (503 mg, 96.5%). LCMS: 338.0 [M+H] + .

[0374] Step 3: To a stirred suspension of compound 34-2 (100.0 mg, 0.29 mmol) in toluene (1 mL) was added DIPEA (383.2 mg, 2.96 mmol) and POCl (227.3 mg, 1.48 mmol) at 0 °C. The resulting suspension was heated at 100 °C for 2 h. After cooling to room temperature, a solution of DIPEA (383.2 mg, 2.96 mmol) and prop-2-yn-1-amine (163.3 mg, 2.96 mmol) in NMP (1 mL) was added. The mixture was stirred at 50 °C for 1 h. Water (10 mL) was added, extracted with dichloromethane (5 mL × 3), and the organic layer was washed with brine, dried over anhydrous NaSO, filtered, concentrated, and purified by column chromatography to give compound 34. LCMS: 375.1 [M+H] + . 1H NMR(400MHz,DMSO-d6)δ 8.96(t,J=5.6Hz,1H),8.72(d,J=4.4,1.2Hz,1H),8.58(d,J=2.4Hz,1H),7.88(d,J=8.4Hz,1H),7.65(d d,J=8.0,4.8Hz,1H),7.14(s,1H),6.13(s,1H),4.34-4.30(m,2H),4.12(s,3H),3.15(t,J=2.4Hz,1H).

[0375] Example 35:

[0376] [ka] To a stirred solution of compound 34-2 (140.0 mg, 0.42 mmol) in toluene (2 mL) was added DIEA (536.5 mg, 4.15 mmol) and POCl (319.0 mg, 2.08 mmol) at 0 °C. The resulting suspension was heated at 100 °C for 2 h. After cooling to room temperature, a solution of but-3-yn-2-amine hydrochloride (263.0 mg, 2.49 mmol) and DIEA (536.51 mg, 4.15 mmol) in NMP (2 mL) was added. The mixture was stirred at room temperature for 16 h. Water was added, extracted with DCM, and the combined organic layer was washed with water, brine, dried over anhydrous NaSO, and concentrated. The residue was purified by column chromatography to give compound 35. LCMS: 389.1 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ 8.72(dd,J=4.8Hz,1.6Hz,1H),8.57-8.53(m,2H),7.89(s,1H),7.67-7.64(m,1H),7.16(s, 1H),6.13(s,1H),5.25-5.21(m,1H),4.15(s,3H),3.36-3.32(m,1H),1.54(d,J=6.8Hz,3H).

[0377] Example 36: Synthesis of 5-methoxy-1-(2-methylpyridin-3-yl)-4-(prop-2-yn-1-ylamino)-7-(trifluoromethyl)quinazoline-2(1H)-1

[0378] [ka] To the suspension, DIPEA (257.0 mg, 1.99 mmol) and POCl (153.0 mg, 1.00 mmol) were added at 0 °C. The resulting suspension was heated at 100 °C for 2 h. After cooling to room temperature, a solution of DIPEA (257.0 g, 1.99 mmol) and prop-2-yn-1-amine (109.6 mg, 1.99 mmol) in NMP (0.5 mL) was added. The mixture was stirred at 50 °C for 1 h. Water (10 mL) was added, extracted with dichloromethane (5 mL × 3), and the organic layer was washed with brine, dried over anhydrous NaSO, filtered, concentrated, and purified by column chromatography to give compound 36 (29.0 mg, 37.9% yield). LCMS: 389.1 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ 8.96(t,J=5.2Hz,1H),8.61(dd,J=4.8,1.6Hz,1H),7.75(dd,J=8.0,1.6Hz,1H),7.47(dd,J=7.6,4.8H z,1H),7.15(s,1H),6.03(s,1H),4.39-4.26(m,2H),4.13(s,3H),3.16(t,J=2.4Hz,1H),2.16(s,3H).

[0379] [Table 5]

[0380] Example 38: Synthesis of 5-(fluoromethoxy)-4-(prop-2-yn-1-ylamino)-1-(pyridin-3-yl)-7-(trifluoromethyl)quinazolin-2(1H)-one

[0381] [ka] Step 1: To a solution of 6-fluoro-2-methoxy-4-(trifluoromethyl)benzoic acid (5.0 g, 20.99 mmol) in DMF (50 mL), K2CO3 (3.2 g, 23.09 mmol) was added and the reaction was stirred at room temperature for 15 minutes. Then, MeI (3.2 g, 23.09 mmol) was added and the reaction was stirred at 40 °C for 2 hours. The mixture was cooled to room temperature and then diluted with EA (500 mL) and water (500 mL). The organic layer was separated, washed with brine, and concentrated in vacuo. The residue was purified by silica gel column to give compound 38-1 (4.92 g, 92.6% yield). LCMS: 253.1 [M+H] + . Step 2: To a solution of compound 38-1 (4.9 g, 19.43 mmol) in DCM (50 mL) was added BBr3 (5.3 g, 21.37 mmol) at −78° C., and the mixture was stirred at −78° C. for 30 min. The mixture was quenched with methanol and concentrated. The residue was purified by silica gel column chromatography to give compound 38-2 (4.50 g, 97.2% yield). 1 H NMR(400MHz, CDCl3)δ 11.42(s,1H),7.06(s,1H),6.86(dd,J=10.8Hz,1.6Hz,1H),4.02(s,3H).

[0382] Step 3: To a solution of compound 38-2 (1.0 g, 4.20 mmol) in MeCN (10 mL) was added fluoroiodomethane (806.3 mg, 5.04 mmol) and CsCO (1.64 g, 5.04 mmol) at room temperature, and the mixture was stirred at room temperature for 6 h. The mixture was filtered, and the filtrate was concentrated and purified by silica gel column chromatography to give compound 38-3 (968.0 mg, 85.3% yield). 1 H NMR (400MHz, CDCl3) δ 7.24 (s, 1H), 7.18 (d, J=8.4Hz, 1H), 5.75 (d, 2H), 3.96 (s, 3H).

[0383] Step 4: To a solution of compound 38-3 (948.0 mg, 3.51 mmol) in THF (5 mL) and water (5 mL), LiOH (740.0 mg, 17.54 mmol) was added at room temperature, and the mixture was stirred at room temperature for 16 h. EA (10 mL) and water (10 mL) were added. The pH of the aqueous layer was adjusted to 2-3 with 4 M aqueous HCl. The precipitate was collected, washed with water, and dried to give compound 38-4 (805.0 mg, 89.6% yield). 1 H NMR (400MHz, DMSO-d6) δ 14.14 (brs, 1H), 7.59 (d, J = 8.8 Hz, 1H), 7.45 (s, 1H), 6.03 (d, 2H).

[0384] Step 5: A solution of compound 38-4 (805.0 mg, 3.14 mmol) in SOCl (6 mL) was stirred at 80 °C for 2 h. The mixture was concentrated, and dioxane (9 mL) was added, followed by NHOH (40%, 9.0 mL). The resulting solution was stirred at room temperature for 1 h. Water was added, and the solid product was collected and washed with water to give compound 38-5 (703.0 mg, 85.6% yield). 1 H NMR (400MHz, DMSO-d6) δ 8.07 (s, 1H), 7.84 (s, 1H), 7.55 (d, J = 8.4Hz, 1H), 7.40 (s, 1H), 6.00 (d, 2H).

[0385] Step 6: To a stirred suspension of compound 38-5 (150.0 mg, 0.59 mmol) in dichloroethane (3 mL) at room temperature, oxalyl dichloride (82.0 mg, 0.65 mmol) was added. The resulting suspension was heated to 80° C. for 1 h. After cooling to room temperature, pyridin-3-amine (110.7 mg, 1.18 mmol) was added to the reaction mixture. The mixture was stirred at room temperature for 16 h and then cooled to 0° C. After 10 min, the precipitate was collected, washed with water, and dried to give compound 38-6 (168.0 mg, 76.3% yield). LCMS: 376.0 [M+H] + .

[0386] Step 7: KHMDS (1.0 mL, 0.98 mmol, 1 M in THF) was added to a mixture of compound 38-6 (168.0 mg, 0.44 mmol) in THF (2 mL) at -20 °C, and the resulting mixture was allowed to warm to room temperature over 3 h. The reaction mixture was concentrated, diluted with water, and the pH was adjusted to 6-7 with 4 M HCl. The precipitate was collected, washed with water, and dried to give compound 38-7 (127.0 mg, 79.8% yield). LCMS: 356.0 [M+H] + .

[0387] Step 8: To a stirred suspension of compound 38-7 (100.0 mg, 0.28 mmol) in MeCN (1 mL) was added DIEA (109.0 mg, 0.84 mmol) and POCl (129.0 mg, 0.84 mmol) at 0 °C. The resulting suspension was heated to 80 °C for 2 h and then cooled to room temperature. A solution of DIEA (366.3 mg, 2.84 mmol) and prop-2-yn-1-amine (156.2 mg, 2.84 mmol) in NMP (1 mL) was added. The mixture was stirred at 50 °C for 1 h. Water (30 mL) was added, extracted with dichloromethane (50 mL × 3), and the organic layer was washed with brine, dried over Na SO , filtered, concentrated, and purified by column chromatography to give compound 38 (18.5 mg, 16.8% yield). LCMS: 393.1 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ 8.96(t,J=5.6Hz,1H),8.72(dd,J=4.8Hz,1.6Hz,1H),8.59(d,J=2.0Hz,1H),7.91-7.88(m,1H),7.66(dd,J =8.0Hz,4.8Hz,1H),7.27(s,1H),6.29-6.16(m,3H),4.33(dd,J=6.4Hz,2.0Hz,2H),3.15(t,J=2.0Hz,1H).

[0388] Example 39: Synthesis of 5-(difluoromethoxy)-4-(prop-2-yn-1-ylamino)-1-(pyridin-3-yl)-7-(trifluoromethyl)quinazolin-2(1H)-one

[0389] [ka] Step 1: To a solution of compound 38-2 (1.0 g, 4.19 mmol) in ACN (10 mL), diethyl(bromodifluoromethyl)phosphonate (1.1 g, 4.19 mmol) and KF (0.5 g, 8.39 mmol) were added at room temperature, and the mixture was stirred at 30° C. for 8 h. The mixture was concentrated and purified by silica gel column chromatography to give compound 39-3 (283.00 mg, 23.3% yield). 1 H NMR (400MHz, CDCl3) δ 7.32-7.28 (m, 2H), 6.58 (t, J=72.4Hz, 1H), 3.97 (s, 3H).

[0390] Step 2: To a solution of compound 39-3 (600.0 mg, 2.08 mmol) in THF / water (5 mL) was added LiOH (437.4 mg, 10.41 mmol) at room temperature, and the mixture was stirred at room temperature for 16 h. The reaction was diluted with EA (200 mL) and water (200 mL). The aqueous layer was collected and the pH was adjusted to 1-2 with HCl. The solid was collected and dried to give compound 39-4 (562.00 mg, 98.9% yield).

[0391] Step 3: A solution of compound 39-4 (562.0 mg, 2.05 mmol) in SOCl (5.0 mL) was stirred at 80 °C for 2 h. It was concentrated and diluted with dioxane (5 mL). Then, the mixture was added to NH OH (10 mL) for 30 min. The mixture was extracted with EA (200 mL × 2), washed with water (200 mL), dried over Na SO , and concentrated to give compound 39-5 (403.00 mg, 71.9% yield). LCMS: 274.1 [M+H] + .

[0392] Step 4: To a solution of compound 39-5 (180.0 mg, 0.66 mmol) in DCE (5 mL) was added oxalyl dichloride (0.36 mL, 0.72 mmol, 2 M in DCM) at room temperature, and the mixture was stirred at 80° C. for 2 hours. The mixture was cooled to room temperature, and then pyridin-3-amine (124.1 mg, 1.32 mmol) was added, and the solution was stirred at room temperature for 16 hours. The solid was collected, washed with water (10 mL×2), and dried to give compound 39-6 (140.0 mg, 54.0% yield). LCMS: 394.0 [M+H] + .

[0393] Step 5: To a solution of compound 39-6 (135.0 mg, 0.34 mmol) in THF (5 mL) was added KHMDS (0.76 mL, 0.76 mmol, 1 M in THF) at -20 °C, and the mixture was then stirred at room temperature for 16 h. The reaction mixture was quenched with water (20 mL). After concentration, the aqueous layer was washed with EA (10 mL) and acidified to pH = 6-7 with 1 M HCl. The formed solid was collected, washed with water (20 mL), and dried to give compound 39-7 (100.0 mg, 78.1% yield). LCMS: 374.0 [M+H] + .

[0394] Step 6: A mixture of compound 39-7 (120.0 mg, 0.32 mmol), POCl (0.09 mL, 0.96 mmol), and DIEA (0.16 mL, 0.96 mmol) in MeCN (2 mL) was stirred at 80 °C for 2 h. The mixture was then cooled to room temperature, and a mixture of prop-2-yn-1-amine (177.1 mg, 3.22 mmol) and DIEA (402.7 mg, 3.22 mmol) in MeCN (2 mL) was added. The mixture was stirred at room temperature for 2 h. After concentration, DCM (20 mL) and water (20 mL) were added. The organic layer was washed with water, brine, dried over NaSO, and concentrated. The residue was purified by silica gel column to give compound 39 (32.0 mg, 24.3% yield). LCMS: 411.0 [M+H] + . 1H NMR(400MHz,DMSO-d6)δ 8.74(dd,J=4.8Hz,1.2Hz,1H),8.60(d,J=2.4Hz,1H),8.38(t,J=5.2Hz,1H),7.94-7.88(m, 1H),7.80-7.31(m,2H),7.32(s,1H),6.41(s,1H),4.36-4.34(m,2H),3.23(t,J=2.0Hz,1H).

[0395] Example 40: Synthesis of 5-(difluoromethoxy)-1-(2-methylpyridin-3-yl)-4-(prop-2-yn-1-ylamino)-7-(trifluoromethyl)quinazolin-2(1H)-one

[0396] [ka] Step 1: To a solution of compound 39-3 (200.0 mg, 0.73 mmol) in dichloroethane (5 mL), oxalyl dichloride (102.2 mg, 0.80 mmol) was added at room temperature, and the mixture was then stirred at 80° C. for 1 hour. After cooling to room temperature, 2-methylpyridin-3-amine (158.3 mg, 1.46 mmol) was added. The solid formed was collected, washed with water, and dried to give compound 40-1 (251.00 g, 84.2% yield). LCMS: 408.0 [M+H] + .

[0397] Step 2: KHMDS (1.35 mL, 1.35 mmol, 1 M in THF) was added to a mixture of compound 40-1 (250.0 mg, 0.61 mmol) in THF (5 mL) at -20 °C, and the mixture was then stirred at room temperature for 2 h. After concentration, water was added and the pH was adjusted to 6-7 with 4 M aqueous HCl. The solid was collected, washed with water and EtO, and dried to give compound 40-2 (212.00 mg, 90.4% yield). LCMS: 388.0 [M+H] + .

[0398] Step 3: To a stirred suspension of compound 40-2 (100.0 mg, 0.25 mmol) in toluene (1 mL) was added POCl (197.9 mg, 1.29 mmol) and DIEA (333.7 mg, 2.58 mmol) at 0 °C. The mixture was heated to 100 °C for 2 h and cooled to room temperature. A mixture of DIEA (333.4 mg, 2.58 mmol) and prop-2-yn-1-amine (142.1 mg, 2.58 mmol) in NMP (1 mL) was added. The mixture was stirred at 50 °C for 1 h, diluted with DCM (50 mL) and water (50 mL), and extracted with DCM (30 mL × 3). The combined organic phase was washed with water (20 mL × 3), brine, dried over NaSO, and concentrated. The residue was purified by silica gel column to give compound 40 (25.60 mg, 21.1% yield). LCMS: 425.1 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ 8.63(dd,J=4.8Hz,1.2Hz,1H),8.36(t,J=4.8Hz,1H),7.80-7.33(m,3H),7.3 2(s,1H),6.32(s,1H),4.38-4.35(m,2H),3.24(t,J=2.4Hz,1H),2.18(s,3H).

[0399] Example 41: Synthesis of 5-(difluoromethoxy)-4-((1-ethynylcyclopropyl)amino)-1-(2-methylpyridin-3-yl)-7-(trifluoromethyl)quinazolin-2(1H)-one

[0400] [ka] To a stirred suspension of compound 40-2 (100.0 mg, 0.25 mmol) in ACN (1 mL) was added POCl (118.7 mg, 0.77 mmol) and DIEA (100.1 mg, 0.77 mmol) at 0 °C. The mixture was heated to 80 °C for 2 h. After cooling to room temperature, a mixture of 1-ethynylcyclopropan-1-amine hydrochloride (104.6 mg, 1.29 mmol) and DIEA (333.4 mg, 2.58 mmol) in ACN (1 mL) was added. The mixture was stirred at 50 °C for 1 h, diluted with DCM (50 mL) and water (50 mL), and extracted with DCM (30 mL × 3). The combined organic phase was washed with water, brine, dried over NaSO, and concentrated. The residue was purified by silica gel column to give compound 41 (76.1 mg, 65.4% yield). LCMS: 451.1 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ 8.64(dd,J=4.8Hz,1.6Hz,1H),8.39(s,1H),7.81(dd,J=8.0Hz,1.2Hz,1H),7.72-7.37(m,2H ),7.29(s,1H),6.33(s,1H),3.08(s,1H),2.18(s,3H),1.36-1.31(m,2H),1.27-1.20(m,2H).

[0401] Example 42: Synthesis of 5-methoxy-1-(2-methylpyridin-3-yl)-4-(prop-2-yn-1-ylamino)-7-(trifluoromethyl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0402] [ka] Step 1: A solution of ethyl 2,4-dihydroxy-6-(trifluoromethyl)pyridine-3-carboxylate (2.0 g, 7.96 mmol) in DMF (2.3 g, 31.85 mmol) and POCl3 (5.5 g, 35.83 mmol) was stirred at 90 °C for 72 h. The mixture was concentrated. The residue was diluted with DCM (50 mL) and water (50 mL). The mixture was treated with saturated aqueous NaHCO3 until pH = 5-6 and extracted with DCM (100 mL × 3). The organic layer was concentrated, and the residue was purified by silica gel column chromatography to give compound 42-1 (1.9 g, 82.9% yield). LCMS: 288.0 [M+H] + .

[0403] Step 2: To a solution of compound 42-1 (2.0 g, 6.94 mmol) in MeOH (20 mL) was added MeONa (412.5 mg, 7.64 mmol) at 0° C., and the mixture was stirred at room temperature for 18 hours. The reaction mixture was quenched with water (50 mL) at 0° C. and extracted with EA (50 mL×3). The organic layer was concentrated, and the residue was purified by silica gel column to give compound 42-2 (1.8 g, 91.4% yield). LCMS: 284.0 [M+H] + .

[0404] Step 3: To a solution of compound 42-2 (1.9 g, 6.70 mmol) in THF (20 mL) and water (20 mL), LiOH (1.4 g, 33.49 mmol) was added at room temperature, and the solution was stirred at 80 °C for 8 h. The reaction mixture was acidified with 1.0 M HCl to pH = 2-3 and extracted with EA (50 mL × 2). The combined organic layer was concentrated to give compound 42-3 (1.6 g, 98.8% yield). LCMS: 256.0 [M+H] + .

[0405] Step 4: A solution of compound 42-3 (4.9 g, 20.58 mmol) in SOCl (50.0 mL) was stirred at 80 °C for 2 h. The reaction mixture was concentrated, and the residue was dissolved in dioxane (10 mL). NHOH (10 mL) was added at 0 °C. The mixture was stirred at 25 °C for 0.5 h. After concentration, water was added, and the solid product was collected, washed with water, and dried to give compound 42-4 (4.0 g, 84.4% yield). LCMS: 255.0 [M+H] + .

[0406] Step 5: To a solution of compound 42-4 (500.0 mg, 1.97 mmol) in DCE (5 mL) was added oxalyl dichloride (275.0 mg, 2.17 mmol) at room temperature, and the mixture was stirred at 80 °C for 2 h. After cooling to room temperature, 2-methylpyridin-3-amine (424.8 mg, 3.93 mmol) was added, and the solution was stirred at room temperature for 16 h. The precipitate was collected, washed with water, and dried to give compound 42-5 (440.0 mg, 51.4% yield). LCMS: 389.1 [M+H] + .

[0407] Step 6: To a solution of compound 42-5 (440.0 mg, 1.13 mmol) in THF (10 mL) was added KHMDS (2.5 mL, 2.50 mmol, 1.0 M in THF) at -20 °C, and the mixture was stirred at room temperature for 2 h. The reaction mixture was quenched with water (20 mL). After concentration, the aqueous layer was extracted with EtOAc (10 mL) and acidified to pH = 6-7 with 1.0 M HCl. The precipitate was collected, washed with water, and dried to give compound 42-6 (250.0 mg, 62.7% yield). LCMS: 353.1 [M+H] + .

[0408] Step 7: A mixture of compound 42-6 (100.0 mg, 0.28 mmol), POCl3 (130.6 mg, 0.85 mmol), and DIPEA (110.1 mg, 0.85 mmol) in MeCN (2 mL) was stirred at 80 °C for 2 hours. After cooling to room temperature, a mixture of DIPEA (366.9 mg, 2.84 mmol) and prop-2-yn-1-amine (156.4 mg, 2.84 mmol) in MeCN (2 mL) was added. The mixture was stirred at room temperature for 16 hours and concentrated. The residue was diluted with DCM (20 mL) and water (20 mL) and extracted with DCM (30 mL × 2). The combined organic layer was washed with water, brine, dried, and concentrated. The residue was purified by silica gel column to give compound 42 (70.0 mg, 63.3% yield). LCMS: 390.1 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ 8.90(t,J=5.2Hz,1H),8.63(dd,J=4.8Hz,1.2Hz,1H),7.79(dd,J=8.0Hz,1.6Hz,1H),7.48(dd,J=8 .0Hz,4.8Hz,1H),6.19(s,1H),4.43-4.26(m,2H),4.14(s,3H),3.18(t,J=2.0Hz,1H),2.20(s,3H).

[0409] Example 43: Synthesis of 4-((1-ethynylcyclopropyl)amino)-5-methoxy-1-(2-methylpyridin-3-yl)-7-(trifluoromethyl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0410] [ka] A mixture of compound 42-6 (100.0 mg, 0.28 mmol), POCl (130.6 mg, 0.85 mmol), and DIEA (110.1 mg, 0.85 mmol) in MeCN (2 mL) was stirred at 80 °C for 2 h. After cooling to room temperature, a mixture of DIEA (366.9 mg, 2.84 mmol) and 1-ethynylcyclopropanamine hydrochloride (166.9 mg, 1.42 mmol) in MeCN (2 mL) was added. The mixture was stirred at room temperature for 16 h. After concentration, the residue was diluted with DCM (20 mL) and water (20 mL) and extracted with DCM (30 mL × 2). The combined organic layer was washed with water, brine, dried over NaSO, and concentrated. The residue was purified by silica gel column to give compound 43 (36.5 mg, 31.2% yield). LCMS: 416.0 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ 8.81(s,1H),8.63(dd,J=4.8Hz,1.2Hz,1H),7.79(dd,J=8.0Hz,1.6Hz,1H),7.48(dd,J=8.0Hz,4.8 Hz,1H),6.18(s,1H),4.12(s,3H),3.07(s,1H),2.20(s,3H),1.34-1.31(m,2H),1.27-1.25(m,2H).

[0411] Example 44: Synthesis of 1-(2,5-dimethylpyridin-3-yl)-4-(prop-2-yn-1-ylamino)-7-(trifluoromethyl)quinazoline-2(1H)-1

[0412] [ka] Step 1: To a stirred suspension of 2-fluoro-4-(trifluoromethyl)benzamide (2.0 g, 9.66 mmol) in dichloroethane (20 mL) at room temperature, oxalyl dichloride (1.3 g, 10.62 mmol) was added. The mixture was heated to 80° C. for 1 hour. After cooling to room temperature, 2,5-dimethylpyridin-3-amine (2.4 g, 19.31 mmol) was added. The mixture was stirred at room temperature for 1 hour. The precipitate was collected, washed with water, and dried to give compound 44-1 (1.7 g, 50.7% yield). LCMS: 356.0 [M+H] + .

[0413] Step 2: To a solution of compound 44-1 (1.7 g, 4.90 mmol) in THF (25.0 mL), NaH (978.0 mg, 24.48 mmol, 60% oil dispersion) was added at room temperature, and the mixture was stirred for 5 h. After concentration, the residue was poured into ice water (50 mL), and the pH was adjusted to 6-7 with 4 M aqueous HCl. The precipitate was collected, washed with water and EtO, and dried to give compound 44-2 (1.2 g, 74.7% yield). 1 H NMR(400MHz,DMSO-d6)δ 12.10(s,1H),8.51(d,J=0.8Hz,1H),8.28(d,J=8.0Hz,1H),7.72(s,1H),7.64(d,J=8.0Hz,1H),6.50(s,1H),2.35(s,3H),2.12(s,3H).

[0414] Step 3: To a stirred mixture of compound 44-2 (200.0 mg, 0.60 mmol) in toluene (2 mL), DIEA (771.0 mg, 5.96 mmol) and POCl3 (458.0 mg, 2.98 mmol) were added at 0 °C. The mixture was heated to 100 °C for 2 h. After cooling to room temperature, a solution of prop-2-yn-1-amine (328.6 mg, 5.96 mmol) and DIEA (771.0 mg, 5.96 mmol) in NMP (1 mL) was added. The mixture was stirred at room temperature for 16 h. Water (50 mL) was added, extracted with DCM (50 mL × 3), and the combined organic layer was washed with water, brine, dried over Na2SO4, and concentrated. The residue was purified by column chromatography to give compound 44 (43.3 mg, 19.5% yield). LCMS: 373.1 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ 9.29(t,J=5.2Hz1H),8.47(s,1H),8.45(s,1H),7.64(d,J=8.4Hz,1H),7.62(s ,1H),6.49(s,1H),4.43-4.29(m,2H),3.25(s,1H),2.35(s,3H),2.12(s,3H).

[0415] Example 45: Synthesis of 1-(2-isopropylpyridin-3-yl)-4-(prop-2-yn-1-ylamino)-7-(trifluoromethyl)quinazoline-2(1H)-1

[0416] [ka] Step 1: To a stirred suspension of 2-chloro-3-nitropyridine (3.0 g, 18.92 mmol) and 4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3-diol in 2-dioxaborolane (9.5 g, 56.77 mmol) in dioxane (20 mL) and water (4 mL), Pd(PPh) (2.2 g, 1.89 mmol) and NaCO (4.0 g, 37.84 mmol) were added, and the mixture was stirred at 100 °C for 2 h. After cooling to room temperature, water (60 mL) was added and extracted with EtOAc (60 mL × 3). The combined organic layer was washed with brine, dried over NaSO, concentrated, and purified by column chromatography to give compound 45-1 (1.5 g). 1 H NMR(400MHz,DMSO-d6)δ 8.82(dd,J=4.8Hz,1.2Hz,1H),8.36-8.34(m,1H),7.62(dd,J=8.0Hz,4.8Hz,1H),5.33(s,1H),5.06(s,1H),2.14(s,3H).

[0417] Step 2: A solution of compound 45-1 (1.0 g, 6.09 mmol) and Pd / C (100.0 mg, 10% activated carbon, 5% wet) in MeOH (10 mL) was stirred at room temperature for 6 h using a hydrogen balloon. The mixture was filtered, washed with EtOAc, and the filtrate was concentrated and purified by column chromatography to give compound 45-2 (500.0 mg, 60.3% yield). 1 H NMR(400MHz,DMSO-d6)δ 7.74(d,J=4.0Hz,1H),6.89-6.87(m,2H),5.01(s,2H),3.15-3.09(m,1H),1.15(d,J=6.4Hz,6H).

[0418] Step 3: To a stirred suspension of 2-fluoro-4-(trifluoromethyl)benzamide (650.0 mg, 3.14 mmol) in dichloroethane (8 mL) at room temperature, oxalyl dichloride (438.0 mg, 3.45 mmol) was added. The mixture was heated to 80° C. for 1 h. After cooling to room temperature, compound 45-2 (854.0 mg, 6.27 mmol) was added. The mixture was stirred at room temperature for 1 h. The precipitate was collected, washed with water, and dried to give compound 45-3 (600.0 mg, 51.8% yield). LCMS: 370.2 [M+H] + .

[0419] Step 4: KHMDS (3.3 mL, 3.33 mmol, 1 M in THF) was added to a mixture of compound 45-3 (560.0 mg, 1.51 mmol) in THF (5 mL) at -20 °C, and the mixture was warmed to room temperature. The mixture was concentrated, diluted with water, and the pH was adjusted to 6-7 with 4 M aqueous HCl. The precipitate was collected, washed with water, and dried to give compound 45-4 (450.0 mg, 84.9% yield). LCMS: 350.0 [M+H] + .

[0420] Step 5: To a stirred solution of compound 45-4 (200.0 mg, 0.57 mmol) in toluene (2 mL) was added DIEA (740.5 mg, 5.73 mmol) and POCl (440.0 mg, 2.87 mmol) at 0 °C. The mixture was heated to 100 °C for 2 h. After cooling to room temperature, a solution of but-3-yn-2-amine (315.0 mg, 5.73 mmol) and DIEA (740.5 mg, 5.73 mmol) in NMP (2 mL) was added. The mixture was stirred at room temperature for 16 h. The mixture was diluted with DCM (50 mL) and water (50 mL) and extracted with DCM (30 mL × 3). The combined organic phase was washed with water, brine, dried over NaSO, and concentrated. The residue was purified to give compound 45 (93.3 mg, 42.1% yield). LCMS: 387.1 [M+H] + . 1H NMR(400MHz,DMSO-d6)δ 9.29(t,J=5.2Hz,1H),8.73(dd,J=4.8Hz,1.2Hz,1H),8.44(d,J=8.4Hz,1H),7.73(dd,J=8.0Hz,1.6Hz,1H),7.64(d,J=8.4Hz,1H),7.47 (dd,J=8.0Hz,4.8Hz,1H),6.44(s,1H),4.36-4.29(m,2H),3.22(s,1H),2.74-2.67(m,1H),1.11(d,J=6.4Hz,3H),0.98(d,J=6.8Hz,3H).

[0421] Example 46: Synthesis of 4-((1-ethynylcyclopropyl)amino)-1-(2-methylpyridin-3-yl)-7-(trifluoromethyl)quinazoline-2(1H)-1

[0422] [ka] To a stirred suspension of compound 33-2 (200.0 mg, 0.62 mmol) in toluene (2 mL) was added POCl (477.6 mg, 3.11 mmol) and DIEA (805.0 mg, 6.23 mmol) at 0 °C. The resulting suspension was heated to 100 °C for 2 h. After cooling to room temperature, a mixture of 1-ethynylcyclopropanamine hydrochloride (366.0 mg, 3.11 mmol) and DIEA (805.0 mg, 6.23 mmol) in NMP (2 mL) was added. The resulting mixture was stirred at 50 °C for 1 h. The mixture was diluted with DCM (50 mL) and water (50 mL) and extracted with DCM (50 mL × 3). The combined organic phase was washed with water, brine, dried over NaSO, and concentrated. The residue was purified by silica gel column chromatography to give compound 46 (128.0 mg, 53.5% yield). LCMS: 385.1 [M+H] + . 1H NMR(400MHz,DMSO-d6)δ 9.33(s,1H),8.65(dd,J=4.8Hz,1.2Hz,1H),8.41(d,J=8.4Hz,1H),7.84(d,J=7.2Hz,1H),7.61(d,J=8.0Hz,1H ),7.52(dd,J=8.0Hz,4.8Hz,1H),6.49(s,1H),3.07(s,1H),2.19(s,3H),1.32-1.30(m,2H),1.26-1.23(m,2H).

[0423] Example 47: Synthesis of 4-((1-ethynylcyclopropyl)amino)-5-methoxy-1-(pyridin-3-yl)-7-(trifluoromethyl)quinazoline-2(1H)-1

[0424] [ka] To a stirred solution of compound 34-2 (150.0 mg, 0.44 mmol) in toluene (3 mL) was added DIPEA (574.8 mg, 4.45 mmol) and POCl (341.0 mg, 2.22 mmol) at 0 °C. The resulting suspension was heated to 100 °C for 2 h and then cooled to room temperature. A solution of 1-ethynylcyclopropanamine hydrochloride (313.8 mg, 2.67 mmol) and DIPEA (574.8 mg, 4.45 mmol) in NMP (2 mL) was added to the mixture. The reaction mixture was stirred at room temperature for 16 h. Water (30 mL) was added, extracted with DCM (50 mL × 3), and the combined organic phase was washed with water (50 mL × 3), brine, dried over Na SO , and concentrated. The residue was purified by gel column chromatography to give compound 47. LCMS: 401.1 [M+H] + . 1H NMR(400MHz,DMSO-d6)δ 8.88(s,1H),8.73(dd,J=4.8Hz,1.6Hz,1H),8.58(d,J=2.0Hz,1H),7.91-7.88(m,1H),7.66(dd,J=8.0Hz ,4.8Hz,1H),7.12(s,1H),6.12(s,1H),4.12(s,3H),3.04(s,1H),1.33-1.30(m,2H),1.26-1.23(m,2H).

[0425] Example 48: Synthesis of 5-methoxy-1-(3-methylpyrazin-2-yl)-4-(prop-2-yn-1-ylamino)-7-(trifluoromethyl)quinazoline-2(1H)-1

[0426] [ka] Step 1: To a stirred suspension of compound INTC-2 (300.0 mg, 1.27 mmol) in dichloroethane (6 mL) at room temperature, oxalyl chloride (177.0 mg, 1.39 mmol) was added. The resulting suspension was heated to 80° C. for 1 hour. After cooling to room temperature, 3-methylpyrazin-2-amine (276.0 mg, 2.53 mmol) was added. The mixture was stirred at room temperature for 16 hours. The precipitate was collected by filtration, washed with water, and dried to give compound 48-1 (400.0 mg, 77.2% yield). LCMS: 373.1 [M+H] + .

[0427] Step 2: NaH (116.0 mg, 2.91 mmol, 60% oil dispersion) was added to a mixture of compound 48-1 (360.0 mg, 0.97 mmol) in THF (5 mL) at -20 °C. The mixture was warmed to room temperature and stirred at 40 °C for 16 h. The reaction mixture was poured into ice water (3 mL) and the pH was adjusted to 6-7 with 4.0 M aqueous HCl. The precipitate was collected, washed with water, and dried to give compound 48-2 (220 mg, 64.7% yield). LCMS: 353.1 [M+H] + .

[0428] Step 3: To a stirred suspension of compound 48-2 (100.0 mg, 0.28 mmol) in acetonitrile (2 mL) was added DIPEA (110.0 mg, 0.85 mmol) and POCl (130.0 mg, 0.85 mmol) at 0 °C. The mixture was heated to 80 °C for 2 h. After cooling to room temperature, a mixture of DIPEA (362.0 mg, 2.80 mmol) and prop-2-yn-1-amine (154.0 mg, 2.80 mmol) in NMP (1 mL) was added. The mixture was stirred at 50 °C for 1 h. The mixture was diluted with DCM (5 mL) and water (15 mL) and extracted with DCM (10 mL × 3). The combined organic phase was washed with water, brine, dried over NaSO, and concentrated. The residue was purified by gel column chromatography to give compound 48 (63.4 mg, 57.3% yield). LCMS: 390.1 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ 9.06(m,1H),8.74(m,1H),8.63(s,1H),7.18(s,1H),6.12(s,1H),4.35(s,2H),4.13(s,3H),3.17(s,1H),2.31(s,3H).

[0429] Example 52: Synthesis of 1-(2,4-dimethylpyridin-3-yl)-4-(prop-2-yn-1-ylamino)-7-(trifluoromethyl)quinazoline-2(1H)-1

[0430] [ka] Step 1: To a stirred suspension of 2-fluoro-4-(trifluoromethyl)benzamide (2.0 g, 9.66 mmol) in dichloroethane (20 mL) at room temperature, oxalyl dichloride (1.3 g, 10.67 mmol) was added. The mixture was heated to 80° C. for 1 h. After cooling to room temperature, 2,4-dimethylpyridin-3-amine (2.4 g, 19.31 mmol) was added. The mixture was stirred at room temperature for 16 h and then cooled to 0° C. The precipitate was collected by filtration, washed with water and EtO, and dried to give compound 52-1 (2.2 g, 64.1% yield). Lcm: 356.1 [M+H] + .

[0431] Step 2: NaH (743.0 mg, 18.58 mmol, 60% oil dispersion) was added to a mixture of compound 52-1 (2.2 g, 6.19 mmol) in THF (20 mL) at −20° C., and the resulting mixture was allowed to warm to room temperature over 3 h. The reaction mixture was concentrated, diluted with water, and the pH was adjusted to 6–7 with 4 M aqueous HCl. The precipitate was collected by filtration, washed with water, and dried to give compound 52-2 (2.0 g, 96.3% yield). 1 H NMR(400MHz,DMSO-d6)δ 12.18(s,1H),8.53(d,J=5.2Hz,1H),8.33(d,J=8.4Hz,1H),7.69(d,J=8.0Hz,1H),7.41(d,J=4.8Hz,1H),6.46(s,1H),2.22(s,3H),2.07(s,3H).

[0432] Step 3: To a solution of compound 52-2 (200.0 mg, 0.60 mmol) in toluene (2 mL) was added DIEA (771.0 mg, 5.96 mmol) and POCl (457.3 mg, 2.98 mmol) at 0 °C. The resulting suspension was heated to 100 °C for 2 h. After cooling to room temperature, prop-2-yn-1-amine (328.6 mg, 5.96 mmol) and DIEA (771.0 mg, 5.96 mmol) in NMP (1.5 mL) were added. The mixture was stirred at room temperature for 16 h. Water (50 mL) was added and extracted with DCM (50 mL × 3). The combined organic layer was washed with water, brine, dried over NaSO, and concentrated. The residue was purified by column chromatography to give compound 52 (48.1 mg, 21.6% yield). LCMS: 373.1 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ 9.38(t,J=5.2Hz,1H),8.50-8.47(m,2H),7.67(d,J=7.6Hz,1H),7.38(d,J=4.8Hz,1H),6. 44(s,1H),4.38(dd,J=5.2Hz,2.4Hz,2H),3.27(t,J=2.4Hz,1H),2.11(s,3H),1.96(s,3H).

[0433] Example 53: Synthesis of 4-(prop-2-yn-1-ylamino)-1-(pyrazin-2-yl)-7-(trifluoromethyl)quinazoline-2(1H)-1

[0434] [ka] Step 1: To a stirred suspension of 2-fluoro-4-(trifluoromethyl)benzamide (3.0 g, 14.49 mmol) in dichloroethane (30 mL) at room temperature, oxalyl dichloride (2.0 g, 15.94 mmol) was added. The mixture was heated to 80 °C for 1 h. After cooling to room temperature, pyrazin-2-amine (2.7 g, 28.98 mmol) was added. The mixture was stirred at room temperature for 16 h. The precipitate was collected by filtration, washed with water, and dried to give compound 53-1 (4.5 g, 95.7% yield).1 H NMR(400MHz,DMSO-d6)δ 11.58(s,1H),10.81(s,1H),9.26(s,1H),8.44(s,2H),7.96-7.90(m,2H),7.76(d,J=8.0Hz,1H).

[0435] Step 2: KHMDS (30.0 mL, 30.18 mmol) was added to a mixture of compound 53-1 (4.5 g, 13.72 mmol) in DMF (30 mL) at −20° C., and the resulting mixture was warmed to room temperature over 1 h. The mixture was concentrated, diluted with water, and the pH was adjusted to 6–7 with 4 M aqueous HCl. The precipitate was collected, washed with water, and dried to give compound 53-2 (3.0 g, 71.0% yield). 1 H NMR(400MHz,DMSO-d6)δ 12.21(s,1H),8.97(s,1H),8.91(d,J=2.4Hz,1H),8.86-8.85(m,1H),8.30(d,J=8.4Hz,1H),7.68(d,J=8.0Hz,1H),6.86(s,1H).

[0436] Step 3: To a solution of compound 53-2 (100.0 mg, 0.32 mmol) in toluene (1 mL) was added DIEA (419.3 mg, 3.24 mmol) and POCl (249.0 mg, 1.62 mmol) at 0 °C. The mixture was heated to 100 °C for 2 h. After cooling to room temperature, a solution of prop-2-yn-1-amine (89.5 mg, 1.62 mmol) and DIEA (168.0 mg, 1.30 mmol) in NMP (1 mL) was added. The mixture was stirred at room temperature for 16 h. The reaction mixture was diluted with DCM (30 mL) and water (20 mL) and extracted with DCM (30 mL × 2). The combined organic phase was washed with water, brine, dried over Na SO and concentrated. The residue was purified by preparative HPLC to give compound 53 (27.5 mg, 24.5% yield). LCMS: 346.0 [M+H] + . 1H NMR(400MHz,DMSO-d6)δ 9.40(d,J=5.2Hz,1H),8.89(d,J=0.8Hz,1H)),8.83(d,J=2.4Hz,1H),8.81(d,J=1.2Hz,1H),8.44( d,J=8.8Hz,1H),7.67(d,J=8.0Hz,1H),6.80(s,1H),4.36(d,J=2.4Hz,2H),3.25(t,J=2.4Hz,1H).

[0437] Example 54: Synthesis of 5-methoxy-4-(prop-2-yn-1-ylamino)-1-(pyrazin-2-yl)-7-(trifluoromethyl)quinazoline-2(1H)-1

[0438] [ka] Step 1: To a stirred suspension of compound INTC-2 (300.0 mg, 1.27 mmol) in dichloroethane (6 mL) at room temperature, oxalyl chloride (177.0 mg, 1.39 mmol) was added. The mixture was heated to 80° C. for 1 hour. After cooling to room temperature, pyrazin-2-amine (240.6 mg, 2.53 mmol) was added. The mixture was stirred at room temperature for 1 hour, then cooled to 0° C. and stirred for 10 minutes. The precipitate was collected, washed with water, and dried to give compound 54-1 (300.0 mg, 66.2% yield). LCMS: 359.1 [M+H] + .

[0439] Step 2: NaH (87.0 mg, 2.26 mmol, 60% oil dispersion) was added to a mixture of compound 54-1 (270.00 mg, 0.75 mmol) in THF (5 mL) at -20 °C, and the resulting mixture was heated to 40 °C for 16 h. The reaction mixture was concentrated, poured into ice water (20 mL), and the pH was adjusted to 6-7 with 4 M aqueous HCl. The precipitate was collected, washed with water and EtO, and dried to give compound 54-2 (150.0 mg, 58.8% yield). LCMS: 339.1 [M+H] + .

[0440] Step 3: To a stirred mixture of compound 54-2 (130.0 mg, 0.38 mmol) in ACN (2 mL) was added DIEA (149.0 mg, 1.15 mmol) and POCl (177.0 mg, 1.15 mmol) at 0 °C. The resulting suspension was heated to 80 °C for 2 h. After cooling to room temperature, a solution of prop-2-yn-1-amine (212.0 mg, 3.84 mmol) and DIEA (497.0 mg, 3.84 mmol) in ACN (2 mL) was added. The mixture was stirred at room temperature for 16 h. Water (50 mL) was added and extracted with DCM (50 mL × 3). The combined organic layer was washed with water, brine, dried over NaSO, and concentrated. The residue was purified by column chromatography to give compound 54 (57.8 mg, 40.1% yield). LCMS: 376.0 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ 9.07(t,J=5.2Hz,1H),8.86(s,1H),8.83(d,J=2.4Hz,1H),8.81(d,J=1.2Hz,1H),7.17( s,1H),6.23(s,1H),4.34(dd,J=5.6Hz,2.0Hz,2H),4.13(s,3H),3.16(t,J=2.4Hz,1H).

[0441] Example 55: Synthesis of 4-(prop-2-yn-1-ylamino)-1-(pyridin-3-yl)-7-(trifluoromethyl)pyrido[3,2-d]pyrimidin-2(1H)-one

[0442] [ka] A mixture of compound 55-1 (100.0 mg, 0.32 mmol), POCl3 (248.7 mg, 1.62 mmol), and DIEA (209.7 mg, 1.62 mmol) in acetonitrile (2 mL) was stirred at 80 °C for 2 hours. After cooling to room temperature, a mixture of DIEA (419.5 mg, 3.24 mmol) and prop-2-yn-1-amine (179.0 mg, 3.24 mmol) in acetonitrile (2 mL) was added. The mixture was stirred at room temperature for 16 hours. Water (30 mL) was added and extracted with DCM (50 mL × 3). The combined organic layer was washed with water (50 mL × 3), brine, dried over anhydrous Na2SO4, and concentrated. The residue was purified by column chromatography to give compound 55. LCMS: 346.1 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ 9.41(t,J=6.0Hz,1H),8.82(d,J=1.2Hz,1H),8.73(dd,J=4.8Hz,1.2Hz,1H),8.63(d,J=2.0Hz,1H),7.94-7.91( m,1H),7.66(dd,J=8.4Hz,4.8Hz,1H),7.11(d,J=1.2Hz,1H),4.30(dd,J=6.0Hz,2.4Hz,2H),3.17-3.16(m,1H).

[0443] Example 56: Synthesis of 4-((1-ethynylcyclopropyl)amino)-1-(pyridin-3-yl)-7-(trifluoromethyl)pyrido[3,2-d]pyrimidin-2(1H)-one

[0444] [ka] A mixture of compound 55-1 (100.0 mg, 0.32 mmol), POCl3 (248.9 mg, 1.62 mmol), and DIEA (209.8 mg, 1.62 mmol) in MeCN (2 mL) was stirred at 80 °C for 2 h. After cooling to room temperature, a mixture of DIEA (419.6 mg, 2.84 mmol) and 1-ethynylcyclopropanamine hydrochloride (229.0 mg, 1.95 mmol) in MeCN (2 mL) was added. The resulting mixture was stirred at room temperature for 16 h. After concentration, the residue was diluted with DCM (20 mL) and water (20 mL) and extracted with DCM (30 mL × 2). The combined organic layer was washed with water, brine, dried over Na2SO4, and concentrated. The residue was purified by silica gel column chromatography to give compound 56 (21.4 mg, 17.6% yield).

[0445] Example 57: Synthesis of 4-(prop-2-yn-1-ylamino)-1-(pyridin-3-yl)-7-(trifluoromethyl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0446] [ka] To a stirred mixture of compound 57-1 (100.0 mg, 0.32 mmol) in toluene (1 mL) was added DIEA (419.6 mg, 3.24 mmol) and POCl3 (248.9 mg, 1.62 mmol) at 0 °C. The mixture was heated to 100 °C for 2 h. After cooling to room temperature, a solution of prop-2-yn-1-amine (178.5 mg, 3.24 mmol) and DIEA (419.6 mg, 3.24 mmol) in NMP (1 mL) was added. The mixture was stirred at room temperature for 16 h. The reaction mixture was diluted with DCM (20 mL) and water (30 mL) and extracted with DCM (30 mL × 2). The combined organic phase was washed with water, brine, dried over Na2SO4, and concentrated. The residue was purified by column chromatography to give compound 57. LCMS: 346.1 [M+H] + . 1H NMR(400MHz,DMSO-d6)δ 9.45(t,J=5.2Hz,1H),8.84(d,J=8.0Hz,1H),8.60(dd,J=4.8Hz,1.2Hz,1H),8.51(d,J=2.0Hz,1 H),7.81-7.78(m,2H),7.57-7.54(m,1H),4.36(dd,J=5.2Hz,2.4Hz,2H),3.27(t,J=2.0Hz,1H).

[0447] Example 58: Synthesis of 4-(prop-2-yn-1-ylamino)-1-(pyridin-3-yl)-7-(trifluoromethyl)pyrido[4,3-d]pyrimidin-2(1H)-one

[0448] [ka] Step 1: To a mixture of TEMP (54.3 g, 384 mmol) in THF (250 mL), n-BuLi (2.5 M, 153 mL) was added dropwise at −78° C. under N , and the mixture was stirred at −78° C. for 0.5 h. Then, a solution of 6-(trifluoromethyl)nicotinic acid (24.5 g, 128 mmol) in THF (250 mL) was added dropwise at −78° C. The mixture was stirred at −78° C. for 1 h, and 1,1,1,2,2,2-hexachloroethane (60.7 g, 256 mmol) in THF (250 mL) was added and stirred at −78° C. for 3 h. Aqueous ammonium chloride solution (250 mL) was added slowly at −78° C., and the mixture was stirred at 25° C. for 20 min. The mixture was extracted with ethyl acetate (250 mL × 3). The combined organic layers were concentrated to give compound 58-1 (42.0 g, crude). LCMS: 226.0 [M+H] + .

[0449] Step 2: Compound 58-1 (40.0 g) was dissolved in DCM (240 mL), and then DMF (77.1 mg, 1.06 mmol) was added at 0 °C, followed by oxalyl chloride (34.5 g, 271 mmol). The mixture was stirred at 25 °C for 2 h. After concentration, the residue was dissolved in THF (24 mL) and added to NH OH (108.0 g, purity 28.0%) under ice cooling. The mixture was poured into water (250 mL) and extracted with DCM (300 mL × 3). The combined organic layer was dried over Na SO and concentrated to give compound 58-2 (32.0 g, crude). LCMS: 225.1 [M+H] + .

[0450] Step 3: To a stirred suspension of compound 58-2 (29.0 g, purity 59.3%) in DCE (290 mL) at 25° C., oxalyl chloride (10.6 g, 84.2 mmol) was added. The mixture was heated to 80° C. for 1 h. The mixture was cooled to 25° C., and pyridin-3-amine (8.65 g, 91.8 mmol) was added. The mixture was stirred at 25° C. for 30 min. The precipitate was collected by filtration, washed with DCM, and dried to give compound 58-3 (26.0 g, crude). LCMS: 345.1 [M+H] + .

[0451] Step 4: A slurry of compound 58-3 (10.0 g, 29.0 mmol) in DME (5 mL) was cooled to 0 °C and treated with NaH (3.60 g, 89.9 mmol, 60% oil dispersion). The reaction mixture was warmed to 25 °C for 3 h and poured into aqueous NH4Cl (40 mL). Extraction was performed with EtOAc (50 mL x 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated to give compound 58-4. LCMS: 309.1 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ 12.36(s,1H),9.22(s,1H),8.87(d,1H),8.79(d,1H),8.12(s,1H),7.83(m,1H),6.82(s,1H).

[0452] Step 5: To a stirred suspension of compound 58-4 (100.0 mg, 0.32 mmol) in MeCN (1 mL) was added POCl (149.2 mg, 0.97 mmol) and DIPEA (125.8 mg, 0.97 mmol) at 0 °C. The mixture was heated to 80 °C for 2 h. After cooling to room temperature, a mixture of DIPEA (419.3 mg, 3.24 mmol) and prop-2-yn-1-amine (178.7 mg, 3.24 mmol) in MeCN (1 mL) was added. The mixture was stirred at 50 °C for 1 h, diluted with DCM (10 mL) and water (10 mL), and extracted with DCM (30 mL × 2). The combined organic phase was washed with water, brine, dried over NaSO, and concentrated. The residue was purified by silica gel column to give compound 58 (33.80 mg, 30.1% yield). LCMS: 346.1 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ 9.54(t,J=4.8Hz,1H),9.43(s,1H),8.74(dd,J=4.8Hz,1.2Hz,1H),8.62(d,J=2.0Hz,1H), 7.93-7.90(m,1H),7.66(dd,J=8.0Hz,3.2Hz,1H),6.65(s,1H),4.38(m,2H),3.28(m,1H).

[0453] Example 59: Synthesis of 4-(but-3-yn-2-ylamino)-1-(pyridin-3-yl)-7-(trifluoromethyl)pyrido[4,3-d]pyrimidin-2(1H)-one

[0454] [ka] To a stirred suspension of compound 58-4 (200.0 mg, 0.64 mmol) in MeCN (2 mL) was added POCl (298.4 mg, 1.94 mmol) and DIPEA (251.6 mg, 1.94 mmol) at 0 °C. The mixture was heated to 80 °C for 2 h. After cooling to room temperature, a mixture of DIPEA (838.6 mg, 6.48 mmol) and but-3-yn-2-amine hydrochloride (224.2 mg, 3.24 mmol) in MeCN (1 mL) was added. The mixture was stirred at 50 °C for 1 h and diluted with DCM (50 mL) and water (30 mL). Extraction was performed with DCM (50 mL × 2). The combined organic phase was washed with water, brine, dried over anhydrous NaSO, and concentrated. The residue was purified by silica gel column chromatography to give compound 59 (78.20 mg, 32.5% yield).

[0455] Example 60: Synthesis of 4-((1-ethynylcyclopropyl)amino)-1-(pyridin-3-yl)-7-(trifluoromethyl)pyrido[4,3-d]pyrimidin-2(1H)-one

[0456] [ka] To a stirred suspension of compound 58-4 (200.0 mg, 0.65 mmol) in acetonitrile (2 mL) was added DIPEA (251.0 mg, 1.95 mmol) and POCl3 (298.0 mg, 1.95 mmol) at 0 °C. The mixture was heated to 80 °C for 2 h. After cooling to room temperature, a mixture of DIPEA (838.0 mg, 6.50 mmol) and 1-ethynylcyclopropanamine hydrochloride (457.0 mg, 3.89 mmol) in NMP (2 mL) was added. The mixture was stirred at room temperature for 16 h and diluted with DCM (10 mL) and water (15 mL). Extraction was performed with DCM (20 mL × 3). The combined organic phase was washed with water, brine, dried over Na2SO4, and concentrated. The residue was purified by gel column chromatography to give compound 60 (94.3 mg, 39.3% yield). LCMS: 372.0 [M+H] + . 1H NMR(400MHz,DMSO-d6)δ 9.56(s,1H),9.37(s,1H),8.75(d,J=4.0Hz,1H),8.64(d,J=1.6Hz,1H),7.94(d,J=8. 0Hz, 1H), 7.67 (dd, J=4.8Hz, 1.2Hz, 1H), 6.63 (s, 1H), 3.11 (s, 1H), 1.34-1.26 (m, 4H).

[0457] Example 61: Synthesis of 4-(prop-2-yn-1-ylamino)-1-(pyridin-3-yl)-7-(trifluoromethyl)pyrimido[4,5-d]pyrimidin-2(1H)-one

[0458] [ka] To a stirred solution of compound 61-1 (120.0 mg, 0.39 mmol) in MeCN (2 mL) was added DIEA (150.5 mg, 1.16 mmol) and POCl (178.5 mg, 1.16 mmol) at 0 °C. The mixture was heated to 80 °C for 2 h. After cooling to room temperature, a solution of prop-2-yn-1-amine (214.0 mg, 3.88 mmol) and DIEA (501.5 mg, 3.88 mmol) in MeCN (2 mL) was added. The mixture was stirred at room temperature overnight. Water (50 mL) was added and extracted with DCM (50 mL × 3). The combined organic layer was washed with water, brine, dried over NaSO, and concentrated. The residue was purified by column chromatography to give compound 61 (18.8 mg, 14.0% yield). LCMS: 347.1 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ 9.70(t,J=5.2Hz,1H),9.57(s,1H),8.64(dd,J=4.8Hz,1.2Hz,1H),8.54(d,J=2.0Hz,1H),7.83-7 .80(m,1H),7.59(dd,J=8.0Hz,4.8Hz,1H),4.38(dd,J=4.8Hz,2.4Hz,2H),3.28(t,J=2.4Hz,1H).

[0459] Example 62: Synthesis of 4-((1-ethynylcyclopropyl)amino)-1-(pyridin-3-yl)-7-(trifluoromethyl)pyrimido[4,5-d]pyrimidin-2(1H)-one

[0460] [ka] To a stirred solution of compound 61-1 (100.0 mg, 0.32 mmol) in MeCN (2 mL) was added DIEA (125.4 mg, 0.97 mmol) and POCl (149.0 mg, 0.97 mmol) at 0 °C. The mixture was heated to 80 °C for 2 h. After cooling to room temperature, a solution of 1-ethynylcyclopropanamine hydrochloride (228.0 mg, 1.94 mmol) and DIEA (418.0 mg, 3.23 mmol) in MeCN (2 mL) was added. The mixture was stirred at room temperature for 16 h. Water (50 mL) was added and extracted with DCM (50 mL × 3). The combined organic layer was washed with water, brine, dried over anhydrous NaSO, and concentrated. The residue was purified by column chromatography to give compound 62 (30.5 mg, 25.3% yield). LCMS: 373.0 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ 9.71(s,1H),9.51(s,1H),8.64(dd,J=4.8Hz,2.4Hz,1H),8.55(d,J=2.4Hz,1H),7.84-7.81 (m,1H),7.59(dd,J=8.0Hz,4.8Hz,1H),3.14(s,1H),1.38-1.35(m,2H),1.27-1.24(m,2H).

[0461] Example 63: Synthesis of 4-(prop-2-yn-1-ylamino)-1-(pyridazin-3-yl)-7-(trifluoromethyl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0462] [ka] Step 1: To a stirred suspension of 2-chloro-6-(trifluoromethyl)nicotinamide (7.08 g, 31.5 mmol) in DCE (70 mL) was added (COCl) (4.40 g, 34.7 mmol) at 25 °C. The mixture was heated to 80 °C for 1 h. After cooling to 25 °C, pyridazin-3-amine (3.60 g, 37.8 mmol) was added. The mixture was stirred at 25 °C for 30 min. The precipitate was collected by filtration, washed with DCM, and dried to give compound 63-1 (8.20 g, 75.2% yield). LCMS: 346.1 [M+H] + .

[0463] Step 2: A slurry of compound 63-1 (8.20 g, 23.7 mmol) in DME (82 mL) was cooled to 0 °C and treated with NaH (2.94 g, 73.5 mmol, 60.0%). The reaction mixture was warmed to 25 °C for 3 h. The mixture was poured into water. NH4Cl (40 mL) was extracted with ethyl acetate (50 mL × 3). The combined organic layers were dried over Na2SO4 and concentrated to give compound 63-2 (5.50 g, 75.0%).

[0464] Step 3: A mixture of compound 63-2 (200.0 mg, 0.65 mmol), POCl (297.5 mg, 1.94 mmol), and DIPEA (250.8 mg, 1.94 mmol) in MeCN (2 mL) was stirred at 80 °C for 2 hours. After cooling to room temperature, a mixture of DIPEA (835.9 mg, 6.47 mmol) and prop-2-yn-1-amine (356.3 mg, 6.47 mmol) in MeCN (2 mL) was added. The resulting mixture was stirred at room temperature for 16 hours. The mixture was diluted with DCM (20 mL) and water (20 mL) and extracted with DCM (20 mL × 3). The combined organic phase was washed with water, brine, dried over anhydrous NaSO, and concentrated. The residue was purified by preparative TLC to give compound 63. LCMS: 347.1 [M+H] + . 1H NMR(400MHz,DMSO-d6)δ 9.62-9.51(m,1H),9.35(dd,J=4.8Hz,1.2Hz,1H),8.90(d,J=8.0Hz,1H),7.96(dd,J =8.8Hz,4.8Hz,1H),7.90-7.81(m,2H),4.38(d,J=1.2Hz,2H),3.29(t,J=2.4Hz,1H).

[0465] Example 68: Synthesis of 4-((1-ethynylcyclopropyl)amino)-1-(pyridin-3-yl)-7-(trifluoromethyl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0466] [ka] To a mixture of compound 57-1 (100.0 mg, 0.32 mmol) in toluene (1 mL) was added DIEA (419.6 mg, 3.24 mmol) and POCl3 (248.9 mg, 1.62 mmol) at 0 °C. The mixture was heated to 100 °C for 2 h. After cooling to room temperature, a solution of 1-ethynylcyclopropan-1-amine hydrochloride (189.9 mg, 1.62 mmol) and DIEA (419.6 mg, 3.24 mmol) in NMP (1 mL) was added. The mixture was stirred at room temperature for 16 h. The mixture was diluted with DCM (30 mL) and water (30 mL) and extracted with DCM (30 mL × 2). The combined organic phase was washed with water, brine, dried over Na2SO4, and concentrated. The residue was purified by preparative TLC to give compound 68. LCMS: 372.1 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ 9.46(s,1H),8.78(d,J=8.4Hz,1H),8.61(dd,J=4.8Hz,1.6Hz,1H),8.52(d,J=2.4Hz,1H), 7.82-7.77(m,2H),7.57-7.54(m,1H),3.09(s,1H),1.35-1.32(m,2H),1.25-1.22(m,2H).

[0467] Example 69: Synthesis of 4-((1-ethynylcyclopropyl)amino)-1-(pyrazin-2-yl)-7-(trifluoromethyl)quinazoline-2(1H)-1

[0468] [ka] To a mixture of compound 53-2 (200.0 mg, 0.65 mmol) in toluene (2 mL) was added DIEA (841.3 mg, 6.51 mmol) and POCl (499.0 mg, 3.25 mmol) at 0 °C. The mixture was heated to 100 °C for 2 h. After cooli...

Claims

1. Formula (I) or Formula (II) 【Chemistry 1】 or a pharma- ceutically acceptable salt thereof, During the ceremony, 【Chemistry 2】 is C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-10 heteroaryl; Z 1 is CR 7 or N, Z 2 is CR 9 or N, Z 3 is CR 6 or N, Z 4 is CR 6a or N, X is -N(R 4 )-, -O-, and -C(R 5 ) (R 5a ) - is selected from Y is -N(R 4a )-, -O-, and -C(R 5 ) (R 5a ) - is selected from R 1 is hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF 5 , -N(R 10 ) (R 11 ), -C(O)OR 10 , -OC(O)N(R 10 ) (R 11 ), -N(R 12 ) C(O)N(R 10 ) (R 11 ), -N(R 12 ) C(O)OR 13 , -N(R 12 ) S (O) 2 R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 ) (R 11 ), -C(O)C(O)N(R 10 ) (R 11 ), -N(R 12 ) C(O)R 13 , -S(O) 2 R 13 , -S(O) 2 N (R 10 ) (R 11 )-, -N=S(=O)(R 13 ) 2 , -S(=O)(=NH)N(R 10 ) (R 11 ), -S(=O)(=NH)C(R 10 ) (R 11 ), -S(=O)(=NR 13 ) R 13 , -CH 2 C(O)N(R 10 ) (R 11 ), -CH 2 N (R 12 ) C(O)R 13 , -CH 2 S (O) 2 R 13 , -CH 2 S (O) 2 N (R 10 ) (R 11 ), -Si(C 1-6 Alkyl) 3 and -P(O)(R 10 ) 2 is selected from, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is R 15a and optionally substituted with one, two, or three groups selected from R 1a and R 1b are independently hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is R 15a and optionally substituted with one, two, or three groups selected from Each R 2 and each R 3 are each independently hydrogen, halogen, oxo, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF 5 , -N(R 10 ) (R 11 ), -C(O)OR 10 , -OC(O)N(R 10 ) (R 11 ), -N(R 12 ) C(O)N(R 10 ) (R 11 ), -N(R 12 ) C(O)OR 13 , -N(R 12 ) S (O) 2 R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 ) (R 11 ), -C(O)C(O)N(R 10 ) (R 11 ), -N(R 12 ) C(O)R 13 , -S(O) 2 R 13 , -S(O) 2 N (R 10 ) (R 11 )-, -N=S(=O)(R 13 ) 2 , -S(=O)(=NH)N(R 10 ) (R 11 ), -S(=O)(=NH)C(R 10 ) (R 11 ), -S(=O)(=NR 13 ) R 13 , -CH 2 C(O)N(R 10 ) (R 11 ), -CH 2 N (R 12 ) C(O)R 13 , -CH 2 S (O) 2 R 13 , -CH 2 S (O) 2 N (R 10 ) (R 11 ), -Si(C 1-6 Alkyl) 3 and -P(O)(R 10 ) 2 is selected from, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is R 15b or R 2 and R 3 Together with the carbon to which they are attached, C 3-6 Cycloalkyl or C 2-9 forming a heterocycloalkyl, R 4 is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is halogen, —CN, hydroxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, or R 4 and R 3 By combining, halogen, -CN, hydroxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 C optionally substituted with one, two, or three groups selected from heteroaryl 2-9 forming a heterocycloalkyl, R 4a is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is halogen, —CN, hydroxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, or R 4a and R 3 By combining, halogen, -CN, hydroxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 C optionally substituted with one, two, or three groups selected from heteroaryl 2-9 forming a heterocycloalkyl, R 5 and R 5a are independently hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF 5 , -N(R 10 ) (R 11 ), -C(O)OR 10 , -OC(O)N(R 10 ) (R 11 ), -N(R 12 ) C(O)N(R 10 ) (R 11 ), -N(R 12 ) C(O)OR 13 , -N(R 12 ) S (O) 2 R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 ) (R 11 ), -C(O)C(O)N(R 10 ) (R 11 ), -N(R 12 ) C(O)R 13 , -S(O) 2 R 13 , -S(O) 2 N (R 10 ) (R 11 )-, -N=S(=O)(R 13 ) 2 , -S(=O)(=NH)N(R 10 ) (R 11 ), -S(=O)(=NH)C(R 10 ) (R 11 ), -S(=O)(=NR 13 ) R 13 , -CH 2 C(O)N(R 10 ) (R 11 ), -CH 2 N (R 12 ) C(O)R 13 , -CH 2 S (O) 2 R 13 , -CH 2 S (O) 2 N (R 10 ) (R 11 ), -Si(C 1-6 Alkyl) 3 and -P(O)(R 10 ) 2 is selected from, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is halogen, —CN, hydroxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, or R 5 and R 3 By combining, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, or C 2-9 Form a heteroaryl, where C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is halogen, —CN, hydroxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 optionally substituted with one, two, or three groups selected from heteroaryl; R 6 , R 7 , R 8 , and R 9 are independently hydrogen, halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF 5 , -N(R 10 ) (R 11 ), -C(O)OR 10 , -OC(O)N(R 10 ) (R 11 ), -N(R 12 ) C(O)N(R 10 ) (R 11 ), -N(R 12 ) C(O)OR 13 , -N(R 12 ) S (O) 2 R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 ) (R 11 ), -C(O)C(O)N(R 10 ) (R 11 ), -N(R 12 ) C(O)R 13 , -S(O) 2 R 13 , -S(O) 2 N (R 10 ) (R 11 )-, -N=S(=O)(R 13 ) 2 , -S(=O)(=NH)N(R 10 ) (R 11 ), -S(=O)(=NH)C(R 10 ) (R 11 ), -S(=O)(=NR 13 ) R 13 , -CH 2 C(O)N(R 10 ) (R 11 ), -CH 2 N (R 12 ) C(O)R 13 , -CH 2 S (O) 2 R 13 , -CH 2 S (O) 2 N (R 10 ) (R 11 ), -Si(C 1-6 Alkyl) 3 , -P(O)(R 10 ) 2 is selected from, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is R 15c and optionally substituted with one, two, or three groups selected from R 6a is hydrogen, halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF 5 , -N(R 10 ) (R 11 ), -C(O)OR 10 , -OC(O)N(R 10 ) (R 11 ), -N(R 12 ) C(O)N(R 10 ) (R 11 ), -N(R 12 ) C(O)OR 13 , -N(R 12 ) S (O) 2 R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 ) (R 11 ), -C(O)C(O)N(R 10 ) (R 11 ), -N(R 12 ) C(O)R 13 , -S(O) 2 R 13 , -S(O) 2 N (R 10 ) (R 11 )-, -N=S(=O)(R 13 ) 2 , -S(=O)(=NH)N(R 10 ) (R 11 ), -S(=O)(=NH)C(R 10 ) (R 11 ), -S(=O)(=NR 13 ) R 13 , -CH 2 C(O)N(R 10 ) (R 11 ), -CH 2 N (R 12 ) C(O)R 13 , -CH 2 S (O) 2 R 13 , -CH 2 S (O) 2 N (R 10 ) (R 11 ), -Si(C 1-6 Alkyl) 3 and -P(O)(R 10 ) 2 is selected from, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, and C 1-9 Heteroaryl is R 15c and optionally substituted with one, two, or three groups selected from Each R 10 are independently hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is halogen, —CN, hydroxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 optionally substituted with one, two, or three groups selected from heteroaryl; Each R 11 are independently hydrogen, C 1-6 Alkyl, and C 1-6 haloalkyl, or R 10 and R 11 Together with the nitrogen to which they are attached, C 2-9 forming a heterocycloalkyl, Each R 12 are independently hydrogen, C 1-6 Alkyl, and C 1-6 haloalkyl; Each R 13 is independent, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 heteroaryl, wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is halogen, —CN, hydroxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 optionally substituted with one, two, or three groups selected from heteroaryl; Each R 14 are independently halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF 5 , -N(R 10 ) (R 11 ), -C(O)OR 10 , -OC(O)N(R 10 ) (R 11 ), -N(R 12 ) C(O)N(R 10 ) (R 11 ), -N(R 12 ) C(O)OR 13 , -N(R 12 ) S (O) 2 R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 ) (R 11 ), -C(O)C(O)N(R 10 ) (R 11 ), -N(R 12 ) C(O)R 13 , -S(O) 2 R 13 , -S(O) 2 N (R 10 ) (R 11 )-, -N=S(=O)(R 13 ) 2 , -S(=O)(=NH)N(R 10 ) (R 11 ), -S(=O)(=NH)C(R 10 ) (R 11 ), -S(=O)(=NR 13 ) R 13 , -CH 2 C(O)N(R 10 ) (R 11 ), -CH 2 N (R 12 ) C(O)R 13 , -CH 2 S (O) 2 R 13 , -CH 2 S (O) 2 N (R 10 ) (R 11 ), -Si(C 1-6 Alkyl) 3 and -P(O)(R 10 ) 2 is selected from, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryl is R 15d and optionally substituted with one, two, or three groups selected from Each R 15a , R 15b , R 15c , and R 15d are each independently a halogen, oxo, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, -CH 2 -C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH 2 -C 2-9 Heterocycloalkyl, C 6-10 Aryl, -CH 2 -C 6-10 Aryl, C 1-9 Heteroaryl, -CH 2 -C 1-9 Heteroaryl, -OR 10 , -SR 10 , -SF 5 , -N(R 10 ) (R 11 ), -C(O)OR 10 , -OC(O)N(R 10 ) (R 11 ), -N(R 12 ) C(O)N(R 10 ) (R 11 ), -N(R 12 ) C(O)OR 13 , -N(R 12 ) S (O) 2 R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 ) (R 11 ), -C(O)C(O)N(R 10 ) (R 11 ), -N(R 12 ) C(O)R 13 , -S(O) 2 R 13 , -S(O) 2 N (R 10 ) (R 11 )-, -N=S(=O)(R 13 ) 2 , -S(=O)(=NH)N(R 10 ) (R 11 ), -S(=O)(=NH)C(R 10 ) (R 11 ), -S(=O)(=NR 13 ) R 13 , -CH 2 C(O)N(R 10 ) (R 11 ), -CH 2 N (R 12 ) C(O)R 13 , -CH 2 S (O) 2 R 13 , -CH 2 S (O) 2 N (R 10 ) (R 11 ), -Si(C 1-6 Alkyl) 3 and -P(O)(R 10 ) 2 is selected from, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, -CH 2 -C 3-10 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH 2 -C 2-9 Heterocycloalkyl, C 6-10 Aryl, -CH 2 -C 6-10 Aryl, -CH 2 -C 1-9 Heteroaryl, and C 1-9 Heteroaryl is halogen, oxo, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 10 , -SR 10 , -SF 5 , -N(R 10 ) (R 11 ), -C(O)OR 10 , -OC(O)N(R 10 ) (R 11 ), -N(R 12 ) C(O)N(R 10 ) (R 11 ), -N(R 12 ) C(O)OR 13 , -N(R 12 ) S (O) 2 R 13 , -C(O)R 13 , -S(O)R 13 , -OC(O)R 13 , -C(O)N(R 10 ) (R 11 ), -C(O)C(O)N(R 10 ) (R 11 ), -N(R 12 ) C(O)R 13 , -S(O) 2 R 13 , -S(O) 2 N (R 10 ) (R 11 )-, -N=S(=O)(R 13 ) 2 , -S(=O)(=NH)N(R 10 ) (R 11 ), -S(=O)(=NH)C(R 10 ) (R 11 ), -S(=O)(=NR 13 ) R 13 , -CH 2 C(O)N(R 10 ) (R 11 ), -CH 2 N (R 12 ) C(O)R 13 , -CH 2 S (O) 2 R 13 , -CH 2 S (O) 2 N (R 10 ) (R 11 ), and -P(O)(R 10 ) 2 and optionally substituted with one, two, or three groups independently selected from m is 0, 1, 2, 3, 4, or 5; n is 0, 1, 2, 3, 4, 5, or 6; The compound, or a pharma- ceutically acceptable salt thereof.

2. Formula (I) 【Chemistry 3】 2. The compound of claim 1 having the structure: or a pharma- ceutically acceptable salt thereof.

3. Z 3 is CR 6 3. The compound of claim 1 or claim 2, which is: or a pharma- ceutically acceptable salt thereof.

4. R 6 is hydrogen, halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , and -N(R 10 ) (R 11 4. The compound according to claim 1, or a pharma- ceutically acceptable salt thereof, selected from:

5. R 6 is hydrogen and -OR 10 is selected from R 10 is C 1-6 5. The compound of any one of claims 1 to 4, or a pharma- ceutically acceptable salt thereof, wherein R is an alkyl group.

6. R 6 The compound according to any one of claims 1 to 5, or a pharma- ceutically acceptable salt thereof, wherein is hydrogen.

7. Z 3 is N, or a pharma- ceutically acceptable salt thereof.

8. X is -N(R 4 8. The compound according to any one of claims 1 to 7, wherein R is -R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R

9. R 4 is hydrogen or C 1-6 9. The compound of any one of claims 1 to 8, or a pharma- ceutically acceptable salt thereof, wherein: R is an alkyl group;

10. R 4 The compound according to any one of claims 1 to 9, or a pharma- ceutically acceptable salt thereof, wherein is hydrogen.

11. X is -N(R 4 )-, and R 4 and R 3 By combining, halogen, -CN, hydroxy, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 C optionally substituted with one, two, or three groups selected from heteroaryl 2-9 A compound according to any one of claims 1 to 7, or a pharma- ceutically acceptable salt thereof, which forms a heterocycloalkyl.

12. Formula (II) 【Chemistry 4】 2. The compound of claim 1 having the structure: or a pharma- ceutically acceptable salt thereof.

13. Z 4 is CR 6a 13. The compound of claim 1 or claim 12, which is: or a pharma- ceutically acceptable salt thereof.

14. R 6a is hydrogen, halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , and -N(R 10 ) (R 11 14. The compound of claim 13, or a pharma- ceutically acceptable salt thereof, selected from:

15. R 6a is hydrogen and -OR 10 is selected from R 10 is C 1-6 15. The compound of claim 14, or a pharma- ceutically acceptable salt thereof, wherein: R is an alkyl group;

16. R 6a is hydrogen, or a pharma- ceutically acceptable salt thereof.

17. Z 4 is N, or a pharma- ceutically acceptable salt thereof.

18. R 1a and R 1b are independently hydrogen, and R 15a C optionally substituted with one, two, or three groups selected from 1-6 18. The compound of any one of claims 12 to 17, or a pharma- ceutically acceptable salt thereof, wherein: R is selected from the group consisting of alkyl, aryl, arylsulfates, arylalkyl, arylsulfates ...

19. R 1a and R 1b are independently hydrogen and unsubstituted C 1-6 19. The compound of any one of claims 12 to 18, or a pharma- ceutically acceptable salt thereof, wherein: R is selected from the group consisting of alkyl, aryl, arylsulfates, arylalkyl, arylsulfates ...

20. R 1a and R 1b The compound according to any one of claims 12 to 19, or a pharma- ceutically acceptable salt thereof, wherein is hydrogen.

21. Y is -N(R 4a 21. The compound according to any one of claims 12 to 20, or a pharma- ceutically acceptable salt thereof, wherein:

22. R 4a is hydrogen or C 1-6 22. The compound of any one of claims 12 to 21, or a pharma- ceutically acceptable salt thereof, which is alkyl.

23. R 4a The compound according to any one of claims 12 to 22, or a pharma- ceutically acceptable salt thereof, wherein is hydrogen.

24. Each R 2 are independently hydrogen and C 1-6 24. The compound of any one of claims 1 to 23, or a pharma- ceutically acceptable salt thereof, selected from: alkyl.

25. Each R 2 The compound of any one of claims 1 to 24, or a pharma- ceutically acceptable salt thereof, wherein is hydrogen.

26. Each R 3 are independently hydrogen and C 1-6 26. The compound of any one of claims 1 to 25, or a pharma- ceutically acceptable salt thereof, wherein: R is selected from the group consisting of alkyl, aryl, arylsulfates, arylalkyl, arylsulfates ...

27. Each R 3 27. The compound of any one of claims 1 to 26, or a pharma- ceutically acceptable salt thereof, wherein: is hydrogen.

28. R 2 and R 3 Together with the carbon to which they are attached, C 3-6 24. The compound of any one of claims 1 to 23, or a pharma- ceutically acceptable salt thereof, which forms a cycloalkyl.

29. 29. The compound of any one of claims 1 to 28, or a pharma- ceutically acceptable salt thereof, wherein n is 1, 2, or 3.

30. 30. The compound of any one of claims 1 to 29, or a pharma- ceutically acceptable salt thereof, wherein n is 1.

31. Z 1 is CR 7 31. The compound of any one of claims 1 to 30, wherein:

32. R 7 is hydrogen, halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , or -N(R 10 ) (R 11 32. The compound of claim 1, wherein R is an integer from 1 to 31; or a pharma- ceutically acceptable salt thereof.

33. R 7 is hydrogen, halogen, C 1-6 Alkyl, or C 1-6 33. The compound of any one of claims 1 to 32, or a pharma- ceutically acceptable salt thereof, which is haloalkyl.

34. R 7 The compound of any one of claims 1 to 33, or a pharma- ceutically acceptable salt thereof, wherein is hydrogen.

35. Z 1 is N, or a pharma- ceutically acceptable salt thereof.

36. Z 2 is CR 9 36. The compound of any one of claims 1 to 35, which is: or a pharma- ceutically acceptable salt thereof.

37. R 9 is hydrogen, halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , or -N(R 10 ) (R 11 37. The compound of claim 1, wherein R is an integer from 1 to 36, or a pharma- ceutically acceptable salt thereof.

38. R 9 is hydrogen, halogen, C 1-6 Alkyl, or C 1-6 38. The compound of any one of claims 1 to 37, or a pharma- ceutically acceptable salt thereof, which is haloalkyl.

39. R 9 The compound of any one of claims 1 to 38, or a pharma- ceutically acceptable salt thereof, wherein is hydrogen.

40. Z 2 is N, or a pharma- ceutically acceptable salt thereof.

41. Formula (Ia) 【Chemistry 5】 7. The compound of any one of claims 1 to 6, having the structure: or a pharma- ceutically acceptable salt thereof.

42. Formula (Ib) 【Chemistry 6】 7. The compound of any one of claims 1 to 6, having the structure: or a pharma- ceutically acceptable salt thereof.

43. Formula (IIa) 【Chemistry 7】 17. The compound of any one of claims 12 to 16, having the structure: or a pharma- ceutically acceptable salt thereof.

44. 【Chemical 8】 is C 1-10 44. The compound of any one of claims 1 to 43, or a pharma- ceutically acceptable salt thereof, which is heteroaryl.

45. 【Chemical 9】 is selected from pyridyl, pyrimidyl, pyrazinyl, and pyridazinyl 1-10 45. The compound of any one of claims 1 to 44, or a pharma- ceutically acceptable salt thereof, which is heteroaryl.

46. 【Catalog 10】 46. ​​The compound of any one of claims 1 to 45, or a pharma- ceutically acceptable salt thereof, wherein:

47. 【Catalog 11】 44. The compound of any one of claims 1 to 43, or a pharma- ceutically acceptable salt thereof, wherein:

48. Each R 14 are independently halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , and -N(R 10 ) (R 11 48. The compound of any one of claims 1 to 47, or a pharma- ceutically acceptable salt thereof, selected from:

49. Each R 14 are independently halogen and C 1-6 49. The compound of any one of claims 1 to 48, or a pharma- ceutically acceptable salt thereof, wherein: R is selected from the group consisting of alkyl, aryl, arylsulfates, arylalkyl, arylsulfates ...

50. Each R 14 is independently selected from halogen, or a pharma- ceutically acceptable salt thereof.

51. 51. The compound of any one of claims 1 to 50, or a pharma- ceutically acceptable salt thereof, wherein m is 1.

52. 51. The compound of any one of claims 1 to 50, or a pharma- ceutically acceptable salt thereof, wherein m is 0.

53. R 8 is hydrogen, halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , or C 3-6 53. The compound of any one of claims 1 to 52, or a pharma- ceutically acceptable salt thereof, which is cycloalkyl.

54. R 8 is hydrogen, halogen, or C 1-6 54. The compound of any one of claims 1 to 53, or a pharma- ceutically acceptable salt thereof, which is haloalkyl.

55. R 8 55. The compound of any one of claims 1 to 54, or a pharma- ceutically acceptable salt thereof, wherein: is halogen.

56. R 1 is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, and C 1-9 heteroaryl; 1-6 Alkyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, and C 1-9 Heteroaryl is R 15a 56. The compound of any one of claims 1 to 55, or a pharma- ceutically acceptable salt thereof, optionally substituted with one, two, or three groups selected from:

57. R 1 represents hydrogen and unsubstituted C 3-6 57. The compound of any one of claims 1 to 56, or a pharma- ceutically acceptable salt thereof, selected from: cycloalkyl.

58. R 1 is unsubstituted C 3-6 58. The compound of any one of claims 1 to 57, or a pharma- ceutically acceptable salt thereof, which is cycloalkyl.

59. R 1 59. The compound of any one of claims 1 to 58, or a pharma- ceutically acceptable salt thereof, wherein: is unsubstituted cyclopropyl.

60. R 1 58. The compound of any one of claims 1 to 57, or a pharma- ceutically acceptable salt thereof, wherein: is hydrogen.

61. A compound selected from Table 1, or a pharma- ceutically acceptable salt thereof.

62. 62. A pharmaceutical composition comprising a compound according to any one of claims 1 to 61, or a pharma- ceutically acceptable salt thereof, and at least one pharma- ceutically acceptable excipient.

63. 62. A method of treating cancer in a mammal in need thereof, comprising administering to said mammal a compound according to any one of claims 1 to 61, or a pharma- ceutically acceptable salt thereof.

64. 64. The method of claim 63, wherein the cancer is an MTAP-deficient cancer.

65. 65. The method of claim 63 or claim 64, wherein the cancer is selected from liver cancer, colon cancer, pancreatic cancer, prostate cancer, lung cancer, breast cancer, and T-cell leukemia.

Citation Information

Patent Citations

  • Derivative of 5-deoxy-5-fluoro cytidine and its prepn process and use

    CN1931869A

  • Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia

    JP2008540652A

  • Nitrogen-containing heterocyclic compounds and methods for their use

    JP2010509397A

  • Amidopyrimidone derivatives

    JP2023531021A

  • Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors

    WO2008011032A1